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Abstract  
 
Background: Altered autonomic nervous system (ANS) function has been proposed as 
a mechanism in the development of central sensitisation (CS) and visceral pain 
hypersensitivity (VPH). The contribution of the parasympathetic nervous system (PNS) 
and the factors that mediate differences in sensitisation to acid are unclear and their 
study will clarify risk factors for oesophageal pain hypersensitivity (OPH) in gastro-
oesophageal reflux disease. 
Aims:  To investigate psychophysiological and pharmacological manipulation of PNS 
tone in the development of OPH, and to determine factors which predict the 
development of OPH to acid infusion in healthy volunteers in a validated model of acid 
induced OPH. 
Methods: Pain thresholds to electrical stimulation in the proximal oesophagus were 
determined before and after a 30-minute distal oesophageal infusion of 0.15 mol/L 
hydrochloric acid in subjects. Sympathetic (SNS) and PNS parameters were measured 
at baseline and continuously thereafter. Subjects underwent psychological profiling for 
anxiety, depression, attachment vulnerability and personality type. Using this model, five 
studies were undertaken: Study 1 a pilot study to trail modulation suitability for further 
study used. In Study 2, subjects who demonstrated secondary hyperalgesia in the 
proximal non-acid-exposed oesophagus performed deep or sham breathing. Study 3 
subjects, who did not sensitise to acid, underwent a validated stress test to induce OPH. 
With Study 4, deep breathing with IV saline (placebo) or atropine (PNS antagonist) was 
used to evaluate deep breathing’s induced PNS tone in OPH reduction. Study 5, a 
genetic pilot study, exploring the role of the GCH-1 haplotype in VPH.  
Results: ANS control’s key role in CS was clarified. Deep breathing increased PNS tone 
and prevented acid-induced OPH in comparison to sham breathing and confirmed 
increased PNS tone’s reversal of OPH. Psychological factors of anxiety, alexithymia and 
attachment status influence ANS modulation of CS. Individuals’ predisposition to VPH 
due to psychogenetic profiles were clarified and their biopsychosocial role illustrated.  
Conclusions and Inferences: A mechanistic explanation for the analgesic effect of 
deep breathing is provided with potential therapeutic implications in the treatment of 
VPH syndromes. Further clinical study is warranted to develop cost-effective treatments 
for chronic VPH syndromes.  
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1 Introduction 
1.1 “One body-mind”: a brief history 
From the dawn of recorded history, emotions and the body were closely 
knit. To the ancient western and eastern cultures the body and the soul 
were one. Their literature bears witness to the antiquity of concepts, that 
the body in general and viscera in particular are core components of 
normal emotional life. (1) To the physician in the time of Hippocrates the 
‘medical model of the day’ made no distinction between emotional 
and physical wellbeing. (2) Physical and mental concepts were freely 
interchangeable and equally relevant at procuring a diagnosis and 
cure. Present exclamations in the common vernacular; “lump in my 
throat”, “heart skipped a beat” and “sick to the pit-of-my-stomach”, etc. 
still attest to this notion. The Descartes-ian dualism (3) with the separation 
of the roles of brain (body) and emotion (mind), is a recent accretion 
however that in its quest to find something that lies ‘beyond all doubt’, 
fostered the mistaken supposition of focusing on the physical body and 
consigning the mind (psyche) to a mere neglected epiphenomenon. (2, 
4) This then regrettably gave rise to an epoch of misguided 
estrangement.  
 
Further, extreme and persistent emotions/passions, in association with 
‘bodily-states’ presently referred to as “stressed”, “burn-out” or being 
“run-down” making specific individuals because of personal 
constitutional differences more vulnerable, has always been the 
received wisdom and can be traced in early written records ranging 
back to more than 4 thousand years ago.1 (5) Only recently with the 
inclusion of concepts like the brain/mind by cognitive-neuroscience as a 
plausible reality deserving of serious research consideration, have there 
                                                      
1 Galen in the 2nd Century BC 
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been early indications of the reparation of the ancient breach by 
modern scientific and clinical practice. It is with this mind-set, under the 
rubric of neurogastroenterology, that this thesis has been envisioned and 
pursued. 
 
1.2 Modern neuroscience: “A fresh unified perspective”  
From the 90’s, the start of the “Decade of the Brain” until now, the 
integration of objective findings of an array of sciences profoundly 
deepened our understanding of the role relationships play in our day-to-
day subjective lives. By exploring a wide range of sciences, from 
anthropology to neuroscience, and seeking the convergence of findings 
that emerges from their integration, one can arrive at a consilient2 view 
of the “unity of knowledge” (or “consilience, as E.O. Wilson has used the 
term, 1998 (6)). In other words, as in the old tale of the three blind men 
and the elephant, there is a “larger reality” that exists though any single 
perspective can only begin to describe one view of that reality. 
 
Through this present merger of several significant perspectives it has now 
been made possible and necessary for the field of neurophysiology to re-
examine with “better tools” and “fresh eyes” the problem presented with 
regard to the interactions between pain, emotion and autonomic 
regulation. The main contributing factors making this possible and now 
needed include: 
 
                                                      
2 In the Brittanica Dictionary, consilience is defined as “the concurrence of 
generalisations from separate classes of facts in logical inductions so that one set of 
inductive laws is found to be in accord with another set of distinct derivation.” 
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1) Great clinical need: Of late there is a significant increase of functional 
somatic syndromes that has placed a huge strain on an already over-
stretched national healthcare system. Together with the fact that the 
pharmaceutical and academic industries were unable, in spite of 
significant investment, to arrive at a satisfactory improvement in 
diagnosing or treating these conditions, there has never before been a 
greater need for more effective and cost-effective management 
strategies of these poorly understood, and under-treated conditions as 
now.  
 
2) Deeper understanding: This is made plausible due to novel 
conceptual heuristic frameworks, for example: (a) ‘Bud’ Craig (7) who 
has given the scientific community a clearer neurobiological basis from 
which to consider interactions between affect and pain, with the 
development of the concept of “homeostatic processing networks”, 
allowing for the inclusion of sensory or the ‘felt’ aspects of pain. (b) 
Stephen Porges’s (8) development of the “polyvagal theory” that has 
allowed us for the first time to truly understand the key 
psychophysiological responses of the motor outputs of pain/emotion 
responses in the brainstem vagal complex, and (c) “Interpersonal 
neurobiology” by Daniel Siegel (9), that combines a range of disciplines, 
from the interpersonal (communication, attachment theory and social 
psychology) to the neurobiological (psychobiology and the domains of 
affective, cognitive, and developmental neuroscience). 
 
 3) Improved Modern Technology: Technical developments in autonomic 
neuroscience with beat-to-beat (10) and breath-to-breath (11) selective 
cardiac vagal measures and beat-to-beat non-invasive blood pressure 
measures, has allowed for the real time analysis of the autonomic 
nervous system (ANS). This enables the analysis of live, in vivo, time 
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locked observations of physiological correlates that was hitherto 
obscured to previous investigators. 
 
1.3 Syndromes of medically unexplained symptoms 
1.3.1 Unexplained Medically Syndromes are common 
A medical clinic in the USA in 1989 reviewed 1000 of their internal 
patients’ case notes. (12) Kroenke and Mangelsdorff when recording the 
incidence of 10 commonly reported symptoms over a 3-year period 
found that the proportion of these symptoms attributed to “organic 
disease” compared to “unexplained”, was (contrary to expectation) 
mostly due to “unexplained” aetiology.  (White areas in each bar, figure 
1) 
 
 
Figure 1 A case note review of 1000 patients, over a 3-year period to determine what 
proportion of symptoms, was attributed to “organic disease” or “unexplained” causes. 
The majority, across a several systems were due to functional aetiology.      
            (Adapted from Kroenke and Mangelsdorff, 1989) (12) 
 
A similar finding was observed in a UK based study of secondary care 
cardiology, gastroenterology and neurology clinics, where only about 
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60% of patients attracted an “organic” diagnosis. (13) The remaining 40% 
were categorised as either “unexplained” or “functional”. These 
unexplained conditions and resulting deficit in patient expectation are 
cited as a cause of significantly reduced patient satisfaction (14) and 
estranged doctor-patient relationships. (15) Chronic unexplained 
symptoms further contribute to impaired health related quality of life and 
is a health care burden leading to escalating costs. (16) 
 
With regard to this, it is true that to a great extent patient culture 
determines the type of symptom and the severity that would warrant a 
medical consultation, with patho-physiology playing a secondary role. 
(17) But the reverse is also true, whereby physicians control the 
legitimisation of symptoms:  
“…although biological and clinical factors have set boundaries for 
which symptoms might plausibly be linked in a disease concept, 
social influences have largely determined which symptom clusters 
have become diseases.” (18)  
In defining the term diseases, the present medical model would deem 
an underlying clinico-pathological change in tissue, e.g. by an infective 
agent or neoplasm, as the “medical-standard” for example.  Symptoms 
that indicate an underlying disease state (as so defined) would therefore 
be acknowledged and distinguished from those that do not. (19)  
 
Clinically, so doing, any condition “short of the mark”, would consciously 
or unconsciously be deemed of less importance by the physician, and 
therefore stand a greater chance of being accompanied by an 
impudent clinical frustration, and attracting some negative stigma, with 
consequentially less validation and attention. In many instances, this 
would then evoke a counter response in the patients, where contrary to 
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being reassured by the medical consultation, they are left confused and 
frustrated, with an increased desire for validation, leading to increased 
consultation behaviour. The end result poses a picture where after 
several specialist referrals and countless costly special investigations, the 
“medical-standard” is still not met, and due to possible poly-pharmacy 
and poor inter-disciplinary communication, a lack of coherent case 
management leads to a further increase in health care costs (15) and a 
further decrease in the patient’s quality of life. (14) 
 
Academically however, varying combinations of symptoms, the so-
called “functional syndromes” as opposed to merely symptoms, have 
become the main focus of modern research study. (19) Also various 
medical sub-specialties have claimed “ownership” of particular 
symptom clusters (syndromes), and in so doing facilitated the possibility 
of clinical ‘tunnel-vision’ and the potential masking of significant overlap 
between them, inhibiting exploration of common mechanisms. (19-21) 
The resulting on-going debates between the “lumpers and splitters” (22) 
has created an arguable false-dichotomy, whereas a proposed two-
pronged combination of both levels of analysis may have greater 
practical applicability and clinical efficiency. 
 
1.3.2 Functional Disorders in Gastroenterology 
Specifically concerning gastroenterology, clusters of gut-focussed 
symptoms have similarly been designated as syndromes. (23) Progressive 
thinkers like for instance Drossman et al. (24) have given us the ability to 
consider multi-factorial aetiologies concerning these syndromes within a 
frame work like the “biopsychosocial model”, which has successfully 
previously been applied to conditions e.g. peptic ulcer disease and 
ulcerative colitis. (25-31)  
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Unfortunately, this ‘wide-berth’ approach has given us an abundance of 
aetiological possibilities to consolidate, and hence initial intentions of 
unifying and integrating common mechanisms were waylaid. Further 
exacerbation of the aetiological diversity occurs when multiplied by 
subsequent organ-centric anatomical sub-divisions of functional 
syndromes, e.g. oesophagus: non-cardiac chest pain; stomach: 
functional dyspepsia and post-prandial distress syndrome etc., to name 
but a few. The underlining heterogeneity of these clinical divisions is 
reflected generally in their poor treatment response; with the only 
possible unifying indicator being the similarities regarding their high 
placebo response rates when compared to conditions like inflammatory 
disease. (32-34)  
 
This highlights the psychological aspects, that when fully considered, 
potentially further ‘muddies’ the proverbial ‘aetiological waters’ 
regarding functional gastrointestinal disorders (FGID). For instance 
heritability-twin studies in irritable bowel syndrome (IBS), found that social 
learning contributed an equal or even greater influence than genetic 
heredity alone. (17) Similarly there is strong evidence increasingly 
suggesting daily environmental “life-stress” effecting IBS symptoms 
significantly. (35) The effective amelioration of some of these 
psychosocial contributors by means of psychotherapeutic interventions 
along with the previous findings has hence encouraged an increasing 
cognitive emphasis (and greater stigma) in their present FGID 
conceptualisation. (36, 37) 
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1.3.3 Functional Gastrointestinal Disorders – the need for further 
study 
Concerning FGID, the most common presenting complaint is chronic 
episodic pain. These are conditions, such as Functional Dyspepsia, 
Irritable Bowel Syndrome (IBS) and Non-Cardiac Chest Pain (NCCP), 
being responsible for up to 40% of patients seen in secondary care 
gastrointestinal (GI) practice. These symptoms are the cause of 
significant morbidity. Health care costs related to them are 
approximately £21.5 billion3 in the 7 largest western economies. (38, 39)  
 
A third of patients with IBS give a previous history of gut inflammation or 
injury in the form of gastroenteritis or surgery. (40) The majority will recover 
with no further consequences however a proportion may develop 
chronic unexplained pain. Furthermore, patients are more likely to 
develop chronic symptoms if they have increased psychosocial stress at 
the time of injury/inflammation. (41) Similarly, 25-60% of patients with 
NCCP have evidence of gastro-oesophageal reflux disease, with the 
remainder being classified as having Functional Chest Pain of presumed 
oesophageal origin. (42) Although no acid exposure can be 
documented in these latter subjects, it is possible that previous chemical 
exposure has resulted in heightened pain sensitivity, and significantly 
contributes to persistent poor treatment outcomes.  
 
In patients with FGID, visceral pain hypersensitivity (VPH) is thought to be 
an important mechanism in the development of chronic pain, (43) 
however the factors that predict the development of chronic pain or 
VPH in these patients after inflammation or injury to the GI tract are not 
well understood. For instance the precise mechanisms for inter-individual 
                                                      
3  $34 billion: Study done for the costs in the year 2000. 
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differences in the tendency to develop VPH after gut inflammation or 
injury are often difficult to identify. In addition to the severity of the 
external stressor (e.g. bacterial virulence, degree of inflammation and 
magnitude of injury), hosts of factors such as psychological state and 
trait, genotype, early life experiences and physiological factors such as 
bio-mechanical properties of the gut are also likely to be important. 
 
As the pathophysiology is multifactorial there is evidence to suggest that 
psychological processes have a role in these disorders (44) as 60% of 
patients with FGID have tended to have a history of psychosocial stress, 
anxiety or mood disorders. Studies have shown that patients with the 
highest levels of psychosocial disturbance tended to suffer from the most 
FGID syndromes. (45) This information indicates the importance and 
emphasises the need for more accurate psychological profiling, as bio-
psychosocial elements are integral in influencing predisposition to these 
disorders.  
 
1.3.4 “Functional Neural Disturbance” - Time for a new focus 
“Functional neural disturbance” is not a new idea. As a concept, 
Charcot, Willis and Beard have postulated it already in the 20th century. 
An increasingly dualistic biomedical model in the intervening century 
discriminated between the physical and the psychological (24), so that 
the “purely psychological illness” was  firmly imbedded in later literature 
by figures such as Babinski and Freud. (19) This gradually acquired a 
pejorative stigma in which the description of physical symptoms being 
“all in the mind” was unacceptable, offensive and behaviourally 
rejected by patients. (46) For the physician and researcher alike, this was 
also not satisfactory as: 
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 “Traditional psychosomatic models had less predictive value and 
less therapeutic importance than what was hoped for. The main 
problem with these models was the lack of a pathophysiological 
explanation for why psychological problems could be related to 
somatic disease…” (47) 
According to “symptom researchers” Sharpe and Carson, what is now 
required in research and clinical practice is greater integration by means 
of a shift in focus (the so-called “paradigm shift” (19)), whereby 
“functional disturbance of the nervous system” becomes the main 
investigative focus of unexplained medical symptoms, as: 
 “The combination of cognitive psychology and neurophysiology 
offers a model… for the understanding of subjective complaints 
and illness.” (47) 
  
The conception of functional neural disturbances allows a less 
stigmatised “all in the brain” approach that also facilitates more 
biologically based research. Similarly a 
 “…new intellectual framework for psychiatry” has emphasised 
that “there can be no changes in behaviour that are not reflected 
in the nervous system and no persistent changes in the nervous 
system that are not reflected in structural changes on some level 
of resolution… …all mental processes are biological, and therefore 
any alteration in those processes is necessarily organic.” (48, 49)  
 
Although in terms of originality the notion of a functional neural 
disturbance is by no means novel, nonetheless there have been several 
conceptual and technological developments since the time of Charcot, 
which allow for a more sophisticated integrative approach. (50) In 
particular the discovery of genes, neurotransmitters and functional 
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imaging; a deepened understanding of the basic science of 
nociceptors, the autonomic, neuroendocrine and central nervous 
systems; and epidemiological evidence for modulation by psychiatric 
illness and the neurodevelopmental effects of abuse have all converged 
to make this a timely opportunity to revisit the notion of functional neural 
disturbance; especially pain hypersensitivity, as it is one of the most 
commonly cited reasons for patient presentation. 
 
 
1.4 Visceral pain hypersensitivity 
Related to the idea of a “functional neural disturbance” is “visceral pain 
hypersensitivity”. This is based on a proposed mechanism underlying 
unexplained visceral pain by means of spinal, dorsal-horn mediated 
“central  & peripheral nervous system sensitisation”, which has recently 
become the most likely and preferred explanation for observed data. 
(51-54) It displaces the previous out-dated incumbent descriptions of 
visceral motoric disturbances such as “gastric spasm”. (55) 
 
1.4.1 Mechanisms of pain hypersensitivity 
 Research in somatic pain hypersensitivity has suggested that both 
peripheral and central mechanisms can increase nociceptive 
transmission following inflammation or injury to tissues. (Figure 2) 
Peripheral mechanisms include peripheral sensitisation (PS), which is an 
inflammatory mediator-induced reduction in the transduction threshold 
of nociceptor primary afferents. PS causes pain hypersensitivity at the site 
of injury or inflammation, also known as primary hyperalgesia. (56, 57) 
Pain hypersensitivity that occurs in the surrounding healthy tissues 
(secondary hyperalgesia) and is related to an increase in excitability of 
spinal dorsal horn neurones due to upregulation of N-Methyl-D-Aspartate 
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(NMDA) receptors, a phenomena termed central sensitisation (CS). Both 
PS and CS are the major mechanisms in the development of 
inflammatory and neuropathic pain.  
 
 
Figure 2 Schematic depiction of the mechanisms and interactions of peripheral and 
central sensitisation contributing to oesophageal hypersensitivity.      
                                        (Adapted from Aziz, 2000) (58) 
 
1.4.2 Peripheral and central sensitisation in the GI tract 
In the peripheral nociceptive nerve terminals, sequential activation of 
receptors leads to an increased membrane potential which increases 
peripheral axonal firing (Figure 3). This has an effect on the peripheral 
nociceptor sensitisation at a molecular level. This is brought about by 
means of several mechanisms, including a decreased transduction 
threshold, upregulation of ion channel expression and bidirectional 
neuroimmune interactions. Repetitive firing of action potentials from the 
12 
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periphery also activates intracellular signalling cascades within the spinal 
dorsal horn neurons. This leads to amplified responses to both noxious – 
hyperalgesia and innocuous stimuli – allodynia. In figure 1.3 and 1.4, 
Knowles and Aziz (59) give an apt illustration and description of the 
mechanisms of PS and CS at the molecular level. 
        
Figure 3 A: Schematic demonstration of action potential generation in nociceptors in 
response to acid stimulus. Cations are caused to leak from a variety of acid-sensitive 
ion channels—for example, the transient receptor potential channel 1 (TRPV1)— leading 
in turn to an increased (less negative) membrane potential. This causes sequential 
activation of nociceptive (selectively expressed by nociceptors) sodium channels 
NaV1.7–1.9 and axonal firing. B: Mechanisms of nociceptor sensitisation (including to 
acid): (1) decreased transduction threshold by phosphorylation of ion channels 
(mediated by intracellular activation of protein kinases in response to G-protein-
coupled release of cAMP); (2) upregulation of ion channel expression—for example, 
TRPV1 in response to trophins—for example, to nerve growth factor (NGF) with 
retrograde transport from the cell body to nerve terminals; (3) bidirectional 
neuroimmune interactions, especially in respect of neuronal substance-P (SP) release 
acting on mast cells to release NGF. GPCR. G-protein-coupled receptor; 5-HT, 5-
hydroxytryptamine; NK1, neurokinin 1; PAR, protease-acivated receptor; PKA, protein 
kinase A; PKC, protein kinase C; TrkA, tyrosine kinase receptor A.                      
      (Figure and text from Knowles and Aziz, 2008) (59) 
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Direct evidence for PS as a mechanism for VPH is mainly obtained from 
animal studies where inflammation involving primary nerves leads to a 
reduction in their transduction threshold. In humans the evidence is more 
indirect. For instance, patients with post-infectious  - irritable bowel 
syndrome (PI-IBS) and non-erosive reflux disorder (NERD) demonstrate 
VPH and evidence of microscopic inflammation in the colonic and 
oesophageal mucosa respectively, despite absence of macroscopic 
changes. In the oesophagus at least these changes appear to more 
prominent when psychological stress is concomitantly present. 
 
 
Figure 4 Molecular mechanisms of central sensitisation. Incoming action potentials lead 
to release of various neurotransmitters and neuromodulators that act via G-protein-
coupled receptors (GPCRs) (prostaglandins (PGs), 5- hydroxytryptamine (5-HT)), 
neurokinin recptors (substance-P) and tyrosine kinase (brain-derived neurotrophic 
factor (BDNF)) as well as ligand-gated ion channels (glutamate). Subsequent 
intracellular messaging systems (predominantly via increased intracellular calcium and 
activation of protein kinases A and C lead to phosphorylation of N-methyl-Daspartate 
(NMDA) receptors with a reduction in voltage-dependent magnesium block. This 
potentiates its responsiveness to glutamate and leads to central sensitisation in the 
neuron concerned and those adjacent to it (secondary hyperalgesia). AMPA, a-amino-
5-hydroxy-3-methyl-4-isoxazole proprionic acid; PKA, protein kinase A; PKC, protein 
kinase C.                  (Figure and text from Knowles and Aziz, 2008) (59) 
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Evidence for a role of CS as a mechanism for the development and 
maintenance of visceral pain hypersensitivity comes from both animal 
and human studies. (60) Animal studies have demonstrated that 
following somatic inflammation a positive correlation exists between 
visceral pain thresholds and increased afferent discharge of dorsal horn 
neurones demonstrating viscerosomatic convergence. Spinal cFOS 
expression, used as a marker of dorsal horn activity, has also been shown 
to be increased following noxious colorectal distension and this is 
prevented by NMDA receptor antagonism. (59, 60) 
 
It is clear from the above description that peripheral inflammation or 
injury can indeed cause PS and CS. However, it is not clear why chronic 
pain and hypersensitivity only develops in a relatively small proportion of 
patients exposed to such influences. It also seems that there is an 
interaction between the psychological state and the development of 
chronic pain hypersensitivity. How and why this interaction occurs is not 
clear. It is however possible that this interaction is mediated via the 
autonomic nervous system (ANS). (61) 
 
1.4.3 Visceral Pain Hypersensitivity as biomarker 
Although individual variability of visceral hypersensitivity of pain 
thresholds exists at a group level, however it has little clinical utility as a 
discriminatory biomarker. The sensitisation concept is not confined to IBS 
research, nor even to the field of pain, and as such could turn out to be 
but a subset of medically unexplained symptoms. The limiting narrow 
definition of the spinal dorsal horn mechanism of sensitisation could in 
time give way to a broader concept of generalised 
neural/psychological sensitisation, which may have more widespread 
relevance and applicability. (22, 47, 50, 62) An example of this is for 
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instance the recent emphasis of inhibitory and disinhibitory mechanisms 
of hierarchical neural control over sensitisation. (63) Recently individual 
variation in the modulation of activating and inhibitory neural systems 
have been proposed as the fundamental basis of inter-individual 
differences in sensitisation, and so may have greater promise for the 
development of discriminatory biomarkers. (64-66) A more detailed 
understanding of the biological underpinnings of emotion and its 
interactive control thus becomes necessary. 
 
1.5 Homeostasis 
Barnard & Cannon (67) proposed the concept of homeostasis or 
“maintenance of the ‘interieur milieu’”, which is a fundamental 
organising principle in understanding any physiological process. This is of 
particular importance when considering the complex physiological 
processes such as somatic and visceral perception giving rise to 
symptoms. This original idea has been developed to include regulatory 
concepts like “homeodynamic regulation”, “allostasis” and presently 
“allodynamic regulation”. They are dynamic systems without fixed points 
or fixed operating characteristics and with individual differences in 
expression. (68) They include the notion that:  
“Physiological changes associated with behavioural states may 
reflect the active inhibition of set-point regulation – and not 
adoption of an altered regulatory level”. (69)  
However, homeostasis remains the instantly recognisable key-concept of 
fundamental physiological self-regulation.  
 
Craig et al. (68, 69) describes homeostasis as comprising of 3 
fundamental processes:  
1) Detecting the inner needs of the organism (interoception),  
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2) Detecting external environmental sources of supply or threat to 
those inner needs (exteroception) and,  
3) Moving towards or away from the external source appropriately.  
 
For simpler organisms, chemical or chemico-humeral mechanisms are 
sufficient to form the basic response mechanism. The next phylogenetic 
stage utilises the immune system and finally develops a neural system 
that increasingly becomes more elaborate and sophisticated. (70) 
 
As the 3rd step consists of reflex tropisms in the simplest organisms, 
unsophisticated response apparatus are sufficient for steps 1 and 2. As 
organisms differentiate in increasing complexity, greater amounts of 
appraisal occur in steps 1 and 2, and step 3 requires more executive 
control. Consequently the sensory, motor and motivational apparatus 
increases in sophistication. Finally, as individual survival becomes more 
contingent on survival within-and-of the group, the neuro-endocrine and 
immune systems become increasingly orientated towards social 
homeostatic requirements. (70) Inter personal psychology, in the making 
and maintaining of inter group relationships etc., then starts to play a role 
of growing importance in the homeostatic maintenance of the 
individual. 
 
Comparative functional anatomy studies indicate that across the 
phylogenetic spectrum, all vertebrates share the same basic 
homeostatic mechanisms; only the complexity increases and reaches its 
peak in man. As these mechanisms increase in complexity, it becomes 
less obvious that the basic function of these systems is survival of the 
individual through homeostasis.  
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This is particularly the case when considering processes such as emotion, 
memory, social behaviour and even consciousness. These can seem 
distant from basic homeostatic physiological processes such as digestion 
(71) and yet they are based on and developed from these fundamental 
physiological processes and serve the function of homeostasis, as they 
are still intrinsically connected and dependent on them. To 
acknowledge this fundamental function and these simple mechanisms is 
not to depreciate emotion, attention, social behaviour and 
consciousness as in man they do not solely or directly serve only the 
process of homeostasis. As it became increasingly true that 
“…to survive, mankind was not only dependent on ‘survival of the 
fittest’, but rather ‘survival of the [best] nurtured’”. (9) 
To recognise that they share similar physiological “circuitry” derived from 
homeostatic necessity, aids in explaining experimental data and 
facilitates further exploratory research as these seemingly transient 
processes have some knowable and measurable physiological substrate. 
 
1.6. Emotion and Pain 
1.6.1 Definitions and Dimensions of Emotion and Pain  
In philosophy and cognitive-neuroscience, emotion is defined as:  
“…a subjective, conscious experience that is characterised 
primarily by psychophysiological expressions, biological reactions, 
and mental states. Emotion is often associated and considered 
reciprocally influential with mood, temperament, personality, 
disposition, and motivation, as well as influenced by hormones and 
neurotransmitters such as dopamine, noradrenaline, serotonin, 
oxytocin, cortisol and GABA.” (72)  
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Emotion is often the driving force behind motivation, positive or negative. 
(73) Definitions of emotion abound but most include a (i) felt/sensory 
(affect) component, which is significantly neurotransmitter mediated 
(e.g. Lövheim’s cube, see figure 5) and (ii) 
motor/motivational/behavioural components. Emotions are usually 
arranged along the dimensions of hedonic valence (approach/avoid) 
and levels of physiological arousal. (74)  
 
 
 
Figure 5 Lövheim’s cube of emotion; a three-dimensional model of emotion and 
monoamine neurotransmitters. Lövheim proposed a direct relation between specific 
combinations of the levels of the signal substances dopamine, noradrenaline and 
serotonin and eight basic emotions. A model was presented where the signal 
substances form the axes of a coordinate system, and the eight basic emotions 
according to Silvan Tomkins are placed in the eight corners. So joy/enjoyment is, 
according to the model, for example produced by the combination of high serotonin, 
high dopamine and low noradrenaline.             (Adapted from Lövheim, 2012) (75) 
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The International Association for the Study of Pain (IASP) defines pain as  
“...an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of 
such damage.”(76) 
 
Pain is a complex multidimensional psychophysiological phenomenon 
comprising of sensory-discriminative, motivational-affective and 
cognitive-evaluative dimensions together with behavioural and 
physiological responses, and is conceptualised within the pain 
neuromatrix as proposed by Melzac et al. (77, 78) (Figure 6).  
 
 
Figure 6 The components of pain neuromatrix as proposed by Melzac et al.               
(Adapted from Melzack and Casey, 1968 & Melzack and Kat, 1999) (77, 78) 
 
1.6.2 Neural processing of Emotion and Pain  
Damasio (3) has recently contributed substantial evidence for the key 
role played by “somatic markers” in neural processing, including that of 
emotion and pain. He indicated that the mind depends on “brain-body 
Emotional  
Valence 
Attention 
Anticipation 
Intensity 
Site 
  
 
 
42 
 
interactions” for a wide spectrum of cognitive functions ranging from 
unconscious/automatic maintenance of homeostasis, experienced 
sensation and emotion, and even the regulating of higher-order 
reasoning and decision-making. In all these interactions, unconscious 
automaticity is the main modus operandi in their regulation. This is true for 
emotional processing (79-82), facial processing (83) as well as visceral 
afferent and efferent activity. (67, 84) Consciousness, being volitional, is 
almost the single exclusion.4 (85) Figure 7 is derived from PET visceral pain 
studies showing that the majority of brain sites involved in emotion 
generation and processing are sub-cortical and generally associated 
with automatic processes.  
 
Hence when applied to the pain neuromatrix, processing is localised as 
follows: Sensory- discriminative component of the pain experience 
relates to the localisation and intensity rating of the sensation (Figure 7: 
S1 & S2), whereas the affective-motivational aspects relating to its 
unpleasantness gives rise to emotional aspects such as fear and the 
formation of implicit- “felt”(visceral) memories (Figure 7: insula cortex, 
limbic & subcortical structures). Cognitive evaluative aspects facilitate 
the interpretation and contextualisation of pain and are thus involved in 
attention, anticipation and formation of the explicit- “narrative” 
memories of the experience. (Figure 7: Pre-frontal and anterior cingulate 
cortices) (86)  
                                                      
4 Bargh et al. (1999) has estimated that only 5% of human behaviour is consciously 
determined, and coined the phrase “the unbearable automaticity of being!” as a 
result. 
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Figure 7 Shows the subcortical and cortical structures that have been shown to be 
activated in response to visceral pain. Abbreviations: PAG, periaqueductal gray; PB, 
parabrachial nucleus of the dorsolateral pons; VMpo, ventromedial part of the posterior 
thalamic nuclear complex; MDvc, ventrocaudal part of the medial thalamic dorsal 
nucleus; VPL, ventroposterior lateral thalamic nucleus; ACC, anterior cingulate cortex; 
PCC, posterior cingulate cortex; HT, hypothalamus; S1, S2, first and second 
somatosensory cortical areas, respectively; PPC, posterior parietal complex; SMA, 
supplementary motor area; AMYG, amygdala; PF, prefrontal cortex; M1, motor cortex.             
              (Adapted from Price, 2000) (87)  
 
1.6.3 Psychophysiological “over-lap” of Emotion and Pain  
Because pain overlaps and interacts with a diverse range of emotions, 
with a wide scope stretching from satiety to fear, (88) pain has recently 
been redefined as a “homeostatic emotion”. “Homeostatic emotions” 
share psychological, anatomical and physiological features including 
cortical and sub-cortical substrates. Clinically it is observed that pain is 
one of the most common presenting complaints, irrespective of it being 
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explained or unexplained. (89) But equally chronic visceral pain 
conditions, such as FGID’s, are frequently co-morbid with affective 
disorders such as anxiety and depression. (37, 90) 
 
Structures especially implicated, as discussed above, are the so-called 
“interoceptive” insula cortex and the “homeostatic motor” anterior 
cingulate cortex. (7) A common effector for homeostatic emotions is the 
“emotional motor system” (EMS), which includes the central autonomic 
structures, peripheral autonomic network, and the neuro-endocrine-
immune systems.  (88) Thayer and Lane (91) in reviewing the literature for 
these systems, concluded that the Central Autonomic Network (92, 93); 
the Anterior Executive Region also called the “rostral limbic system” 
involved in “assessing the motivational content of internal and external 
stimuli and regulating context-dependent behaviours”(94); and the 
“emotion circuit”(95), 
“…are one and the same functional network identified by different 
researchers from differing orientations. This network of CNS 
structures is associated with the processes of response organisation 
and selection and serves to modulate psychophysiological 
resources in attention and emotion”. (91)  
 Thus these frontal-subcortical structures, which were consistently 
activated during the PET visceral pain studies discussed in the previous 
section, consistently over-lap, or are the very structures regulating 
“executive, social and motivated behaviours”. (96-98) As such these 
represent key central structures in homeostatic functional neural 
networks, which are likely to be of fundamental importance for 
psychophysiological processes and its behavioural assessment. 
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1.6. Psycho Motivational Behaviour of Emotion and Pain  
Porges has provided compelling evidence for the central role of the 
ventral vagal nuclei within the right nucleus ambiguus in emotion and 
pain responses. He highlighted the special connection of the fifth and 
seventh cranial nerves in the homeostatic functional neural network. This 
has led some researchers to include facial expression as “visceral” in 
nature in distinction from other somatic responses. (99, 100) 
 
Charles Darwin was first to observe that facial expression is unique to 
mammals and especially the primates and proposed that together with 
language plays a key role in both the expression and perception of 
emotional and hence homeostatic processes. (101, 102) In simpler 
organisms the homeostatic process is binary and behaviourally obvious: 
the organism either moves towards (approach) external sources (e.g. 
food or a potential mate) which can meet homeostatic need, or moves 
away from (avoid) external sources (e.g. a predator or pain) which 
represent threat. This binary axis underpins the dimensions of emotion: 
valence (aversive vs. appetitive) and arousal (increased vs. decreased). 
The overt behavioural responses of approach or avoidance are thus 
determined by the relative blends of valence and arousal. (74, 103)  
 
The behavioural concomitants are less clear in humans, as social 
homeostatic requirements are much more complex, developing to the 
extent where they can override more basic physiological homeostatic 
functions (for example: courage, empathy, jealousy or spite). In this 
context where the responses are affective-motivational by nature and 
not behaviourally overt, the notions of approach-avoidance is less 
helpful, and should rather be considered in terms of engagement or 
disengagement. (99) Due to ambivalence, assessment of valence can 
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be further blurred, and also needs to be factored in when considering 
the physiological concomitance of human-environmental interactions.  
 
In response to this, the assessment of individual emotional and 
personality differences of pain/threat defence response systems have 
been explicitly incorporated in the neurobiologically revised version of 
personality by Gray and McNaughton. (64-66, 104-106) For this thesis this 
is therefore a particularly important model in tying together relating 
“surface traits”, with individual differences in underlying behavioural 
activation, inhibition and defence systems as well as the “emotional” 
valence dimensions of reward/safety and punishment/threat. The model 
also relates to conditioning, arousal and attention. 
 
According to them, the behavioural inhibition system has a superior 
position in the hierarchy influencing decision-making and conflict 
detection. In reviewing defensive behaviours, they distinguish between a 
variety of possible activation states ranging between (i) classic flight-
freeze behaviour (Figure 8 A) and  (ii) a repertoire of “defensive 
approach” or “risk assessment” behaviours (Figure 8 B). 
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Figure 8 The relationship between defensive distance and behaviour. A: For defensive 
avoidance, B: For defensive approach. The grey arrows represent a fixed change in 
defensive distance produced by anxiolytic drugs both increasing and decreasing risk 
assessment behaviour depending on the initial defensive distance.   
                        (Adapted from McNaughton, 2004) (66) 
 
The neural systems controlling defence is based on two behavioural 
dimensions: ‘defensive distance’ and ‘defensive direction’. Defensive 
direction is a categorical dimension with avoidance of threat 
corresponding to fear and approach to threat corresponding to anxiety. 
Depending on the gravity of threat assessment, and the perceived 
distance to the threat, different defence strategies will be enacted, with 
the appropriate accompanying degree of neural-activation deemed 
necessary to deal with the impending need. These two psychological 
dimensions are mapped to underlying neural dimensions: 
 “Defensive distance is mapped to neural level, with the shortest 
defensive distances involving the lowest neural level 
(periaqueductal grey (PAG)) and the largest defensive distances 
the highest neural level (prefrontal cortex). Defensive direction is 
mapped to separate parallel streams that run across these levels. 
A significant departure from prior models is the proposal that both 
fear and anxiety are represented at all levels.” (66) 
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In this schema, different behavioural and autonomic responses relate to 
“defensive distance” and in particular whether a threat is avoidable or 
unavoidable. (Figure 9) 
 
Figure 9 Categories of emotion and defensive response derived from defensive 
direction (avoid or approach the danger) and avoidability of the threat.          
            (Adapted from McNaughton, 2004) (66) 
 
 
Hence, ‘simple ‘ avoidable threats will be dealt with by straightforward 
behavioural responses, and only lower neural (i.e. PAG) activation. More 
complex inescapable chronic threats will involve the higher neural 
circuits (i.e. prefrontal cortex) where learnt/conditioned factors based on 
personality and prior experience play an ever increasing role, resulting in 
a more complicated portfolio of differing behaviours, associated with 
varying degrees of accompanying neuronal arousal. (Figure 10)  
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Figure 10 The two-dimensional defence system. On either side are defensive avoidance 
and defensive approach respectively (a categorical dimension). Each is divided, down 
the page, into a number of hierarchical levels. These are ordered from high to low (top 
to bottom) both with respect to neural level (and cytoarchitectonic complexity) and to 
functional level. Each level is associated with specific classes of behaviour and so 
symptom and syndrome. Syndromes are associated with hyper-reactivity of a structure 
and symptoms with high activity. Given the interconnections within the system (and 
effects of e.g. conditioning) symptoms will not be a good guide to syndromes.  [OCD: 
obsessive-compulsive disorder, GAD: generalised-anxiety disorder]  
                        (Adapted from McNaughton, 2004) (66) 
 
Finally, they thus relate the two types of defence response and defensive 
distance to a hierarchical neural (defence) response activation system, 
which is associated with specific classes of behaviour, neural 
involvement and resulting ANS activation, which is where we turn to next. 
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1.6.5 Pain, the Autonomic Nervous System, and Psychology 
Emotions during acute stress (e.g. during painful procedures) are 
associated with high heart rate and high pitch vocalisations and cries in 
animals and infants. When considering ANS responses in this context, 
both characteristics are determined by a withdrawal of vagal efferent 
outflow originating in the nucleus ambiguous (NA). This is because the 
branch of the vagus originating in the (right) NA is closely linked to the 
rapid expression and regulation of emotional states. (100) Cardiac vagal 
tone (CVT) can therefore be used as an “index of central-peripheral 
neural feedback and CNS-ANS integration” (107) and in addition to pain 
reactivity has been linked to psychological trait differences such as 
temperament, emotionality and the process of interoception. (70, 108)  
 
Life events, stress and physical strain are potential factors that interact 
with the “emotional motor system” (EMS), and represent the “highest 
neural level” as referred to in the previous section by Gray and 
McNaughton. This is made up by the insula, pre-frontal-and-anterior 
cingulate cortices and the amygdala, that has a regulatory effect on 
the ANS, via the ventral vagal nuclei within the right NA, to modulate 
and govern an individual's visceral pain sensitivity. (70) Stress, either 
exteroceptive (psychological/environmental) or interoceptive 
(somatic/visceral) activates the EMS and the resulting autonomic and 
neuroendocrine responses and so doing modulates the pain response 
sensitivity. (109) Dysfunction of these systems is hence relevant as 
modulators in the pathophysiology of the visceral pain hypersensitivity 
seen in FGID. (110) (Figure 11) 
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Figure 11 Shows the potential factors that interact with the Emotional Motor System 
(EMS) and has an effect on the ANS that governs an individual's visceral pain sensitivity.
                (Adapted from Drossman, 2004) (109) 
 
Traditionally pain researchers exploring the neuroendocrinal defence 
responses have emphasised the “fight-n-flight” pattern and its 
associated behavioural activation, sensitisation and sympathetic nervous 
system (SNS) reactivity. (60, 111)  Recent research has led to a growing 
appreciation and understanding of the hierarchical superiority of the 
inhibitory control over behavioural activation systems brought about by 
the SNS. This includes inhibition or conversely disinhibition especially from 
pre-frontal cortices, together with parasympathetic nervous system (PNS) 
activity in a broad variety of responses ranging from the “freeze” 
defence response to and also including the ‘bonding’ or affiliative 
“mend-n-befriend” behaviours.  (112-117) Describing this arm of the 
neuroendocrinal defence responses has led to a wide range of 
overlapping behaviours and a somewhat confusing nomenclature that 
includes freeze, vigilance, quiescence, cautious-approach, tonic-
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immobility, fright, faint, passiveness, submissiveness and mindful coping. 
(100, 118) 
 
1.8 The Psychosocial determinants of Pain and Attachment Theory 
John Bowlby first used the term "attachment" to describe the affective 
bond that develops between an infant and a primary caregiver.5 (119) 
He believed that the "attachment behavioural system" was one of four 
behavioural systems that are innate and evolutionarily functions to assure 
survival of the species. The quality of attachment evolves over time as 
the infant interacts with his/her caregivers, and is then internalised as 
implicit memories, regulating limbic reactivity. (Figure 12)  
 
 
Figure 12 Shows four behavioural systems of attachment that are innate and 
evolutionarily function to assure survival of the species.                               
         (Adapted from Bowlby, 1958)(119) 
 
                                                      
5 Bowlby’s departure from the traditional psychoanalytic theory at the time was 
considered heretical, and was ostracised by his peers for many years to come.  It 
wasn’t until after his death in 1990 that the British analytic community issued a formal 
apology to his family. 
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Attachment relationships evolve over the first two years of life and 
beyond, but most importantly these early attachment relationships 
overlap with a time of significant neurological development of the brain. 
(120) Experiences in those early relationships encode in the neural 
circuitry of our brains by 12-18 months of age, and because they are 
entirely in implicit memories, they are outside of conscious awareness, 
and hence are “known but not remembered”. Unconsciously they form 
the patterns of attachment, which become the “rules”, templates and 
schemas, for relating that operate lifelong, as the ‘givens’ of our 
interpersonal-relational lives. 
 
This is of significance as it has now been established that experience 
shapes the brain by the following sequence: Any experience causes 
neurons in our brains to fire. Repeated experiences cause neurons to fire 
repeatedly. Neurons that “fire together wire together,”6 (121) 
strengthening neural connections through long-term potentiation. Strong 
neural connections become neural pathways and neural networks, 
which activate genes, which then lead to the production of proteins that 
enable the formation of new synaptic connections. (48, 122) This 
experience-triggered neural firing is how all-neural pathways become 
patterns of response, and how all structures of the brain mature. This is 
how all patterns of attachment are laid down in the brain; it is also how 
they can change. It is likely, though not yet directly proven in human 
studies, that the experiences within attachment relationships shape the 
emerging neural circuitry of the child’s developing brain. This shaping 
process, for example, enables parent-child interactions to shape the 
genetically programmed maturation of the brain to alter the ways in 
                                                      
6 Hebbian theory: a scientific theory in biological neuroscience, which explains the 
adaptation of neurons in the brain during the learning process. It describes a basic 
mechanism for synaptic plasticity wherein an increase in synaptic efficacy arises from 
the presynaptic cell's repeated and persistent stimulation of the postsynaptic cell. 
Introduced by Donald Hebb, 1949. 
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which such fundamental processes as emotion regulation, response to 
stress, autobiographical memory and even theory of mind, which is 
central in assessing interpersonal intention and threat, develop. 
 
Daniel Siegel, expands on this and gives a neuro-scientific understanding 
to our internal subjective and interpersonal social lives, as:  
“…these findings show how the brain has evolved as a social 
organ of the body. Mammals are social creatures, with limbic 
structures that appear to serve the dual purpose of attuning to the 
social environment while regulating the internal state of the body. 
The limbic circuits help us understand the mammalian trait of 
needing the presence of caregivers to help regulate the 
physiology of the young infant.”(123) 
 
 As that infant mammal grows, its ability to regulate its own physiology in 
a balanced manner will develop a more autonomous capacity. Studies 
of maternal deprivation in rats have shown that permanent alterations in 
the behavioural and physiological response to stress occur and impact 
the social functioning and regulation of the maturing animal. (124, 125) 
Bremner states: 
“While infants can be seen in general as being adaptive, research 
clearly shows how early adverse experience can have negative 
effects on growing brains that have persistent effects on 
functioning.” (126)  
 
When differentiation is combined with integration, the complex 
homeostatic system of the brain is able to achieve highly adaptive, 
flexible and stable states of functioning. Such a state can be proposed 
to be synonymous with more mental resilience. (127) In this way secure 
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attachment relationships may promote well-being by supporting the 
integrative capacities of the child’s developing brain. (128) As it is well 
known that “the child is father to the man,”7 these integrative capacities 
associated with attachment and physiological activation become 
stable trait phenomena affecting stress responses on a global level, that 
influence regulatory processes throughout life. (127, 129) This research is 
still at a very early stage however, and further work is needed to assess 
the processes associated with attachment and physiological activation, 
and its eventual longitudinal impact on chronic pain conditions. 
 
1.9 The Neuronal Regulation of Pain 
1.9.1 Pain Regulation by the ANS 
Benarroch (100, 159) and Cortelli (160) have recently extensively 
reviewed neuroanatomical pain regulation of the ANS for both acute 
and chronic pain. They observed that nociceptive processes and the 
ANS interact at the level of the periphery, spinal cord, brainstem, and 
forebrain. (91, 130)  Spinal and visceral afferents provide converging 
ascending afferent information to spinothalamic neurons in the dorsal 
horn and to neurons of the nucleus of the solitary tract (NTS) and 
parabrachial nuclei. As previously discussed above, these structures 
project to sub-cortical areas involved in reflexive, homeostatic, and 
psycho-behavioural control of autonomic outflow, endocrine function, 
and nociception.  
 
The PNS and SNS have mainly reciprocal activities in the modulation of 
pain. Whilst the PNS (vagus) is broadly antinociceptive (131); the SNS is 
broadly pronociceptive. (132, 133) The implication of this is that a 
                                                      
7 William Wordsworth, 1888 
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balance between sympathetic and parasympathetic activities is 
required for normal pain perception. It is however only a “rule of thumb” 
as there remain some contradicting findings that are not fully 
understood, as for example the co-activation of the ANS during pain, 
mediated via the NTS, which includes the possibility of PNS facilitation 
during pain regulation. (134) 
1.9.2 Co-activation in pain and the NTS 
Boscan and Paton (134-137) experimentally confirmed while studying the 
rat’s autonomic control of pain, that there were unanticipated complex 
possibilities of non-reciprocal, co-activation of the ANS. When they 
applied noxious stimulation to the forelimb of rats, it evoked burst 
discharges not only in the inferior cardiac and lumbar sympathetic 
nerves, but surprisingly also in the cardiac branch of the vagal nerve. As 
the usual response was a tachycardia, the increased vagal activation 
was puzzling and unexpected, as it suggested that during nociception 
both sympathetic and parasympathetic cardiac outflows were co-
activated. This led them to propose a novel ‘paradoxical role’ for the 
PNS, which mediates tachycardia during nociception that is integrated 
by the NTS. (Figure 13)(134) 
 
Figure 13 Showing the proposed NTS integration of nociceptive and baroreflex afferent 
input with both sympathetic and ‘paradoxical’ cardiac vagal motor-neurone output.   
                             (Adapted from Pickering, 2003)(134) 
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Because of phenomena like the above mentioned ‘unanticipated 
complex non-reciprocal ANS co-activation’, attempts to come to a 
more coherent understanding of the finer nuances in ANS interaction, 
more sophisticated models of ANS regulation need to be mentioned. 
 
1.9.3 The “Dynamic Systems Approach” of ANS regulation 
Recordati, emphasising the ANS as a key player in any homeostatic 
functional neural network, stated:  
“The autonomic nervous system as a whole may be viewed as a 
dissipative structure progressively assembled in the course of 
evolution, plastically and rhythmically interfaced between 
forebrain, internal and external environments, to regulate energy, 
matter and information exchanges” (138) 
Hence in order to consider the ANS as a single functional unit, the 
interactive function of components of the ANS was conceptualised by 
Berntson et al. as being ‘shaped’ by “Autonomic Determinism”; which 
proposes that, 
“…the multiple modes of autonomic control do not lie along a 
single continuum extending from parasympathetic to sympathetic 
dominance but rather distributed within a 2-dimensional space”. 
(139) 
This concept of ‘2-D autonomic space’ becomes even more 
complicated as levels are included of reactive lability as a function of 
the direction of movement (mode of control) within ‘3-D autonomic 
space’. (Figure 14) These fluctuations in ANS regulation need now to be 
correlated and time locked with specific psychophysiological events in 
laboratory conditions, in order to become more practically applicable in 
aiding deeper understanding of syndromes seen clinically.  
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Figure 14 (A) 2-dimensional model of “autonomic space”, (B) 3-dimensional model of 
autonomic space and its associated functional surface. The functional surface 
represents the operational state of the target organ, expressed in relative units. The axes 
dimensions are in decline units of functional activation. Dotted lines represent iso-
functional contour lines projected on the autonomic space, illustrating loci within 
autonomic space that have equivalent functional outputs. The functional surface of 
autonomic space represents the operational state of the target organ, and depicts the 
gradients [sum of the partial derivatives] of the functional surface across autonomic 
space. Variations in the surface amplitude in these figures illustrate the instantaneous 
changes in organ state associated with the indicated movement from any point in 
autonomic space.               (Adapted from Berntson, 1991)  (139) 
 
1.9.4 The “Polyvagal Theory” of PNS regulation 
Recordati, quoted above with regard to the ‘dynamic systems 
approach’ to ANS regulation, continues to expand on the key-role of the 
PNS in maintaining stability in metabolic homeostatic regulation: 
“…for spontaneously stable states to occur, slowing of the 
metabolic rate, withdrawal of the sympathetic drive and 
reinforcement of the vagal tone to the heart and circulation are 
required, thus confirming that the parasympathetic division of the 
autonomic nervous system is the main controller of homeostasis” 
(138) 
A B 
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In order to comprehend how this is achieved, no other body of 
knowledge has been as influential in shaping our understanding, and 
influencing research in this field, as Porges’s ‘Polyvagal Theory’. (108, 118) 
It has emerged from a phylogenetic (and ontogenetic) study of 
physiological self-regulation with emphasis on the comparative 
functional anatomy of the autonomic nervous system and of the vagus 
in particular. (140) Figure 15 shows the results of this phylogenetic 
comparison of vertebrates.  
 
Figure 15 Showing the phylogenetic comparison of Cardio Vagal Control (CVC)    
               (Adapted from Porges, 1991) (70)  
The vagus nerve emerges from or converges onto four nuclei of the 
medulla. About 90% of the vagus is sensory and is represented by the 
solitary and spino-trigeminal nuclei. The nucleus of the solitary tract (NTS) 
receives afferent taste information and primary afferents from visceral 
organs, which carry information from the thoracic, oesophageal and 
abdominal viscera; including afferents from the aortic body and arch. 
It’s relevance is not only due to its role in oesophageal sensory 
conduction, but also in forming the afferent part of the 
cardiac/respiratory reflex which is a central part of PNS control. (see 
Figure 44, page 120) 
The remaining 10% of the vagus is motoric and has two brainstem nuclei. 
(Figure 16) The nucleus ambiguous (NA) gives rise to myelinated fast-
effector neurones, which innervate the heart; larynx and upper gut, 
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whilst the dorsal motor vagal nucleus (DMNX) gives rise to unmyelinated 
slow effector neurones innervating the heart and lower gut. Extreme 
DMNX output results in a profound bradycardia, occurring in 
immobilisation behaviours such as death feigning and passive 
avoidance in reptiles and lower mammals. It is a very primitive defence 
response and potentially fatal in higher mammals (possibly associated 
with ‘Sudden unexpected death syndrome’ (SUNDS)(141), and ‘Sudden 
infant death syndrome’ (SIDS) (142)), with high oxygen needy metabolic 
rates, although adaptive for organisms with low metabolic rates. (70) 
Recent research findings indicate however that more subtle activation of 
the DMNX occurs throughout day-to-day ANS regulation in environments 
of potential threat, (117) as posited by Gray and McNaughton with their 
hierarchical neural (defence) response activation system. (64-66, 104-
106) (See also table 9, chapter 4, page 201, for stages of ANS activation 
to stress.) 
 
Figure 16 Showing the two vagal brainstem motor nuclei and their extension in the 
viscera.                   (Based on Porges, 2009) (117) 
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In contrast the NA output (CVCNA) allows for subtler beat-to-beat heart 
rate modulation – increased CVCNA causes milder slowing of the heart 
rate which may be involved in behavioural inhibition and bonding whilst 
withdrawal of CVCNA reduces the external constraint on the intrinsic sino-
atrial node (SA) automaticity and therefore a faster heart-rate ensues to 
facilitate behavioural activation. This has been described as the “vagal 
brake”(143), which Recordati describes as the most efficient and neuro-
chemically “cost-effective” way of maintaining homeostatic control of 
the heart and circulation. (138) 
 
1.9.5 Adrenergic modulation of pain 
This occurs in the periphery, spinal and supra-spinal sites. In the periphery 
there is little baseline adrenergic modulation of pain. However, following 
tissue injury, nor-adrenalin induces novel noradrenergic receptors. It also 
induces sympathetic nerve sprouting and alters the ionic channel 
properties of primary afferent nociceptors (N-type Ca2+ channels) and 
all of these are pronociceptive activities leading to hyperalgesia. (144) 
 
1.9.6 Spinal adrenergic modulation of pain 
They are nearly all inhibitory. Pre-synaptic inhibition of the primary 
afferent nociceptor terminals in the dorsal horn of the spinal cord is 
mediated through alpha-adrenoreceptors. There is also evidence of a 
direct adrenergic action on pain relay interneurones through post-
synaptic inhibition mediated by alpha2-adrenoreceptors. Alpha1-
Adrenergic mediated activation of inhibitory interneurones is another 
mechanism of spinal adrenergic antinociception. (144) They are mostly 
peptidergic and contain first class neurones, which express peptide 
neurotransmitters such as substance P and CGRP (calcitonin gene 
related peptide). (Figure 17) (145) 
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Figure 17 Showing the spinal α1 and α2- adrenergic synapses in the dorsal horn. Post-
synaptic inhibition mediated by alpha2-adrenoreceptors, activation of inhibitory 
interneurones, which is another mechanism of spinal adrenergic antinociception, which 
express peptide neurotransmitters such as substance P, and calcitonin gene related 
peptide (CGRP).             (Adapted from Pertovaara, 2006) (144) 
 
1.9.7 Supra-spinal adrenergic modulation of pain 
The visceral projection from the spinal cord to subcortical and cortical 
structures consists of several pathways. The spinothalamic tract 
terminates in the medial and posterior thalamus. Thalamocortical fibres 
then project to the somatosensory cortex. The spinoreticular tract 
terminates in the reticular formation in the brainstem. The 
reticulothalamic tract projects from the dorsal and caudal medullary 
reticular formation to the medial thalamus. The spinomesencephalic 
tract projects to various regions in the brain stem, including the 
periaqueductal grey, locus coeruleus, and dorsal reticular nucleus in the 
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medulla. Thalamocortical projections from the medial thalamus project 
to the cingulate cortex and insula, which are involved in processing 
noxious visceral and somatic information. The brain regions innervated 
by these pathways that respond to painful visceral stimuli include the 
thalamus, insula, amygdala and anterior cingulate cortex (ACC). The 
ACC is comprised of two components, the perigenual ACC (pACC) 
involved in affect and midcingulate cortex (MCC) with behavioural 
response modification. (146)(Figure 18)  
 
Supra-spinal adrenergic modulation of pain varies depending on the site 
of activity, the type of adrenoceptors, the duration and pathophysiology 
of the pain. The general observation is that at baseline conditions there is 
little adrenergic effect on pain perception. However, during sustained 
pain there is supra-spinal noradrenergic feedback inhibition of pain. 
(144) In the brainstem, the ventrolateral medullar oblongata, brainstem 
reticular formation, parabrachial nucleus and periaquaductal grey 
matter all receive ascending nociceptive afferents. (Figure 18) The rostral 
ventrolateral medullar oblongata is the main area where pre-
sympathetic vasomotor neurones are situated together with other 
sympathetic driver neurones. (147) They are arranged here in 
organotopic manner and also occur in the dorsal vagal complex, in the 
bulbar reticular formation, in the ventrolateral pons, and in the Locus 
Coeruleus and others.  
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Figure 18 Shows the principal visceral projections from the spinal cord to subcortical 
and cortical structures (green lines). The spinothalamic tract terminates in the medial 
and posterior thalamus. Thalamocortical fibres then project to the somatosensory 
cortex. The spinoreticular tract terminates in the reticular formation in the brainstem. The 
reticulothalamic tract projects from the dorsal and caudal medullary reticular formation 
to the medial thalamus. The spinomesencephalic tract projects to various regions in the 
brain stem, including the periaqueductal grey, locus coeruleus, and dorsal reticular 
nucleus in the medulla. Thalamocortical projections from the medial thalamus project 
to the cingulate cortex and insula which are involved in processing noxious visceral 
and somatic information. The brain regions innervated by these pathways that respond 
to painful visceral stimuli include the thalamus, insula, amygdala and anterior cingulate 
cortex (ACC). The ACC is comprised of two components, the perigenual ACC (pACC) 
involved in affect and midcingulate cortex (MCC) with behavioral response 
modification. Other pathways for transmission of noxious visceral stimuli (such as the 
dorsal column pathway) exist, but are not shown.  (Adapted from Drossman, 2004) (109)  
 
1.9.8 Cholinergic modulation of pain: In the periphery 
Cholinergic efferent nerve fibres in the vagus are the main source of 
parasympathetic activity in most organs in the abdomen and the thorax. 
Vagotomy induces hyperalgesia in the area supplied by the severed 
part of the vagus nerve, which can be reversed by denervation of the 
sympathetic supply to the adrenal medulla. (148) These observations 
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suggest that in the modulation of gut pain, vagal parasympathetic 
activity is balanced by adrenergic activity. Moreover, alpha2-adrenergic 
antagonists can reduce vagotomy-induced hyperalgesia in the gut. 
(149) 
 
1.9.9 Spinal cholinergic modulation 
Cholinergic activity within the spinal cord modulates pain perception via 
M2-muscarinic receptors that also mediate parasympathetic activity in 
the heart, smooth muscle and lacrimal glands. It is postulated that 
activation of spinal M2-muscarinic receptors causes release of adrenal 
catecholamines and that the anti-inflammatory effects of the 
catecholamines reduce inflammatory pain. (150) 
 
1.9.10 Supra-spinal modulation 
 The autonomic centres relevant to supra-spinal modulation of pain are 
discussed above. However, in adults the consistent pattern emerging is 
that higher resting blood pressures are associated with relative 
hypoalgesia probably mediated by reflex PNS activation via 
baroreceptor stimulation. (151)  
 
1.9.11 The Autonomic Nervous System, pain and the viscera 
The principal components of descending pain modulatory pathways 
which are activated in response to painful visceral stimulus are the 
Ponto-medullary networks, including the periaqueductal grey (PAG), 
rostral ventral medulla (RVM) and the raphe nuclei, which are 
modulated by inputs from the anterior cingulate cortex (ACC), 
amygdala, and other cortical regions. (Figure 19)  
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Figure 19 Shows the principal components of descending pain modulatory pathways 
(yellow lines), which are activated in response to a painful visceral stimulus such as 
noxious balloon distension of the colon. Ponto-medullary networks including the 
periaqueductal grey (PAG), rostral ventral medulla (RVM) and the raphe nuclei are 
modulated by inputs from the anterior cingulate cortex (ACC), amygdala, and other 
cortical regions. The major descending pain inhibitory pathways are mediated via the 
opioidergic, serotonergic and noradrenergic systems. These pathways modulate pain 
transmission at the level of the dorsal horn of the spinal cord.                             
                                                                       (Adapted from Drossman, 2004) (109) 
 
The major descending pain inhibitory pathways are mediated via the 
opioidergic, serotonergic and noradrenergic systems. These pathways 
modulate pain transmission at the level of the dorsal horn of the spinal 
cord. There is mounting evidence to suggest that the interface between 
the gut lumen and sensorineural pathways is regulated closely by the 
ANS. (152) Increasing SNS activity has been shown to increase colonic 
sensitivity in healthy volunteers. (153) Enhanced sympathetic dominance 
to oesophageal acid infusion has been documented in patients with 
gastro-oesophageal reflux disease, (154) and reduced vagal activity has 
been reported in NCCP patients. (88, 155) 
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1.10 Modulation of pain by pharmacological modulation of the ANS 
1.10.1 Pharmacological modulation of the SNS 
There is evidence for both SNS and PNS influences on pain. Relationship 
between the SNS and pain has been repeatedly demonstrated in 
animals and humans and conditions such as ‘reflex sympathetic 
dystrophy’, sympathetically maintained pain’ and the all-encompassing 
‘complex regional pain syndrome’ which are well recognised 
sympathetically mediated clinical pain conditions. In these conditions 
sympathetic modulators such as alpha1 antagonist (phentolamine 
prazosin, terazosin) and ganglion blockers such as guanethidine are 
used as diagnostic tools. Efficacy of clonidine has been shown in these 
conditions as well as in numerous animal studies of sympathetically 
mediated pain. In animal studies, alpha 2 adrenergic agonists produce 
analgesia by actions in the periphery, supraspinal CNS, and in the spinal 
cord (156) Clonidine is believed to produce analgesia at the spinal level 
in part through stimulation of cholinergic interneurons in the spinal cord. 
Alpha 2 adrenergic agonists produce sedation and reduced blood 
pressure in addition to analgesia. Clonidine can be administered orally, 
transdermally (53) or spinally. When given orally it has 100% bioavailability 
and its peak concentration and maximal hypotensive effect is observed 
1-3 hours later, and its half-life is 6-24 hours. Its analgesic effect is evident 
even when used as a single dose and has such been extensively used in 
anaesthesiology. In specific reference to the viscera, clonidine has 
effects on visceral pain perception in dyspeptic patients (107, 157) and 
in the colon of volunteers. 
 
1.10.2 Pharmacological modulation of the PNS 
 This is effective in reducing pain in animal and human studies. 
Muscarinic agonists and antagonists (atropine) have been shown to 
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reduce and increase pain sensitivity respectively in rodents. This effect 
was associated with a corresponding increase or decrease in intraspinal 
release of acetylcholine depending on whether an agonist or antagonist 
was used. Furthermore there is evidence for the pro-algesic effects of 
atropine in humans. (158) During the 1990s, the discovery of the 
antinociceptive properties of the potent nAChR agonist epibatidine in 
rodents sparked interest in the analgesic potential of this class of 
compounds. A number of novel nAChR agonists with antinociceptive 
activity and improved safety profiles in preclinical models have now 
been identified, of these ABT-594 is the most advanced and is currently in 
Phase II clinical evaluation. 
 
1.10 The human oesophagus 
The main physiological function of the oesophagus is that of transporting 
nutrition and fluids to the rest of the digestive system. The human 
oesophagus is unique in its anatomical composition, as the proximal third 
is composed of striated muscle while the distal two thirds are composed 
of smooth muscle. (159) The proximal oesophagus has a dense spinal 
somatic-like innervation containing mostly myelinated visceral afferents. 
On the other hand the distal oesophagus contains mostly unmyelinated 
C-fibres with a comparatively less dense spinal innervation as would be 
found in other gut structures. 
 
1.11 Sensory Innervation of the oesophagus 
1.11.1 Sensory innervation at mucosal level 
The alimentary canal is innervated by four populations of sensory neurons 
(Figure 20), - two intrinsic and two extrinsic.  
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Figure 20 Innervation of the GI tract by intrinsic and extrinsic sensory neurons. The two 
populations of intrinsic primary afferent neurons originate in the submucosal plexus 
(SMP) and myenteric plexus (MP), respectively. The two populations of extrinsic sensory 
neurons are vagal afferents originating from the nodose ganglia (NG) and spinal 
afferents originating from the dorsal root ganglia (DRG). CM, circular muscle; LM, 
longitudinal muscle.                   (Adapted from Holzer, 2001) (160) 
 
The populations of intrinsic primary afferent neurons (IPANs) have their 
cell bodies either in the myenteric plexus (Auerbach plexus) or in the 
submucosal plexus (Meissner plexus) and innervate both mucosal and 
muscular layers of the gut. (Figure 20 & 21)  (146) Being part of the 
enteric nervous system (ENS), they comprise mucosal chemosensors, 
mucosal mechanosensors and muscular tension receptors. In addition, 
IPANs synapse with each other and in this way form self-reinforcing 
networks that issue outputs to interneurons, motor neurons, secretomotor 
neurons and vasodilator neurons. (161, 162) 
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Figure 21 The arrangement of the enteric plexuses, depicted for the small intestine. A: 
appearance in separated layers. The myenteric plexus (Auerbach plexus), consisting of 
numerous ganglia and connecting nerve fibre bundles, lies between the longitudinal 
and circular muscle layers. A second ganglionated plexus (Meissner plexus) is in the 
submucosa. These plexuses provide nerve fibre plexuses in the muscle, in the mucosa 
and around arterioles. B: The enteric plexuses shown in a cross section of the intestine.
                       (Adapted from Furness, 2007) (163) 
 
The two populations of extrinsic sensory neurons (ESN) are vagal afferents 
with cell bodies in the nodose ganglia and spinal afferents with cell 
bodies in the dorsal root ganglia, and also contribute to the innervation 
of the circular muscle and the longitudinal muscle. Both the IPANs and 
the ESNs provide the ENS with the kind of information that is known as the 
“brain in the gut”, and enables the requirements for autonomic control 
of digestion. 
 
1.11.2 Sensory innervation at spinal level 
As mentioned above the oesophagus receives innervation from both 
vagal and spinal nerves (Figure 22), however the majority of the 
oesophageal pain pathways are probably located in the spinal nerves. 
Dorsal root ganglia of cardiac and splanchnic nerves provide 
John%B.%Furness%(2007),%Scholarpedia,%2(10):4064%
Auerbach)plexus))
Meissner)plexus))
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craniocaudal innervation to the oesophagus. Afferent fibres then ascend 
centrally via spinothalamic tracts and dorsal columns to the thalamus 
and then on to the primary somatosensory cortex, insula, and anterior 
cingulate gyrus. (164) The spinal nerves enter the central nervous system 
through the dorsal root ganglion of the spinal cord from C1 to L2. 
 
 
Figure 22 Schematic diagram of vagal and spinal nerve supply to the oesophagus.
                (Adapted from Sengupta, 1989) (113) 
 
1.11.3 Sensory innervation at cranial nerve level 
The vagal afferents travel with the main branch of the vagus nerve, 
primarily entering the central nervous system (CNS) via the nodose and 
Insula	 
  
 
 
72 
 
jugular ganglia and synapsing in the nucleus of the solitary tract. Most of 
these afferents (70-90%) are unmyelinated C fibres. (Figure 22) (164) 
 
1.11.4 Sensory innervation at supra-spinal level 
Positron electron tomography (PET) and functional magnetic resonance 
imaging (fMRI) have demonstrated that non-painful oesophageal 
sensation results in an increased regional blood flow bilaterally in the 
primary somatosensory cortex, bilaterally in the insular cortex, and 
frontal/parietal operculum. (165) Hobson et al. (166) found that painful 
oesophageal stimulation also activates the same regions but at an 
increased level as well as the involvement of the right anterior insular 
cortex and the anterior cingulate gyrus, further supporting and 
establishing the functional anatomical basis for the central component 
of pain processing in what is known as the "brain-gut axis".  
 
When looking at the efferent functions, the division of the SNS and the 
PNS is true. However when one is looking at the afferent functional 
representation of the ANS, a division into the vagal and spinal afferent 
fibres is made. (167) (Figure 23) The vagal afferents nerves are composed 
mostly of unmyelinated C-fibres with few A-delta fibres terminating in 
bare nerve endings in each layer of the gut wall including serosa and 
mesentery. The spinal afferents have a greater role in visceral 
nociception. (168) Spinal afferents nerves can be further divided into 
splanchnic and pelvic afferents, which follow the actions of sympathetic 
and parasympathetic systems respectively. Spinal afferents may be 
divided into two nociceptive sensory receptor types, which innervate the 
viscera. (145) 
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Figure 23 Showing the reciprocal actions of the para-and-sympathetic nervous systems.
               (Adapted from Wikipedia, 2013) (169) 
 
Low threshold receptors have an encoding function (the relation 
between stimulus intensity to nerve activity) response, which is activated 
by innocuous and noxious stimuli.  These receptors encode intensity and 
have been found in the oesophagus, heart, colon, bladder and testes. 
(48) High threshold mechano-receptors, these are activated entirely from 
a noxious stimulus to generate nerve activity. Silent nociceptors are a 
third group of receptors involved in nociceptor pain but they only 
become active after exposure to inflammatory mediators. 
 
1.12 Oesophageal Pain Hypersensitivity  
As mentioned above functional oesophageal pain or non-cardiac chest 
pain (which affects up to one third of those who undergo arteriograms 
for chest pain) (170) are also chronic functional symptoms which mimic 
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oesophageal disease yet do not have the same organic aetiology (171). 
As such they form part of the FGID group of disorders. VPH has been 
attributed as a factor underlying the pathophysiology in functional 
oesophageal disorders, as demonstrated in figure 24, (below) but the 
aetiology remains poorly understood. Gastro-oesophageal reflux disease 
(GORD) is common, with estimates of 20–44% of Western populations 
having symptoms of GORD at least once a month and 20% weekly.  
 
 
Figure 24 Oesophageal Pain with Balloon distension indicating clearly that there is 
hypersensitivity in the patient group. The graph indicates that their pain scores are 
much higher or lower volumes of balloon distension.                   
           (Adapted from Paterson, Wang, & Vanner, 1995) (172) 
 
In GORD there exists interplay between visceral hypersensitivity and acid 
exposure, leading to a spectrum of conditions (Figure 25, below), 
whereby moving from the right to the left there is an increase in acid 
exposure. Likewise moving from left to right there would be an increase 
in the role of hypersensitivity. In so doing one would then have a 
spectrum of conditions starting with erosive oesophagitis (EO) on the left 
side, where there is a clear emphasis on the acid exposure as the main 
aetiological factor and where ulceration or erosions are evident. On the 
right side the present evidence would support that the main aetiological 
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factor is VPH, presenting in conditions like functional heartburn (FH). This 
leaves us with the interaction of both acid exposure and visceral 
hypersensitivity in conditions like non-erosive reflux disease (NERD) in the 
middle.  
 
 
Figure 25 Shows the relationship that exists between acid exposure and visceral 
hypersensitivity in the aetiological role of gastro-oesophageal reflux disease (GORD). 
From left to right we have erosive oesophagitis (EO) where there is a high exposure to 
oesophageal acid. Then we have non-erosive reflux disease (NERD), where there is a 
combination of both acid exposure and visceral hypersensitivity and finally on the right-
hand side we have functional heartburn (FH), where visceral hypersensitivity is clearly 
cited as the main aetiological cause.      (Adapted from Knowles & Aziz, 2009)(167) 
 
The proportion of patients with NERD is estimated to be between 50–70% 
of the GORD population. In these conditions it would be probable to 
expect that both the acid exposure and visceral hypersensitivity are 
contributing to the overall symptom profile observed, producing a 
perpetuating, mutually exacerbating course. What is presently still not 
clearly understood is the exact relationship that exists between the acid 
exposure and the visceral hypersensitivity and its interplay. This 
understanding would contribute significantly to the development of a 
more appropriate approach to treatment resulting in possible 
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substantially improved outcomes in the treatment resistant NERD patient 
group. Although VPH contributes to the clinical presentation in both EO & 
NERD, the fact that established responses to standard acid suppressive 
treatments are 20–30% lower in patients with NERD than those with EO, 
understanding the interaction between acid and VPH specifically in the 
NERD group remains a priority, and is thus the main concern of this thesis. 
 
1.13 The need for a change in focus 
Current management of pain in FGID involves the use of either 
antispasmodics or antidepressants. (173) Meta-analysis suggests that the 
former approach is no better than placebo while the latter approach 
produces global improvement without improving pain directly. (173) 
Pharmaceutical companies have invested heavily in the last two 
decades to develop the ‘magic bullet’ for managing pain in FGID, 
however their efforts have not met with success. Most medications 
developed on the basis of promising pre-clinical studies have either 
shown no effect or only a modest effect in clinical trials. (174) Part of the 
problem is that FGID is diagnosed on the basis of symptom-based criteria 
and hence there are considerable inter-individual differences in 
pathophysiology leading to heterogeneity in study populations. 
Furthermore, as discussed previously, there is a lack of disease biomarkers 
and good models of disease that can be used to test proof of 
mechanism for pharmacological preparations before large-scale clinical 
drug trials are performed. With the above considerations in mind what is 
proposed in this thesis is a mechanism-based approach to identify 
reasons for inter-individual differences in the development of VPH. This 
approach is based on a model of VPH previously developed and 
validated by several researchers in the field. 
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1.14 Work conducted on Human oesophageal model of peripheral and 
central sensitisation 
 
 To address the question whether inflammation/injury can induce PS and 
CS in the human GI tract, a model was developed which demonstrated 
that infusion of 0.15M hydrochloric acid into the healthy oesophagus 
reduced pain threshold reproducibly not only in the acid exposed region 
(peripheral sensitisation), but also in the adjacent unexposed region 
(central sensitisation). This effect was prolonged lasting up to 5 hours 
after 30 minutes of acid exposure (Figure 26) although a shorter 5 minute 
acid infusion also produced a transient hypersensitivity lasting for 2 hours. 
(175) Evidence of facilitated afferent pathways in the model has been 
obtained by a cortical evoked potential study demonstrating a 
decrease in latency and increase in amplitude of the response after 
acid infusion in comparison to saline. 
 
 
Figure 26 Mean change in pain threshold in upper oesophagus after 30 min infusion of 
acid or saline into the lower oesophagus in healthy volunteers, administered 2 h apart. 
Error bars=SE. Shaded area=95% CI calculated from change in pain threshold in upper 
oesophagus when no infusion was administered.                      
          (Figure adappted from Sarkar, Aziz, Woolf, Hobson, & Thompson, 2000)(175) 
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Pharmacological studies have been used to block receptors involved in 
CS in this oesophageal model. It has been demonstrated that 
administration of prostaglandin receptor antagonist (EP1) prior to acid 
infusion blocks the subsequent development of oesophageal 
hypersensitivity suggesting that prostaglandins play an important role in 
mediating PS and CS. (176) Furthermore it was recently demonstrated 
that ketamine, an NMDA receptor antagonist, not only prevents 
development of oesophageal hypersensitivity in response to acid infusion 
but that it also reverses established hypersensitivity in healthy volunteers. 
(51) In contrast cox2 inhibitors and Neurokinin 1 receptor antagonists did 
not reverse the hypersensitivity in the model. 
 
1.15 Variability in the development of oesophageal sensitisation 
Despite the fact that it has repeatedly been shown that acid infusion 
causes oesophageal pain hypersensitivity, (175) around 15-35% of 
subjects do not sensitise to acid at all. (177) (Figure 27)  
 
Figure 27 Shows the inter-individual differences in change in pain threshold (PT) after 
saline and acid infusions. The factors that mediate post-injury gut sensitisation are 
poorly understood.         
        (Adappted from Sarkar, Aziz, Woolf, Hobson, & Thompson, 2000) (175) 
Figure 
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Among those who do sensitise, the mean reduction in pain threshold 
from baseline for n=24, is -7.4mA (-8.4 to 16.3 CI, p<0.001) (177) at 30 
minutes post acid infusion. This is reproducible in those sensitisers who 
have had more than one study. Pain thresholds remain reduced up to 
120 minutes after the infusion, and there are no statistically significant 
differences between the pain thresholds at different time points between 
30-120 minutes. The factors that mediate post-injury visceral sensitisation 
are poorly understood, however recent studies have shown that in 
healthy subjects there is variability in oesophageal pain thresholds 
depending on their level of state anxiety. Higher levels of anxiety are 
associated with lower oesophageal pain thresholds. (178) It is likely 
therefore that a number of psychological and physiological factors are 
responsible for inter-individual differences in pain hypersensitivity in this 
model.  
 
Figure 28 A: showing that there is an inverse correlation (r=-0.66) between the change in 
an individual’s pain threshold (PT) and the change in heart rate, i.e. the bigger the 
change in heart rate, the more the drop in pain threshold. B: Correlation between 
baseline Spielberger State Anxiety Inventory (SSAI) score and degree of sensitisation 
[maximum change in proximal oesophageal pain threshold (PT) post-infusion (n=14)]. A 
statistically significant relationship was apparent such that as the SSAI score increased, 
the degree of sensitisation (fall in proximal oesophageal PT) to acid increased.         
                                       (Adapted from Sharma, 2008) (179) 
 
A B
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A study (180) of the selective activation of these systems in the human 
model of acid-induced oesophageal sensitisation (as described above) 
in 25 healthy volunteers, using novel real-time techniques for measuring 
the parasympathetic and sympathetic tone, has indicated the ANS may 
have a modulatory role on visceral pain transmission with the SNS and 
PNS proposed as being facilitatory and inhibitory respectively. (153, 181) 
Oesophageal acidification was also associated with an increase in 
unpleasantness and anxiety scores in conjunction with a rise in 
sympathetic and a fall in parasympathetic activity. Nine subjects did not 
sensitise to acid at all. (Figure 28(A), above) Amongst those who 
sensitised, subjects who showed a greater increase in heart rate during 
acid infusion also sensitised more. (Figure 28(B), above) Individuals who 
withdrew vagal (parasympathetic) tone during acid infusion the most 
also developed the greatest oesophageal sensitisation and resultant 
pain hypersensitivity. (Figure 29, below) In addition, higher state anxiety 
scores at baseline were associated with a greater likelihood of 
withdrawing vagal tone to oesophageal acidification, suggesting that 
these individuals may have been predisposed to greater sensitisation by 
their psychological state.  
 
Figure 29 Showing the correlation between pain threshold (PT) and cardio vagal tone 
(CVT) measured on a linear vagal scale (LVS).           (Adapted from Sharma, 2008) (179) 
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This data suggests that the parasympathetic nervous system may have 
anti-hyperalgesic properties in the human viscera, and that anxiety may 
predispose to greater post-injury gastric sensitisation through the 
withdrawal of vagal tone. The rationale then for this thesis is to take this 
concept one step further: 
“If visceral pain hypersensitivity correlates with a decrease in cardio 
vagal tone; then what would the effect of a deliberate increase in cardio 
vagal tone be on visceral hypersensitivity?” 
The plan of investigation described below is therefore based on the 
concept that physiological and pharmacological modulation of the ANS 
will lead to modulation of the oesophageal pain hypersensitivity. 
1.16 Research Questions/Objectives 
1.16.1 Principal research questions/objectives (Hypotheses testing) 
 In a model of human oesophageal pain hypersensitivity in healthy 
subjects: 
I. Does physiological modulation of the ANS influence the degree of 
oesophageal pain hypersensitivity? 
II. Does the increase of PNS by means of physiological methods 
decrease oesophageal pain hypersensitivity?  
III. Does the increase of SNS by stress induction cause an increase in 
oesophageal pain hypersensitivity? 
IV. Does inhibition of PNS by atropine cause an increase in 
oesophageal pain hypersensitivity due to the unopposed effect of the 
SNS? 
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1.16.2 Secondary research questions/objectives (Hypotheses 
generating) 
In a model of acid induced human oesophageal pain hypersensitivity 
in healthy subjects:   
I. What are the psychological predisposing factors that would 
predict vulnerability to VPH? 
II. What is the difference in ANS response of subjects vulnerable to 
acid exposure compared to those that are not? 
III. What is the role of psychosocial, environmental and genetic 
factors in ANS activation in context of VPH aetiology? 
 
 
 
 
1.17 Aims 
1.17.1 Hypothesis Testing 
1.17.1.1	  General	  hypothesis	  
The autonomic nervous system modulates the development of human 
VPH. 
 
1.17.1.2	  Specific	  hypotheses	  
Physiological modulation that will increase the parasympathetic tone of 
the ANS will decrease the degree of central sensitisation in the human 
healthy volunteer model of acid induced oesophageal VPH. 
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1.17.2 Hypothesis Generating 
1.17.2.1	  General	  hypothesis	  
Individual psychophysiological factors will correlate with autonomic 
nervous system activation that will affect the degree of central 
sensitisation in the human healthy volunteer model of acid induced 
oesophageal VPH.  
 
1.17.2.2	  Specific	  hypotheses	  
Individual psychophysiological factors that will correlate with the 
sympathetic & parasympathetic activation of the ANS across differing 
stress environments will affect the degree of central sensitisation in the 
human healthy volunteer model of acid induced oesophageal VPH. 
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2 Methods and Materials  
 
2.1 Ethics Committee Approval and Funding 
All protocols within this thesis were submitted and approved by the 
University Senate Ethics Committee, ‘East London and The City Research 
Ethics Committee - Alpha’ (ref: 09/H0704/71) and, where appropriate, 
protocols, were also approved by the Research Ethics Committee of 
North Jutland, Denmark (ref: N-20120065vII).  Written informed consent 
was obtained from all subjects prior to their entry into the studies.  ‘Data 
& Identity Protection Protocols’ were strictly maintained. All studies 
adhered to the guidelines of the World Medical Association Declaration 
of Helsinki (revised edition: Seoul, South Korea, 2008), the guidelines of 
the International Conference on Harmonization (ICH) Guidelines for 
Good Clinical Practice (CPMP/ICH/135/95), and the ‘Amendment 
Regulations of 2006’ concerning ‘Clinical Trials in Humans’. This project 
was funded by a Medical Research Council project grant (ref: 
G0701706). 
 
2.2 Subjects 
Healthy asymptomatic adult male and female volunteers, aged 18 to 50, 
were recruited by advertisement. All subjects were naïve to the 
experimental protocol and had never previously been subjected to the 
model of acid perfusion used in my studies. All had normal medical 
assessments including detailed medical interview and examination, and 
were non-smokers, not taking any regular medication (excluding 
acceptable forms of contraception). According to the “best practice” 
guidelines for pain research with respect to sex and gender, females 
were all studied in the follicular phase of their menstrual cycle. (182) Urine 
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tests were performed at all visits to exclude drugs of abuse (Triage 8™, 
Biosite San Diego USA) and pregnancy for females (First Step™ FS208 
Euromed Limited, UK). Written informed consent was obtained from all 
after the study had been explained and only after the volunteers had in 
excess of 48 hours to consider the information provided. All volunteers 
were allowed to withdraw at any time should they wish to for any reason, 
or if the investigator judged that it was necessary due to any medical 
reasons or if non-compliance to the protocol occurred.  
 
2.3 Oesophageal Manometry 
Standardised oesophageal manometry (183) was performed in the first 
five subjects to determine the positions of the upper and lower 
oesophageal sphincter (UOS and LOS) from the nostril. A stationary pull 
through manometric technique was performed by a research assistant 
accredited in the procedure. Intraluminal pressures were measured via 4 
channels (0.9mm diameter) incorporated into the solid state catheter, 
the ends of which opened as side holes 5, 10, 15 and 20cm from the 
distal tip of the catheter (Polygram™ for Windows® 1995, Synectics 
Medical, Enfield, Middlesex, EN1 3BT, UK). This measurement was then 
compared with the measurement obtained using a stationary pull 
through ‘pH change technique’. A 1mm diameter twin channel pH 
catheter (Synectics Medical, Enfield, Middlesex, EN1 3BT, UK) was used to 
measure the relative LOS position indicated by the pH change as the pH 
catheter was slowly withdrawn from the stomach. The LOS positions on 
these first five subjects were found to be identified accurately enough by 
the pH change technique for the purpose of this study, and only the ‘pH 
change’ pull through technique was used for the remainder of the 
subjects. (Specific corrections in possible case of hiatus hernia were not 
made.) Determination of LOS position was essential for later positioning 
of the stimulation and infusion catheter assembly. 
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2.4 Catheter Assembly 
All experiments were conducted with subjects having fasted for a 
minimum of 8 hours. A bespoke naso-oesophageal catheter consisting of 
two electrical stimulation electrodes 15cm apart with a infusion port 1cm 
above the lower electrical stimulation electrode, (UniTip™-Katheter 6F, 
UNISENSOR AG, Attikon, Switzerland) were taped together with a 
disposable 15cm twin channel pH catheter (VersaFlex® Sierra Scientific 
Instruments, LA, CA, USA). The catheter-pH probe assembly was passed 
nasally into the oesophagus until the distal infusion site and the proximal 
stimulating electrodes were 4cm and 18cm above the lower 
oesophageal sphincter respectively, with the pH sensors sited adjacent 
to the infusion and stimulation sites (Figure 30; and Figure 38(f)). Local 
anaesthetic spray was not used to avoid contamination of the proximal 
oesophagus, which in turn may have affected the sensory 
measurements, but passage was eased through the naso-pharynx with a 
water-based lubricant jelly (KY jelly™, Johnson & Johnson).  
 
To ensure correct placement, a ‘Flush through-test’ was performed, 
whereby 10ml sterile water was injected via the infusion port into the 
oesophagus. The subject was then closely observed to ensure that the 
cough reflex was not triggered, and was asked to respond to a few 
questions to ensure that they could speak with unobstructed vocal 
chords. The reusable infusion-simulation catheter was sterilised (Pera 
safe™, Antec International- a DuPont company, Suffolk, UK) at the end 
of every experimental session. 
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Figure 30 The naso-oesophageal catheter assembly, consisting of a pH probe (blue 
label) and an infusion-stimulation catheter (green label) strapped together.  Illustrated 
is (a) the positioning in the oesophagus, (b) its schematic proportions, and (c) a 
photograph of the actual assembly.  
 
2.5 Oesophageal acid infusion 
Four 60ml disposable syringes were pre-loaded with 0.15M hydrochloric 
acid (HCl) (Stockport Pharmaceuticals, Stockport, UK) which was 
warmed to body temperature in a water bucket priority to the infusion 
and then infused via an infusion pump (Omni fuse™, Graseby Smiths 
Medical Inc. MN, USA; see Figure 38(i)) into the distal oesophagus, 4cm 
above the LOS, through the infusion port of the infusion-stimulation 
catheter at a constant rate of 8ml/min for 30 minutes (Figure 31) to a 
total infusion volume of 240mls. The proximal oesophagus remained acid- 
free (pH >4) while the distal oesophagus was exposed to acid (pH < 2).  
 
The$Catheter$Assembly:$
(a)$Placement$ (b)$Schema/cs$ (c)$Infusion$Func/on$
(c)$Photograph$
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2.6 Oesophageal pH monitoring 
A 1mm diameter twin channel pH catheter (VersaFlex® Sierra Scientific 
Instruments, LA, CA, USA; see Figure 30 and Figure 38(f)) continuously 
measured pH in the proximal and distal oesophagus (at the sites of acid 
infusion and electrical stimulation respectively) for the duration of each 
study. Recordings were made using a twin channel pH box (Synectics 
Medical™, Enfield, Middlesex, EN1 3BT, UK; see Figure 38(l)). 
 
2.7 Visceral Pain Hypersensitivity Model 
Sarkar et al. (175) have developed a robust healthy volunteer model of 
human oesophageal sensitisation as illustrated by Figure 31. In this model, 
to explore mechanisms of visceral hypersensitivity in the oesophagus, 
acid is infused in the distal oesophagus. Subsequent pain hypersensitivity 
to electrical stimulation has been demonstrated in the distal acid-
exposed region (primary hyperalgesia), the proximal non-acid-exposed 
oesophagus and the area of somatic referral on the anterior chest wall 
(secondary hyperalgesia). (175) Oesophageal pain hypersensitivity has 
been repeatedly shown to occur following acid infusion using this model 
in several studies. (184-190) A significant variability in developing this 
sensitisation has been recorded, with around 15-35% of healthy 
volunteers not being sensitive to acid infusion. (51) This model provides a 
validated reproducible basis for standardised comparative study into the 
underlining mechanisms and modulators of acid sensitisation; and as 
such, was ideally suited for use in this study.  
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Figure 31 The naso-oesophageal catheter assembly, illustrating with actual pH-metry 
that the distal pH drops during acid infusion while simultaneously maintaining an acid 
free environment 15cm proximal in the oesophagus in a fasting volunteer, where the 
pain tolerance threshold changes are measured.   
 
2.8 Sensory and Pain Threshold Measurements 
Sensory and pain thresholds to electrical stimulation were determined in 
the proximal oesophagus (18cm above the lower oesophageal 
sphincter), the distal oesophagus (3cm above the lower oesophageal 
sphincter), and foot (somatic control). Oesophageal sensory testing was 
performed via a pair of silver-silver chloride bipolar ring electrodes (inter-
electrode distance 1cm) sited proximal to the tip of a 3mm diameter 
catheter (UniTip™-Katheter 6F, UNISENSOR AG, Attikon, Switzerland). 
Stimulation consisted of electrical impulses of increasing strength 
delivered using a constant current stimulator (Digitimer™, model DS7A, 
Digitimer Ltd, Hertfordshire, England; see figure 30(j)). An established 
stimulation protocol was used based on previous studies. (53, 175, 191) 
The intensity of the stimulus was increased in a step-wise manner by 2mA 
15cm%
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(at 200V) intervals, beginning at an intensity of 0mA up to a maximum of 
98mA. Stimuli were delivered at a frequency of 0.5Hz (i.e. 
1pulse/2second), using square wave pulses 500µs8 in duration. At each 
site, three measurements of sensory and pain tolerance were recorded, 
60 seconds apart, and the mean value calculated (Figure 30).  
 
For each stimulus set, the sensory threshold at which the subject felt the 
sensation, as well as the pain tolerance, was recorded. Subjects were 
instructed that this should be the level beyond first pain sensation at 
which they could not tolerate further increase. Hence this is most 
accurately described as a pain “intolerance” threshold, i.e. that at which 
they become intolerant of pain, rather than a pain “tolerance” 
threshold, i.e. the last level at which they can still tolerate it. This level was 
equivalent to a rating of 7 on a Visual Analogue Scale (VAS) (192) (Figure 
32) ranging from 0 (no sensation) to 10 (unbearable pain). This scale 
shows a linear relationship with that of the pain descriptor and stimulus 
intensity. (193)  
 
Figure 32 The 11-point VAS for the quantification and measurement of the pain and 
unpleasantness. This was used after every sensory and pain threshold measurement.    
                       (Adapted from Drewes, 2003) (192) 
                                                      
8 For a more detailed description see appendix one (2).  
Visual'Analogy'Scale:'
'
0='no'percep5on'of'sensa5on'
1'='vague'percep5on'of'sensa5on'
2'='definite'percep5on'of'mild'sensa5on'
3'='vague'percep5on'of'moderate'sensa5on''
4'='definite'percep5on'of'moderate'percep5on'
5'='pain'detec5on'threshold''
6'='slight'pain''
7'='Moderate'pain'&'tolerance'threshold''
8'='medium'pain'intensity''
9'='intense'pain''
10'='unbearable'pain'
.'
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Electrical stimulation was immediately stopped when pain intolerance 
threshold was indicated. Control (somatic) pain thresholds were taken in 
an identical manner using a pair of disposable surface electrodes 
(Oxford Instruments, Medical Systems Division, Woking, Surrey, GU22 9JU, 
England; see Figure 38(e)) that were placed on the dorsum of the right 
foot 2cms above the 4th metatarsophalangeal joint. 
 
2.9 Pain Tolerance Threshold Calculation  
Using measurements taken in the proximal oesophagus at each time 
point, baseline, prior to acid infusion (T0), then 60 minutes (T60), 90 
minutes (T90) and 120 minutes (T120) post acid infusion, pain tolerance 
threshold (PT) was used to characterise subjects as either sensitisers or 
non-sensitisers. The change in PT (∆) was determined by calculating the 
mean of the three pain tolerance threshold measures at each post 
infusion time point (T60, T90 & T120) and then subtracting this value from 
the mean of the three pain threshold values, prior to acid infusion (T0). 
(185, 194) (Figure 33) 
 
The three values thus obtained were then averaged to obtain the PT. 
Subjects were classified as  sensitisers if there was a fall in the proximal 
oesophageal pain threshold (PT) of ≥ 6mA after distal oesophageal 
acidification during a non- modulation visit (i.e. screening- or sham 
breathing protocols only; see section 2.20), as compared with the pre-
infusion threshold. They were classified as non-sensitisers if the decrease 
of proximal oesophageal PT was < 6mA during a non-modulation visit. 
(185, 194) 
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Figure 33 This diagram shows the calculation of the ∆Pain Tolerance Threshold (PT). A 
represents the mean of the three-baseline pain threshold measures at T0. B, C & D 
represent the average at T60, T90 and T120. The difference between A-B is represented 
by a’ and A-C as b’ & A-D as c’. The PT therefore represents the mean of the values for 
a’+b’+c’.  
 
2.10 Cannula insertion and blood sample 
An 18 gauge (green) intravenous cannula was inserted into the right 
antecubital fossa prior to the nasogastric intubation, where appropriate 
(Figure 38(d)). This was used to administer the atropine or placebo, 5 
minutes prior to starting the acid infusion. The cannula was also used at 
the end of the study when a 5ml blood sample was obtained and frozen 
at -80°C. This sample was later used to prepare an assay for genomic 
DNA extraction and genotyping.  
 
2.11 Psychological assessment  
During the first visit, subjects completed a set of computer-administered 
profiling, state and trait questionnaires. (Figure 38(k)) For all subsequent 
T0       T60        T90    T120 
Pain%Tolerance%Threshold%(PT)%=!average(a’+%b’%+%c’);!
where:!a’!=!A(avr).B(avr);!b’%=!A(avr).C(avr);!c’%=!A(avr).D(avr)!!
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visits, only a state questionnaire was completed. The questionnaires 
included the:9 
 
2.11.1 Big Five Inventory (BFI)  
The 44-item questionnaire (195) allows efficient and flexible assessment of 
the 5 dimensions of personality, i.e. extraversion, agreeableness, 
conscientiousness, neuroticism and openness to experience. Essentially, 
the big five inventory is used to explore the broad factors of personality 
traits developed through factor analysis of a large population through 
empirical research. As previously demonstrated in preliminary studies, the 
personality of traits of extraversion and neuroticism have an association 
with autonomic nerves system (ANS) responses to visceral pain. (196, 197) 
 
2.11.2 The Weinberger Adjustment Inventory (WAI) 
This is a well-validated trait measure of repression of negative affect. It 
measures the way in which an individual reacts to conflict and stressful 
situations through three dimensions; distress (anxiety, depression, low self-
esteem, low well-being), restraint (suppression of aggression, impulse 
control, consideration of others and responsibility), and defensiveness 
(repressiveness, denial of distress). (198) 
 
2.11.3 Toronto Alexithymia Scale (TAS- 20)  
The TAS is a 20-item instrument that is one of the most commonly used 
measure of alexithymia. Alexithymia refers to people who have trouble 
identifying and describing emotions and who tend to minimise emotional 
experience and focus attention externally. Research using the TAS-20 
                                                      
9 For the questioners see appendix two. 
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demonstrates adequate levels of convergent and concurrent validity. 
(199) 
2.11.4 Hospital Anxiety and Depression Scale (HADS)  
The 14-item questionnaire was designed as a screening tool to detect 
depression and anxiety. It consists of 14 questions with seven related to 
anxiety and seven related to depression. It was originally designed for 
use in general hospital outpatients but has been extensively used and 
validated in primary care. (200) 
 
2.11.5 Spielberger State (SSAI) and Trait (STAI) anxiety 
Questionnaire 
The Spielberger state and trait anxiety questionnaire is a widely used self-
report questionnaire. As one may expect, the state questionnaire asks 
how the subject feels at the present moment, whereas the trait 
questionnaire enquires about long-term feelings of anxiety. Some 
authorities suggest that trait anxiety and neuroticism are mutually 
exclusive. (201) 
 
2.11.6 Vulnerable Attachment Style Questionnaire (VASQ) 
The Vulnerable Attachment Style Questionnaire was developed to 
provide a brief self-report research tool to assess adult attachment style 
in relation to depression and validated against an existing investigator-
based interview (Attachment Style Interview – ASI). (202) It is based on 
Attachment theory (119), which describes the dynamics of long-term 
relationships between humans. It explains how the parents' relationship 
with the child influences development and becomes the basis for later 
attachment behaviour known as the adult attachment style. 
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2.12 Measurement of the Autonomic Nervous System 
 
The role of the ANS in the pathophysiology of a number of disorders 
including cardiovascular mortality and chronic pain has only been 
recognised and fully appreciated in the last three decades. (203) Partly 
the problem has to do with the lack of suitably sophisticated technology 
to measure and study the ANS and its systemic impact. Using an inserted 
needle recording of the peroneal nerve the ANS function can be 
measured directly. Similarly the vagus nerve can be facilitated through 
subcutaneous pacemakers-like stimulators. These methods are 
unfortunately very invasive and impractical for experimental studies. The 
need has arisen to develop accurate indirect measures by which ANS 
function can be monitored. The most popular method has been the 
heart rate variability (HRV). In the following section is a critique of the 
theory underlying HRV, and a description of more novel non-invasive, 
beat-to-beat measures of autonomic tone used in this thesis. 
 
2.12.1 Heart Rate Variability (HRV) 
Early studies related HRV to physiological mechanisms, and only a few 
historical studies highlighted the emergence of HRV as a physiologically 
meaningful measure. An example of this is Wundt (204), who used HRV to 
study repertory sinus arrhythmia (RSA). As interest in HRV increased, it was 
used both as an individual difference variable in obstetrics, paediatrics, 
developmental psychology, psychiatry, and health psychology and as a 
response variable in ergonomics, human factors engineering, and 
cognitive sciences. 
 
Almost all the studies investigating HRV have occurred during the past 40 
years. Clinical interpretations and applications have an even shorter 
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history. The linking and integration of central nervous system structures to 
autonomic functions, as seen in theories like the Polyvagal Theory (100, 
108), have only emerged during the past few decades. (91, 93, 98, 205-
207) Presently a non-physiological “operational” model still dominates 
the literature and still influences how HRV is quantified and interpreted in 
the literature. For example, various strategies to quantify RSA have 
focused on phenomenological features (e.g. relation to respiration) and 
not on neurophysiological (e.g. medullary interneurons, neuropeptides, 
neurotransmitters) or neuroanatomical features (e.g. source nuclei of 
vagal efferent pathways). In 1965 Hon at al. (208) demonstrated that 
foetal distress was predicted by alterations in the inter-beat intervals 
between successive R waves in the electrocardiograph (ECG), before 
detecting any changes in the heart rate (HR). This highlighted the direct 
clinical relevance of HRV for the first time, and since then the majority of 
research in autonomic nervous system has preferred using the HRV rather 
than the crude HR. HRV analysis has mostly been done by means of two 
methods; the time domain analysis and the frequency domain analysis 
with its emphasis on the power spectrum density (PSD). 
 
2.12.2 Time Domain Analysis 
In a continuous ECG recording, the interval between consecutive normal 
QRS complexes on the ECG is known as the normal-to-normal (NN) 
interval. Two statistical classes are derived from the normal-to-normal 
interval. The first class uses direct measurement of the NN intervals, while 
the second focuses on the differences between the NN intervals. The 
simplest variable is the SDNN (standard deviation of normal-to-normal RR 
intervals). (209) This value reflects the variability of the cyclic components 
in an ECG recording. Other commonly used measures are detailed in 
Table 1. This method’s major disadvantage is its statistical power 
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limitations, as it only allows for short-term recordings (less than five 
minutes) to be evaluated. (118, 210) 
 
Table 1 Commonly used domain analysis variables. (From Farmer, 2010) (211) 
 
 
2.12.3 Spectral Domain Analysis 
The sympathetic and parasympathetic components of the autonomic 
nervous system oscillate at different frequencies, and hence can be 
distinguished by means of the quantitative breakdown (power) of the 
different frequencies influencing the HRV. This is known as the power 
spectral density (PSD) and has become one of the preferred methods of 
analysing the autonomic nervous system to date. (212) When 
considering short-term recordings claimed in resting conditions (3 to 5 
minutes) the PSD is subdivided into three main frequency bands: high-
frequency (HF: 0.15-0.4Hz), low-frequency (LF: 0.08-0.14Hz) and very low 
frequency (VLF: 0.003-0.07Hz). (Figure 34) Some researchers also 
distinguish a fourth band known as the ultralow frequency (ULF: 
<0.003Hz). These rhythms can be divided further and are considered to 
reflect as demonstrated in Figure 34, below. (210, 212, 213) 
 
Variable!
(units)!! !!Description! Physiological Relevance!!
SDNN!
(ms)!!
!!
Standard deviation of the normal RR (NN)!
interval! reflecting! all! of! the! cyclic!
components! responsible! for! variability! in!
the period of recording.!!
!!
An! overall! estimate! of! HRV,! but!
does not indicate the contribution!
of any particular influence.!
SDANN!
(ms)!! !!Standard deviation of the averages of NN!intervals calculated over a short period of!time, usually less than five minutes.!!
!!
Reflects! the! influence! of! circadian!
rhythms on autonomic function.!
pNN50!
(%)!! !!The! proportion! of! NN! intervals! having!a!difference of >50mSec.!! !!Reflects! predominant! vagal!influence on variability.!
Triangular!
Index!
(ms)!!
!!
The integration of the density distribution!
of all the NN intervals as a function of the!
maximum density.!!
!!
Overall estimate of HRV similar to!
SDNN.!
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The term cardiac vagal control (CVC) refers to the vagal output to the 
heart and it is thought to correlate with respiratory sinus arrhythmia (RSA) 
that is represented by the HF band. A further interesting phenomenon of 
this is that when the respiratory rate is between 10 to 12 breaths per 
minute (0.16-0.2Hz), the RSA assumes semi-stationarity. Due to this 
phenomenon, experimenters need the co- operation of the subject, in 
controlling their breathing rate when recording for normal physiological 
analyses. When the respiratory rate reaches about 6 breaths per minute 
by means of ‘paced breathing’ techniques, it can be observed within 
the HF band (±0.1Hz) and is referred to by some authors as achieving 
‘resonance’, and maximises the CVC. (213) A central methodological 
criticism of this measure of CVC was highlighted by Denver, who 
commented that, “…techniques such as paced breathing artificially 
elevate the CVC making its measurements unreliable…” and is hence 
ambiguous with regard to normal physiological analyses. (208) Of note is 
that this also creates the ideal opportunity to stimulate the CVC and 
increase parasympathetic tone when breathing at a similar frequency of 
0.1Hz (i.e. 6 breaths per minute). (213) (See section 2.20.3, page 114) 
 
A further complicating factor in using the PSD is that the physiological 
mechanisms responsible for the modulation of LF and HF components 
cannot be considered to be stationary for long HRV recordings, in 
particular those over 24 hours, due to the aforementioned difficulties 
associated with ‘stationarity-assumptions’. Problems are not confined to 
respiratory frequency only, for example in the literature, spectral analyses 
recordings taken over such periods of time are often reported in a single 
time block, i.e. the whole 24-hour period, or in shorter segments, usually 
five minutes, with the results averaged over the whole time period. (212) 
Hence, spectral analyses performed in either of these periods provide 
averages of the modulations attributable to the LF and HF components, 
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but such averages obscure detail regarding specific autonomic 
modulation. 
 
 
Figure 34 Power Spectrum Density (PSD) frequency bands, with physiological 
correlations. Below is illustrated a 3D-PSD (change over time, z-axis) of a healthy young 
subject during supine rest. (213)       (Adapted from McCarty, 2009) (210, 213) 
 
Finally, spectral analysis provides a representation of modulatory 
influences rather than autonomic tone as such (see beat-to-beat 
measure in section 2.12.5), as it provides a degree of the autonomic 
modulation of HRV by its different components, rather than the level of 
autonomic tone per se. 
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2.12.4 LF:HF – The Sympathovagal Balance Controversy 
Many studies in the literature derive a measure of sympathovagal 
balance, through the examination of the ratio between LF and HF. This 
method is potentially unclear, due to the assumption of two factors: (i) 
that LF and HF purely represent the sympathetic and parasympathetic 
modulation of HRV, and (ii) that there is direct reciprocity between LF 
and HF. (203) 
 
 
Figure 35 This diagram illustrates the methodological short-comings of using the LF:HF 
ratio as sole measure of sympathovagal balance in HRF analysis.                 
                  (Adapted from McCarty, 2009) (213) 
 
For a number of reasons these assumptions are not totally scientifically 
sound. Eckberg and colleagues demonstrated that blocking the vagal 
component of the LF with atropine had little effect on LF, whereas the 
converse was evident with sympathetic blockade. (214) There is thus a 
greater parasympathetic influence in the LF in comparison to the 
sympathetic nervous system. (Figure 35) Based on similar findings, Porges 
et al. suggested that HF might reflect CVC from the nucleus ambiguous 
…but%it%remains%a%mixed%measure,%where%LF%has%both%
PNS%&%SNS%components.%
The%LF:HF%ra=on%is%a%commonly%used%measure%of%sympathovagal%balance…%
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(NA), whereas the LF may reflect CVC from the dorsal motor nucleus 
(DMNX). (215) Porges designed a moving polynomial filter in an attempt 
to redress these methodological issues. (216) It entails a complex 
statistical method that utilises a time domain approach (moving 
averages) and smoothing filters to evaluate dynamically the rhythmic 
oscillations of the varying RR frequencies.  
 
In spite of Porges’ technique having the added value of pre-existing sex 
and age normal values for humans, the filter is not easily practically 
applied. This technique’s temporal resolution is poor beyond one minute 
for LF and two minutes for HF. To be exact, it has been recommended 
that this method of analysis is not used for more than two minutes’ worth 
of data. Despite these drawbacks, the LF:HF ratio of the sympathovagal 
balance remains a commonly utilised method of measurement in 
autonomic neuroscience research. 
 
2.12.5 Overcoming ANS Measurement Difficulties 
In order to overcome the aforementioned difficulties beat-to-beat 
measures were developed, as they represent direct measures of 
autonomic tone, irrespective of time frame or assumptions of respiratory 
stationarity. Examples of beat-to-beat measures are cardiac vagal tone 
(CVT) and cardiac sensitivity to the baroreflex (CSB). 
 
2.12.6 Measuring Cardiac Vagal Tone (CVT) 
The measure of parasympathetic stimulation to the heart via the vagus 
nerve is known as CVT. The momentarily blood pressure (BP) increase 
during ventricular systole causes baroreceptor activation in the carotid 
sinus and pulmonary circulation to increase their rate of discharge. (217) 
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In turn, via medullary neurones in the nucleus of the solitary tract (NTS), a 
vago-vagal reflex is initiated, which then stimulates vagal preganglionic 
neurones to increase firing. This increased cardiac vagal activity causes 
a reduction in the rate of spontaneous depolarisation of the sino atrial 
node, and widens the RR interval and decreasing HR. As the vagal 
response to baroreceptor stimulation in humans takes about 240ms, it is 
fast enough to delay the subsequent systole, resulting in beat-to-beat 
changes, known as heart rate variability (HRV). (218) (Figure 44) (This 
physiology underpins the clinically used measure of carotid sinus 
massage as a “vagal manoeuvre” in the treatment of supra-ventricular 
tachycardia.) Thus, even though the SNS influences the HR, for example 
through changes in peripheral vascular resistance which takes place 
more slowly, it is possible to deduce vagal tone in a non-invasive manner 
by measuring of the beat-to-beat changes in RR intervals. 
 
Based on these principles, the NeuroScope™ (MediFit Diagnostics Ltd, 
London; see Figure 38(a)), is a novel piece of technology that analyses 
the RR interval to produce the real time index of parasympathetic 
activity known as CVT. (219) A standard 3 lead ECG is recorded and the 
Neuroscope samples this ECG waveform at 5kHz. The acquired QRS 
complexes are then compared to a QRS template generated from the 
initial stages of the recording. If there is sufficient similarity between the 
recorded complex and template, a 1mV pulse is generated by voltage 
oscillators. Thus, the time between 1mV pulses is equivalent to the RR 
interval on the ECG. The Neuroscope circuit sends this pattern of 1mV 
pulses into two circuit limbs known as the high pass limb and the low pass 
limb. The high pass limb tracks the incoming signal without transforming it, 
whereas the low pass limb produces a damped version of the signal. 
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The lower the rate of HRV, the slower the rate of change of the incoming 
signal, and the closer the output match between the high and low pass 
limbs, and the lower the CVT. Conversely, the higher the HRV, i.e. the 
faster the rate of change of the incoming signal, the more damped the 
low pass circuit output is in comparison to the high pass limb, resulting in 
a higher CVT reading (Figure 36). This process has been termed phase 
shift demodulation. 
  
 
Figure 36 The beat-to-beat measure of cardiac vagal tone (CVT) as measured by the 
Neuroscope, using voltage oscillators with high (non-damped) and low (damped) 
circuit limbs. CVT variability is calculated on a linear scale (Lvs).                     
        (Adapted from Farmer, 2010) (211) 
 
This methodology of measuring CVT has been validated in humans and 
animals. (10) CVT is measured on an experimentally derived linear vagal 
1mV$signal$passed$into$2$circuits$
High$Pass$Limb$
Non:damped$
Low$Pass$Limb$
Damped$
Non:damped$and$Damped$signals$compared$
Low$variability$
(High$HR)$
Low$Cardiac$Vagal$Tone$
High$variability$
(Low$HR)$
High$Cardiac$Vagal$Tone$
QRS$complexes$compared$by$NeuroScope$
ECG$sampled$at$5KHz$ QRS$template$established$at$the$baseline$of$the$recording$
If$QRS$complexes$are$similar$a$1mV$signal$is$
generated$by$voltage$oscillators$
CV
T$
(lv
s)
$
Subject(
Baseline(
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104 
 
scale (Lvs). Zero on the Lvs was derived from six fully atropinised healthy 
volunteers, and 10 units on the Lvs established in the same volunteers in 
the supine position in the fasting state (i.e. maximal vagal activity). (219) 
Thus, CVT can be considered a validated marker of efferent 
parasympathetic tone from the brainstem on the heart. 
 
2.12.7 Cardiac Sensitivity to the Baroreflex 
In addition to the derivation of CVT, the Neuroscope also measures CSB, 
a validated, non-invasive beat-to-beat measure of parasympathetic 
afferent activity. Incorporated in the Neuroscope system is a non-
invasive continuous BP measurement using the Portapress™ system 
(Finapress®, Amsterdam, Netherlands). From this, the Neuroscope uses 
the raw Nexfin® waveform to calculate the arithmetic mean of the 
blood pressure (MBP), as opposed to the mean arterial blood pressure 
(MAP) that is commonly used in the clinical setting (MAP = DBP + 1/3(SBP 
– DBP); where DBP & SBP is diastolic and systolic BP respectively). The MBP 
that is calculated by the Neuroscope is the true arithmetic mean of the 
BP, i.e. DBP, dicrotic notch and the SBP. By integrating the RR interval 
data with the BP data, the change in pulse interval per unit change in 
SBP over a 10-second period can be calculated; this is termed CSB, 
which is expressed as a ratio of mmHg/ RR interval (ms/mmHg). (219) 
 
From section 2.12, it is clear that the Neuroscope allows the beat-to-beat 
measures of both the efferent and afferent limbs of the parasympathetic 
tone on the heart, without the methodological difficulties that are 
associated with spectral analysis of HRV. 
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2.13 Selective Sympathetic Measures 
2.13.1 Vasomotor – arithmetic Mean of the Blood Pressure (MBP) 
Mean arterial pressure (MAP) has been shown to correlate with invasively 
recorded sympathetic activity, as assessed by photo-plesythymography. 
(220) Photo-plesythymography records MAP on a beat-to-beat basis and 
has been validated against invasive arterial pressure measurements in 
humans. (221) However, it must be noted that if the cuff is applied to a 
subject’s finger for a considerable period of time, a degree of 
vasoconstriction can ensue. Selecting the correct size cuff is of utmost 
importance, as selecting the wrong size can result in large fluctuations in 
BP readings. The BP cuff was placed on the subject’s left middle finger in 
this series of experiments. The analogue readings from the Nexfin® were 
transmitted to the Neuroscope, where they were digitised and 
integrated into the beat-to-beat data, as discussed. Blood pressure was 
measured continuously with a Finometermodel 2, Finapress® Medical 
Systems™, finger cuff and a Portapress™ non-invasive blood pressure 
monitor (Finapress™ Medical Systems, Amsterdam ZO, The Netherlands 
(Figure 38(g)). 
 
2.13.2 Sudomotor – Skin Conductance Response (SCR) 
The sudomotor, or skin conductance response (SCR), (222) measurement 
has been used for more than 100 years, and is a measure of selective 
central sympathetic control over sweat gland activity. It can be defined 
as the 
 “…momentary change of the electrical potential of the skin, [it] 
may be spontaneous or reflexively evoked by a variety of internal 
or by externally applied arousal stimuli.” (223)  
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This simple electro- physiological measure assesses sympathetic 
cholinergic sudomotor function, and represents a transient change in the 
electrical resistance of the skin that is associated with sweat gland 
activity elicited by a stimulus that evokes an arousal or orienting 
response. Although human neuroanatomical efferent sweat pathways 
have not been fully determined yet, animal studies have shown that 
efferent sweat fibres originate in the hypothalamic preoptic sweat 
centre and descend through the ipsilateral brainstem and medulla to 
synapse with the intermediolateral cell column neurons. Unmyelinated 
postganglionic sympathetic class C fibres arise from the sympathetic 
ganglia to join the major peripheral nerves and reach the sweat glands. 
(223) There are two interacting types of sweat response, namely thermal 
and emotional. Emotional (mental) sweating control has multiple 
interactions, with emotional, cognitive and neuroendocrine functions, 
and is controlled at multiple levels within the CNS, mainly at the ACC. 
 
There are two main methods of SCR acquisition, firstly to measure 
spontaneous impedance changes across digits (often referred to as 
galvanic skin responses or “GSR”), or secondly to pass a small, constant 
current across the digit and record impedance changes as it crosses the 
digit (usually called the SCR) – with the latter felt to be more reliable. 
(222) The Powerlab™  (AdInstruments, UK) biosignals acquisition (Figure 
38(b)&(c)) system can digitally record SCR, which were recorded at 
baseline and during acid infusion. The SCR electrodes were placed on 
the subject’s left index and ring finger in this series of experiments. (Figure 
38(h))(224) SCR is measured in micro-Siemens (mS), and is a measure of 
pure sympathetic sudomotor activity. (Figure 37) 
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Figure 37 A typical SCR tracing. The black vertically dashed lines represent the 
application of a noxious stimulus, and the red line represents the SCR trace.      
       (Adapted from Farmer, 2010) (211) 
 
2.14 Summery of Autonomic Measures and Recordings 
The Neuroscope was used to make all ANS recordings during the set of 
experiments described in this thesis, and CVT and CSB were taken as the 
main measures of parasympathetic activity in subjects. (225, 226) This 
facilitated the study of both temporal and causal relationships of 
brainstem responses to external stimuli, as mentioned above. The CVT is 
measured and quantified in units of a linear vagal scale (Lvs) (219), 
whereas CSB is defined as the increase in pulse interval per unit increase 
in systolic blood pressure and is expressed as R-R interval (ms/mmHg). The 
full complement of autonomic measures used in this series of studies 
covers mixed measures (HR), parasympathetic efferent tone from the 
brainstem (CVT), parasympathetic afferent tone (CSB), sympathetic 
vasomotor (MBP) and sympathetic sudomotor (SCR). 
 
During experimental recordings, participants were instructed to remain 
strictly motionless and quiet while seated in a fully supported 80° upright 
examination couch (not illustrated in Figure 38 below) to minimise 
artefacts on autonomic recordings. The first five-minute pre-intervention 
baseline recording was acquired before intubation or cannula insertion, 
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and was used for inter-group comparisons. After intubation and a 10-
minute rest period a second five-minute baseline recording was 
acquired and used to compare with a 30-minute recording performed 
during the infusion period. Figure 38 (below), demonstrates the 
equipment and their attachment layout. 
 
 
Figure 38 This photograph depicts an assistant demonstrating the equipment and its 
experimental attachment. The equipment is as follows: [a] NeuroScope™, [b] 
Powerlab™, [c] Laptop for Powerlab™ data acquisition, [d] Cannula in right antecubital 
fossa, [e] Foot electrodes, [f] Catheter assembly passed trans-nasally, [g] Finapress® 
blood pressure monitor, [h] skin conductance response electrodes, [i] Omni fuse™ 
infusion pump, [j] Digitimer™ electrical stimulator, [k] Computer-administered 
questionnaires, [l] Synectics Medical™ continuous pH recording device.                 
(Photo courtesy of Abhi Sharma.) 
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2.15 Electrocardiograph (ECG) 
 Skin was firstly prepared by light excoriation (Nuprep® gel; Weaver and 
Co, Aurora Co, USA) to reduce impedance, electrodes (Ambu® blue 
sensor-P, Ballerup, Denmark) were subsequently placed in 3 areas; below 
the lateral aspects of the right and left clavicles and the left mid-
clavicular line below the breast.  A modified Einthoven’s lead II 
electrocardiogram (ECG) was acquired at a rate of 2kHz using a 
commercial bio signals acquisition system (Powerlab™, AD instruments, 
Figure 38(a)) and monitored on the Neuroscope system. 
 
2.16 Respiratory Monitoring 
Respiration via a transducer (Braebon™ smart belt) placed around the 
lower chest recorded the in-line lung filling and chest inflation of the 
subject in real-time and was monitored on the Neuroscope system.  
 
2.17 Study Procedure and Design 
The specific study designs will be discussed in each chapter dealing with 
those results. What will be covered here is the experimental design and 
procedures, which were common to all studies performed. The five 
studies were performed over three years in three different locations in 
Denmark and the UK (Figure 39): 
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Figure 39 The time schedule of the five studies and there geographical locations. 
 
 
 
In order to conduct the experiment efficiently, three assistants were 
required (Figure 40):  
• The first assistant performed the administration of the acid infusion; 
pH observations, electrical pain stimulation and recorded pain 
threshold response in each subject, and were blinded to all other 
data during the experiment. 
• The second assistant was responsible for the ANS and skin 
conductance response (SCR) reading and recordings, as well as 
supervising the specific psychophysiological interventions, and was 
blinded to all other data during the experiment.  
• ANS data analysis was conducted by the third person (analyser) 
who was not involved in the experiment, except for the 
administration of intravenous (IV) atropine or placebo. The third 
!Year! !!!!!!!!!!!!!!!!!!!!2010! !! !!!!!!!!!!!!!!!!!!!!2011! !! !!!!!!!!!!!!!!!!!!!!2012! !!
!Quarter! 1! 2! 3! 4! 1! 2! 3! 4! 1! 2! 3! 4!
!! !! !! !! !! !! !! !! !! !! !! !! !!
1.!Modula3on!Pilot!Study! !! !! !!
2.!Breathing!&!3.Stress>!Studies! !! !! !!
4.!Atropine!Study! !! !! !!
5.!GCH>1!Gene3c!Comparison!Study!
! !! !! !!
Study!Time!Schedule!&!Loca3ons:!!
Wingate!Ins3tute,!London!UK!
Aalborg!Hospital,!Aalborg,!Denmark!
Chapterhouse!Square,!London!UK!
Study!1!
Study!2!&!3!
Study!4!
Study!5!
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assistant was blinded to the subject experimental and sensitisation 
status. 
• Subjects were blinded to all data during the experiment and to 
their sensitisation status between studies. 
 
 
Figure 40 This photograph depicts the experimental setup, the healthy volunteer and the 
role of the three research assistants. 
 
The study design was a double blind, randomised, crossover, prospective 
study, as the same recruited subjects were followed up throughout the 
duration of each specific study. The cohorts formed their own controls on 
subsequent visits by means of the cross over design. For the atropine 
study (study 4), there was a placebo control. Subjects were required to 
complete two to three visits, depending on the type of study, their 
sensitisation status and randomisation. For the pilot (study 1) and the 
The$Study$Procedure:$
First$Assistant:$
Acid%infusion,%pH%&%PT%
measurements%%
Healthy(Volunteer(
Second$Assistant:$
ANS%and%SCR%recordings%&%
Psychophysiological%
interven?ons%%
Third$Assistant:$
Administra?on%of%Atropine%
or%placebo%&%data%analysis.%%
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atropine (study 4) studies, the subjects first completed a screening visit, 
before being randomised. During the ‘Breathing & Stress’ study (studies 2 
and 3), both sham (normal) and deep breathing protocols were 
randomly allocated directly after recruitment, and the non-sensitises 
(study 3) identified during the sham-breathing visit. All the subjects’ 
subsequent crossover visits were undertaken a minimum of two weeks 
after the preceding visit. The studies therefore produced "paired data 
sets" in the majority of cases. To randomise the subjects without bias, 
approved statistical software was used (www.randomisation.com) in 
advance, and subjects were randomised in a "2 x 5 - block 
randomisation" pattern. 
 
2.18 Experimental Design & Protocol 
Subjects were asked to fast from midnight prior to the experiment. All 
experiments were started at 9 AM in the morning to compensate for, and 
rule out, HPA-axis diurnal variation fluctuations. There was no external 
interference during the duration of the experiment.  
 
On the day urine pregnancy test and general health screening 
questionnaires and checks were completed prior to starting the 
experiment. This was to confirm that all inclusion and exclusion criteria 
were met. The same experimental design was used on all visits, with only 
the type of psychophysiological modulation altering (see Figure 41).  
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* IV atropine or placebo – study 4 
 
 
Figure 41 Detailed Time and Events (a) Diagram and (b) Table, showing the stages and 
approximate time durations in minutes of each part of the experimental protocol. The 
timing of the procedures is shown above the time line, and that of the measurements 
below. T0, illustrates the PT at baseline (i.e. pre acid infusion); T60, T90 & T120, illustrates 
the PT at 60, 90 & 120 minutes post acid infusion cessation, respectively.   
 
Studies were performed in healthy volunteers, as described in section 2.2, 
who contacted our department in response to a posted advertisement. 
Full informed consent was obtained. Subjects with any history of current 
or chronic gastrointestinal, neurological or psychiatric medical problems 
or taking any medication affecting GI, pain or neuropsychological 
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function were excluded. Subjects then completed a set of 
questionnaires answered directly on a computer specifically provided for 
this purpose. In female subjects experimental visits were arranged to 
coincide with the follicular phase of their menstrual cycle. Where this was 
not possible, visits were scheduled so that subsequent visits occurred 
during the same phase of their cycle as their initial visit.  
 
All studies were performed in a sound and temperature controlled 
laboratory. Temperature of the room was adjusted between 21-25 
degrees Celsius according to the subject’s preference. The subject was 
sitting upright in a comfortable couch throughout the study at an 80° 
angle with their head fully supported.  Patients were then attached to 
ECG electrodes to monitor autonomic parameters, blood pressure and a 
breathing belt. When a baseline recording of 5-minutes was completed, 
the nasogastric catheter assembly was placed into the oesophagus. 
After a further period of rest, a second "post intubation" baseline 
recording of 5-minutes was acquired. Where necessary, the intravenous 
cannula would now be placed. 
 
The subject’s baseline pain tolerance thresholds were then recorded for 
the proximal oesophagus, distal oesophagus and foot. Subjects were 
then connected to a syringe driver, which delivered the hydrochloric 
acid over a 30-minute period into the distal oesophagus. Subjects were 
asked to rate their subjective pain and unpleasantness on an 11 point 
visual analogue scale after completing the acid exposure. (Figure 32) 
 
Depending on the study type and random allocation, during the acid 
exposure each subject was asked to complete or was coached through 
a psychophysiological modulation protocol, for the duration of the acid 
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exposure phase. This could include: 1. Normal screening protocol, 2. 
Sham breathing protocol, 3. Deep breathing protocol, 4. Deep breathing 
protocol with atropine or placebo 5. Isometric “hand-grip” test protocol, 
and 6. A “dichotomous listening” stress test protocol (see section 2.20). 
Then followed a 30-minute-rest period, after which pain thresholds were 
once again recorded at 60, 90 and 120 min after the start of the acid 
infusion. The last procedure was to obtain a 5ml blood sample for 
genetic analysis (study 5), which was immediately labelled and frozen 
down. 
 
2.19 Use of Psychophysiological Modulation 
 
In the following section is an explanation of the neurobiology and 
underling theory of the psychophysiological modulations used in this 
thesis: 
 
2.19.1 Physiological role of Respiratory Sinus Arrhythmia 
Respiratory Sinus Arrhythmia (RSA) is an intrinsic resting function of the 
cardiopulmonary system. It is an active physiological function that has its 
own biological roles. By matching alveolar ventilation and capillary 
perfusion (V/Q matching, see figure 42) throughout the respiration cycle 
RSA improves respiratory gas exchange efficiency. With increase in 
alveolar ventilation during inspiration (V), there is an increase in capillary 
perfusion (Q) due to a SNS mediated increased HR in order to facilitate 
blood-gas transport. This is better understood when contrasted with the 
inverse effect of RSA, which gives rise to alveolar dead space (wasted 
ventilation) and increased intrapulmonary shunt (ineffective perfusion). 
Hence during expiration the PNS outflow-mediated drop in HR facilitates 
alveolar gas exchange. This function of RSA is useful as it saves cardiac 
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and respiratory energy in resting animals and humans. (227) In mammals, 
the effectiveness of certain cardiac reflexes is markedly modified by 
respiration. Reductions in heart rate are evoked by brief stimuli applied to 
the arterial baro- and chemoreceptors (Figure 44), but only if they are 
applied during expiration. (228) Stimuli given during inspiration are less 
effective or totally ineffective, as this will only enhance the “dead space 
or shunt” phenomena (Inverse RSA). It can be predicted that any 
cardiac reflex would be modulated by respiration, since the 
preganglionic neurons themselves are under respiratory control, which is 
mediated by these neurons. In contrast, stimulation of receptors in the 
airways and cardiac C-fiber receptors all evoke reflex excitation of 
cardiac vagal outflow, potentially resulting in a bradycardia, which is 
modified by respiratory drive and is evident as RSA.  
 
 
Figure 42 Schema showing the effects of RSA and its inversion (inverse RSA) on the 
relationship between alveolar gas volume and capillary blood flow during inspiration 
and expiration. Horizontal bows and vertical arrows indicate the volume of blood flow 
and the direction of gas flow, respectively. RSA improves respiratory gas exchange 
efficiency by matching alveolar ventilation and capillary perfusion throughout the 
respiratory cycle, while inverse RSA results in increased alveolar dead space (wasted 
ventilation) and increased intrapulmonary shunt.     (Adapted from Hayano, 2003)  (227) 
 
Even though evidence indicates that RSA magnitude and cardiac vagal 
tone seems to be regulated separately, RSA’s HF component of HRV is 
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ubiquitously used as an index of cardiac vagal function, and is 
intrinsically physiologically connected. (229) 
 
2.19.2 RSA as a component of HRV 
Short-term HRV measured as beat-to-beat variation of RR interval shows 
unique behaviours in response to stress and diseases. Most physiological 
parameters are kept constant around their own set points in the 
absence of external or internal turbulence/stressors. Hence states in 
which such constancy is lost could arguably be considered as indicative 
of disorders. Following this concept, RR interval is expected to be stable 
at rest (health) and to become unstable under distress (disease). 
However, the reverse is clinically observed. In Figure 43, RSA fluctuations 
of RR interval is most variable in healthy subjects at rest, and it reduces 
with mental and physical stresses, and is almost non-existent in patients 
with severe heart failure even at rest. This indicates that increased 
fluctuation of RR interval is a characteristic of health and is suppressed in 
distress and diseases. (227, 230, 231) 
 
  
 
 
118 
 
 
Figure 43 Trendgrams showing fluctuation of beat-to-beat RR interval in various 
conditions. (A) RR intervals were measured from 2-min ECG in healthy young subjects 
during supine rest, (B) mental arithmetic stress testing, (C) and ergometer exercise 
testing and (D) in a patient with severe congestive heart failure at rest.     
                      (Adapted from Hayano, 2003) (227) 
 
In short-term HRV such as those shown in Figure 43, RSA is the most 
prominent and consistent component. RSA is an oscillation of heart 
period in synchrony with respiration, which appears in power spectrum of 
RR interval as a peak within the so-called HF band (0.15–0.45 Hz, Figure 
34) or, more appropriately, as a peak at respiratory frequency. Due to 
the difference in frequency characteristics of signal transfer between 
sympathetic and vagal modulation of heart rate, it is believed that the 
NA branch of the vagus solely mediates RSA. (232) RSA has been 
proposed and widely used as a quantitative index of cardiac vagal 
function, because the magnitude of RSA is attenuated with progressive 
suppression of cardiac vagal activity and abolished by complete vagal 
blockage with atropine. (212, 233-235) This is now controversial since 
improved understanding brought by theories of the divergent influences 
of different parts of the vagus nerve. (70) 
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2.19.3 RSA and Cardiorespiratory Control 
Historically, the first references to RSA were made in the beginning of the 
1900s. Wundt (204) stated that "...respiratory movements are therefore 
regularly accompanied by fluctuations of the pulse, whose rapidity 
increases in inspiration and decreases in expiration." H.E. Hering (236) 
observed as early as 1910 that a functional relationship exists between 
the amplitude of RSA and the concept of vagal tone. He reported that, 
“…breathing provides a functional test of vagal control of the heart.” He 
when on to say "…it is known with breathing that a demonstrable 
lowering of heart rate ... is indicative of the function of the vagi."  
 
Presently it remains that central control of the cardiorespiratory system is 
complex and interactive. It is modulated by afferent inputs from areas in 
the mid- and forebrain such as the hypothalamus, amygdala and cortex, 
and is operated by means of a direct feed-forward control from the 
brainstem. (237) Emotional states and several routine behavioural 
responses like, for instance “the orientation” and “fight or flight” 
responses, causing marked variation in the HR. The amygdala receives 
projections from several nuclei involved in cardiovascular control that 
includes the hypothalamus, parabrachial nuclei, nucleus of the solitary 
tract (NTS), and dorsal motor column of the vagus. (238) The infralimbic 
and insular cortices are also linked and influence control. Consequently, 
it is a critical site for cardiovascular control and has the role of integrating 
the autonomic responses to emotional stimuli like fear, anger and stress. 
(237)  
 
In the control of the ANS function the hypothalamus is a further key area, 
since it integrates information from somatic motor areas, emotional state 
and also humeral efferent activity. (238) It has connections to both 
sympathetic and parasympathetic control, as the hypothalamic nuclei 
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connects directly with the ventrolateral areas in the brainstem and the 
intermediolateral neurons of the cervical and thoracic medulla. (237) As 
a result of these rich midbrain and brainstem neuronal connections, 
cardiorespiratory control overlaps and is also intrinsic to the 
neurophysiological control, which mediates between emotional and 
physical states. This overlap forms the anatomical and physiological basis 
for a two-way regulation, where cardiorespiratory changes can 
influence emotional and autonomic states, and vice versa.  
 
A physiological example of this is the observation that heart rate 
decreases during expiration. This occurs because HR is generated 
centrally by an inhibitory input from inspiratory neurons in the respiratory 
group projecting to the caudal ventral-posterior nucleus (CVPN) outside 
of the dorsal ventral nucleus (DVN) in the ventrolateral nucleus 
ambiguous (NA). (229)(Figure 44) As respiration-related fluctuations in the 
efferent pathway drives the inhibitory supply to the heart via the cardiac 
vagus, respiration is hence a physiological means of regulating RSA, and 
through its neurological connections gives a clear physiological window 
into modulating vagal outflow as reflected in the changes seen in PSD 
analysis. As such respiratory control effects cardio-autonomic regulation 
and has a psychophysiological effect, which proposes a mechanism for 
arbitrary modulation in laboratory conditions. 
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Figure 44 Diagram illustrating the pathways relating the interaction of cardiac and 
respiratory reflexes instrumental in producing RSA changes (illustrated by the red 
arrows). On expiration there is a lengthening in the RR interval, as seen on the ECG, due 
to reflexive vagal (CVT) inhibition.           (Adapted from Daly, 1997)  (228) 
 
Applying this practically, it is observed that during isometric exercise and 
psychological stress, there is an increase in heart rate (and HRV) which is 
associated with an increase in the VLF frequency band, suggesting an 
increase in sympathetic dominance, compared to the baseline of 
healthy young subjects during supine rest. (Figure 45, upper red arrow) 
On the other hand during paced deep breathing the HR indicates 
exaggeration of RSA as observed in the HR trendgram and an increase 
in the 0.10Hz frequency band (HF) suggestive of parasympathetic 
dominance. (Figure 45, lower green arrow)(227, 235, 239) This supplies 
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strong neurophysiological support and justifies the use of these specific 
psychophysiological states as modulators that can be used to increase 
and decrease brainstem autonomic outflow. 
 
 
Figure 45 This diagram illustrates the effect of three different psychophysiological 
modulated states (column on the right) as compared with regards to Heart Rate (HR) 
Trendgrams (column on the left) and Heart Rate Variability Power Spectrum Density 
(PSD) (centre column): Isometric exercise and psychological stress (top row) has a 
gradual increase in HR and a VLF peak on PSD, suggestive of sympathetic dominance. 
Baseline supine rest in young healthy volunteers (middle row) has a responsive HR with 
RSA fluctuation. The PSD is balanced across VLF, LF & HF, suggestive of autonomic 
equilibrium. With paced deep breathing (bottom row), the HR trendgram indicates an 
exaggerated RSA pattern with HF peak on PSD. This would indicate an enhanced 
parasympathetic response.                                       (Adapted from McCarthy, 2009) (213) 
 
2.20 Psychophysiological Modulation Protocols 
As discussed in section 2.19.3, the vasomotor centre (VMC) located in 
the medulla is vital to the maintenance of the autonomic tone and its 
activity is modulated by a number of psychological and physiological 
stimuli. As was seen (Figure 45), psychological distress and physical 
exercise increases the sympathetic tone while reciprocally decreasing 
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the parasympathetic tone. This increases the heart rate, cardiac output 
and blood pressure. In contrast, forced deep inspiration and expiration 
exaggerates the normal RSA regulated by the parasympathetic output 
of the brainstem vasomotor centre leading to a slowing of the heart rate. 
These physiological alterations in the autonomic tone therefore provide 
an excellent opportunity to modulate the ANS selectively and observe its 
effect on oesophageal sensitisation to acid. Hence the 
psychophysiological modulations that were used in this thesis were:  
 
2.20.1 Screening visit protocol 
 
Figure 46 Diagram illustrating the psychophysiological modulation protocol for the 
screening visit. As this visit during study 1 was to serve as a baseline visit, no 
psychophysiological modulation was performed during the 30minitus acid infusion 
period (red bar). Autonomic measurement (brown bars) was done before and during 
the acid infusion. Pain thresholds (blue bars) were done before and three times after 
acid infusion. PH-metry (green bar) was started 20mins before acid infusion, and 
stopped 30mins after acid infusion ended (see figure 41). 
 
This protocol has no psychophysiological modulation component (Figure 
46), and functioned primarily to provide a baseline for comparison, and 
to discriminate between sensitisers and non-sensitisers. Normal 
autonomic fluctuation patterns were observed, as illustrated in Figure 53 
(panel 1). 
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2.20.2 Sham breathing protocol 
This protocol was designed to simulate the cognitive distraction, 
interpersonal interaction and somatic focus components of the deep 
breathing protocol and in doing so, provide a psychological control 
intervention.  
 
 
Figure 47 Diagram illustrating the psychophysiological modulation protocol for the 
‘sham breathing’ visit. The subject was asked to count 6 breaths on six occasions 
(purple figures) during the 30minitus acid infusion period (red bar). Autonomic 
measurement (brown bars) was done before and during the acid infusion. Pain 
thresholds (blue bars) were done before and three times after acid infusion. PH-metry 
(green bar) was started 20mins before acid infusion, and stopped 30mins after acid 
infusion ended (see figure 41). 
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Figure 48 This diagram shows two actual healthy volunteer NeuroScope™ ‘screenshots’. 
The graphs in the upper half of each panel show the blood pressure labelled BP (upper 
red graph: systolic, lower red graph: diastolic and yellow graph: MAP), and the RR-
interval labelled RR (white graph). The graphs in the lower half of etch panel shows the 
CSB (green graph) and CVT (white graph) each labelled as such. In panel 1.DB (left) the 
yellow oval highlights the RSA changes in the BP & RR, brought about by six consecutive 
breaths of the ‘deep breathing protocol’. The red box below highlights the coinciding 
increase in CSB & CVT from baseline. Compared to this the yellow oval in panel 2.SB 
(right) highlights the normal RSA fluctuations in the BP & RR, brought about by six 
consecutive breathes of the ‘sham breathing protocol’. Highlighted in the red box 
below, is normal CSB & CVT similar to that which is observed at baseline. 
 
Here the subject was asked to periodically focus and count six normal 
consecutive breaths, every five minutes, throughout the 30-minute acid 
infusion period. The subject was not given any specific instructions with 
regard to respiratory rate, depth or type (Figure 47). The intervention was 
not associated with any RSA changes and the respiration component of 
this intervention had thus no physiological effect, as illustrated in Figure 
48 (panel 2). 
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2.20.3 Deep breathing protocol 
The deep breathing protocol used in this study was based and modified 
from a procedure described by Roland D. Thijs et al. (240) They used the 
original "deep breathing through pursed lips" protocol, as a respiratory 
countermanoeuvre to maintain the blood pressure (BP) of patients 
diagnosed with orthostatic hypotension in context of autonomic failure. 
This manoeuvre was designed to activate the “respiratory pump” and 
affect the BP in several ways. It augments venous return when the 
intrathoracic pressure becomes more negative during inspiration and in 
doing so, stimulates the aortic arch and carotid baro- and 
chemoreceptors to increase afferent stimulation of the nucleus of the 
solitary tract (NTS) and VMC. (229)(Figure 44) It thereby increased the 
cardiac vagal outflow to the heart and blood vessels that is associated 
with synchronised augmentation of the RSA. (Figure 48, panel 1) They 
further demonstrated that patients who trained with BP biofeedback 
improved the effectiveness of the countermanoeuvres while fully 
preventing hyperventilation, and reproducibly could increase 
parasympathetic outflow in laboratory conditions. (210) 
 
The enhanced parasympathetic outflow in this study was achieved by 
paced breathing at full inspiratory capacity in 4 sec, followed by 
exhaling to forced expiratory vital capacity in 6 sec. This was repeated at 
a frequency of 0.1Hz (6 breaths per minute), for a one-minute period. This 
manoeuvre was repeated every 5 minutes for the 30-minute duration of 
the acid infusion phase of the experiment, thus allowing for about 6 
deep breathing cycles per 30-minute period (Figure 49). The amplified 
RSA and the coinciding increase in CSB and CVT, in contrast to the sham 
breathing protocol is illustrated in Figure 48, panel 1, as measured on the 
Neuroscope. 
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Figure 49 Diagram illustrating the psychophysiological modulation protocol for the 
‘deep breathing’ visit. The subject was paced to perform 6 deep breaths on six 
occasions (purple figures) during the 30minitus acid infusion period (red bar). 
Autonomic measurement (brown bars) was done before and during the acid infusion. 
Pain thresholds (blue bars) were done before and three times after acid infusion. PH-
metry (green bar) was started 20mins before acid infusion, and stopped 30mins after 
acid infusion ended (see figure 41). 
 
2.20.4 Deep breathing with atropine or placebo protocol 
In both treatment arms of study 4, subjects were asked to perform the 
deep breathing protocol, as described in section 2.20.3, while they 
received the acid infusion. In one treatment arm subjects received IV 
saline (placebo) while in the other arm they received IV atropine in a 
double blind manner, given by the unblinded third assistant (see section 
2.17). (Figure 50) 
 
After baseline measurements of ANS and upper/lower oesophageal pain 
thresholds to electrical stimulation, the volunteers received a dose of 
0.5mg atropine sulphate administered intravenously (IV) 5-minutes before 
the start of acid infusion (Figure 41). Its mechanism of blocking 
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parasympathetic tone has been shown to be pro-algesic in previous 
similarly performed studies. (241, 242) 
 
 
Figure 50 Diagram illustrating the psychophysiological modulation protocol for the 
atropine-placebo study. The subject was paced to perform 6 deep breaths on six 
occasions (purple figures) during the 30minitus acid infusion period (red bar) on all 
visits. Atropine or placebo was administered 5mins before the start of acid infusion. 
Autonomic measurement (brown bars) was done before and during the acid infusion. 
Pain thresholds (blue bars) were done before and three times after acid infusion. PH-
metry (green bar) was started 20mins before acid infusion, and stopped 30mins after 
acid infusion ended (see figure 41). 
 
Atropine is a cholinergic (muscarinic) antagonist that in humans, at a 
low-dose, (≤ 2µg/kg IV) paradoxically decreases heart rate and 
increases RSA because of increased parasympathetic activity. At high 
doses (≥15µg/kg IV) atropine causes blockade of muscarinic receptors 
at the cardiac sinoatrial node and a marked reduction in 
parasympatholytic tone as seen by an increase in heart rate and 
decreased heart rate variability. This paradoxical response is not fully 
understood but atropine effectively antagonises the parasympathetic 
inputs to the SA node, therefore there is unopposed sympathetic activity, 
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which causes the increased heart rate. However it is thought that at low 
doses it doesn't cause this vasolytic function and instead causes a 
vagotonic reaction, which causes further bradycardia. (243) It has a half-
life of approximately 4 hours, which covered the duration of the 
experiment adequately.  
 
 
Figure 51 This diagram shows 3 x deep breathing cycles (numbered in blue) of an 
actual healthy volunteer’s NeuroScope™ ‘screenshot’. The subject received 0.5mg 
Atropine IV between breath cycle 1 & 2 (green dashed line). The graphs in the upper 
half of the panel show the blood pressure labelled BP (upper red graph: systolic, lower 
red graph: diastolic and yellow graph: MAP), and the RR-interval labelled RR (white 
graph). The graphs in the lower half of the panel shows the CSB (green graph) and CVT 
(white graph) each labelled as such. The first yellow oval (left) highlights the RSA 
changes in the BP & RR, brought about by six consecutive breaths of the deep breathing 
protocol before the administration of the atropine. The red box below highlights the 
coinciding increase in CSB & CVT from baseline. Compared to this the second yellow 
oval (right) highlights reduced RSA changes in the BP & RR, indicating that even though 
the subject was doing six consecutive breaths of the deep breathing protocol the 
brainstem outflow is now reduced. The RSA, CSB & CVT is noticeably diminished by the 
second breath cycle, and almost totally unresponsive by the third. The red box on the 
right highlights the total block of the coinciding CSB & CVT response by atropine. 
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In study 4, largely due to regulatory concerns over cardiovascular safety, 
a standard dose of 0.5mg of atropine sulphate IV was chosen and was 
used in accordance with the indications and dosing guidelines of the 
British National Formulary. This equates to approximately 7µg/kg. The 
methodological requirement was for a marked reduction in the RSA due 
to the antagonism of the parasympathetic outflow, in spite of 
implementing an effective deep breathing protocol. At this dose 
however there is not a marked tachycardic effect expected, which 
would allow for the active agent to remain blinded with regards to the 
participating subject. As a result of atropinisation the CSB and CVT will 
remain unresponsive during deep breathing, as illustrated in Figure 51. 
The increasing blockade of atropine is demonstrated in comparing the 
progression of three breathing cycles, one pre- and two post- atropine 
administration, and would thus be observable by the second assistant. 
(See 2.17, page 110.) 
 
2.20.5 Isometric “handgrip” exercise test protocol 
Isometric exercise stimulates the vasomotor centre located in the 
medulla and thereby increases the sympathetic tone while reciprocally 
decreasing the parasympathetic tone. This increases the heart rate, 
cardiac output and blood pressure. The protocol’s aim was to examine 
the effect of enhancing the sympathetic tone in previously non-
sensitising individuals to oesophageal acid sensitisation as identified by 
the screening visit. This was used to explore if an increase in sympathetic 
tone has any effect on subject’s vulnerability to sensitisation, and 
explores the effects of physical stress on pain sensitisation. 
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Figure 52 Diagram illustrating the psychophysiological modulation protocol for the 
‘handgrip’ visit. The subjects were directed to complete three separate isometric 
handgrips sustained for 5mins (purple figures) during the 30minitus acid infusion period 
(red bar). Autonomic measurement (brown bars) was done before and during the acid 
infusion. Pain thresholds (blue bars) were done before and three times after acid 
infusion. PH-metry (green bar) was started 20mins before acid infusion, and stopped 
30mins after acid infusion ended (see figure 41). 
 
Sympathetic tone was increased with isometric exercise using a 
specifically designed handgrip equipped with a ‘power feedback’ 
meter. To standardise the force applied by selected subjects in this study, 
30% of the maximal force possible was applied and maintained over five 
minutes. (162, 244, 245) This physiological modulation was then repeated 
three times during the 30-minute acid infusion. What is experimentally 
observed is a gradual increase in the BP and heart rate (decrease in RR-
interval) over the 5-minute period. (Figure 52) This is associated with a 
gradual decrease of both the CSB and CVT, as illustrated in Figure 53, 
panel 2. 
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Figure 53 This diagram shows two actual healthy volunteer NeuroScope™ ‘screenshots’. 
The graphs in the upper half of each panel show the blood pressure labelled BP (upper 
red graph: systolic, lower red graph: diastolic and yellow graph: MAP), and the RR-
interval labelled RR (white graph). The graphs in the lower half of each panel shows the 
CSB (green graph) and CVT (white graph) each labelled as such. Panel 1.SV (left) is a 
recording during the ‘screening visit’ protocol.  The yellow oval highlights normal RSA 
fluctuations in the BP & RR during baseline recording. Similarly, highlighted in the red 
box below, is normal CSB & CVT observed at baseline. Compared to this the yellow oval 
in panel 2.HG (right) highlights a gradual increase in BP, with a decrease in RR, brought 
about buy the ‘Handgrip protocol’. Highlighted in the red box below, is the coinciding 
decrease in CSB & CVT. 
 
2.20.6 “Dichotomous listening” psychological stress test protocol 
Psychological stress increases the sympathetic tone while reciprocally 
decreasing the parasympathetic tone. This increases the heart rate, 
cardiac output and blood pressure. Psychological stress induction was 
achieved by using dichotic listening, which involves two conflicting types 
of music delivered simultaneously at 30 dB, via separate headphone 
channels. The subject heard Folk music in a foreign language in one ear 
and “heavy metal” music in the other ear. All subjects were exposed to 
the same pre-recorded music selection. This technique, which has been 
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previously validated by other investigators, has also been used to 
examine the impact of stress on visceral perception in patients with 
irritable bowel syndrome. (246-248) Following the results of study 1, to 
increase the subjective degree of psychological stress induction, subjects 
in study 3 were also asked to perform a standardised reading and 
mental arithmetic task while listening to the dichotomous music tract. This 
adaption was used to further increase the degree of psychological stress 
induction and has been validated by our group in inflammatory bowel 
disease  (IBD) studies. (249) 
 
 
Figure 54 Diagram illustrating the psychophysiological modulation protocol for the 
’stress test’ visit. Subjects listened to a conflicting duel track sound recording (purple 
figures) during the 30minitus acid infusion period (red bar). During study 3, it was 
augmented to include a mental arithmetic task as well. Autonomic measurement 
(brown bars) was done before and during the acid infusion. Pain thresholds (blue bars) 
were done before and three times after acid infusion. PH-metry (green bar) was started 
20mins before acid infusion, and stopped 30mins after acid infusion ended (see figure 
41). 
 
2.21 Data handling and statistical analysis 
All statistical analyses were performed using proprietary software (SPSS® 
v.19, IBM Inc., USA, Excel® Microsoft Inc., California USA & Prism® v.6.0c 
GraphPad Software Inc., California USA, Stata® V10.0, Stata Corp., Texas 
USA) in consultation with an accredited bio-statistician. Analysis 
included: 
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2.21.1 Primary endpoint analysis 
In healthy volunteers an absolute fall in pain threshold (Δ Avr PT) of ≥6mA 
from baseline in the distal oesophageal following acidification was 
required for sensitisation to be documented as previously reported in the 
model (51, 191). Changes in PT were analysed using linear mixed effects 
regression models with maximum restricted likelihood (fixed effects: time, 
interventions i.e. deep breathing/sham breathing; atropine/placebo; 
random effect = subject) with T0 thresholds accounted for in the model 
as zero to yield a regression coefficient for intervention effect (with 
confidence interval (CI)). In study 2 & 3 the trapezoid area-under-the-
curve (AUC) was calculated for all subjects at each time point for 
oesophageal pain thresholds. Comparisons of AUCs were undertaken 
with Mann-Whitney U test (pilot-&-study 2) and a repeated measures 
analysis of variance (ANOVA) with appropriate correction for multiple 
testing. Comparisons between groups were made using either the 
Student's t-test if parametric, or the Wilcoxon signed ranks test if non-
parametric (pilot study). Comparisons between unpaired groups were 
made with an unpaired t-test or Mann-Whitney U-test depending on 
distributional assumption. All tests were two-tailed, and paired (same 
group) and non-paired (inter group) t-tests were used. All confidence 
intervals are given to 95% and p value significance was taken at p<0.05.  
 
For the autonomic measures, normality of distribution was tested with 
histograms for each data set and was parametrically distributed. Analysis 
of Variance (ANOVA) was used to determine the measures of effect of 
ANS regulation for the differing modulations over multiple time points. For 
pain thresholds, the change in threshold from baseline was calculated 
for each time point and averaged to give a mean change in threshold 
for each individual subject. (250) The mean change of differing 
modulations across all time points was analysed using multivariate 
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analysis of variance (MANOVA). Baseline threshold was accounted for in 
the model. It allowed for repeated measures within patients, and for 
missing data. The residual variance from the model was used to 
calculate 95% confidence intervals for the differences in least square 
means between groups, and p value significance was taken at p<0.05. 
Distributional assumptions underlying this analysis were assessed by 
inspection of residual plots. Homogeneity of variance was assessed by 
plotting the residuals against the predicted values from the model, whilst 
normality was assessed by the use of normal probability plots.  
 
2.21.2 Secondary endpoint analysis 
To identify the factors associated with the magnitude of sensitisation, 
simple linear regression was used to determine the relationship between 
groups. Regression analyses on subgroups were performed if a 
relationship was present. Pearson's ‘product-moment coefficient’ was 
used for the correlations. The Bonferroni correction was used during 
multiple comparisons for all illustrated correlations. For some of the minor 
observational correlations, where the correction was not applied, it was 
clearly stated. Confidence intervals are given to 95% and p value 
significance was taken at p<0.05.  
 
2.21.3 Sample size power calculation 
The primary endpoint of these studies was the utility of 
psychophysiological manipulation of ANS in modulating oesophageal 
VPH in healthy volunteers who sensitise to acid. Calculation of sample 
size was done from this endpoint. The sample size calculation on the 
large amount of data we have over our research group’s 5-year 
experience of manipulating the oesophageal VPH. (184-190) The group 
has produced summary data from these trials that show the mean effect 
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of placebo and acid in reducing sensory thresholds to electrical 
stimulation at 30 and 60 minutes as well as the mean and standard 
deviations of responses. 
 
For studies 2 and 3, a 7.2mA was used as the between-subject standard 
deviation of the two groups (acid plus breath), and we estimated the 
within-subject standard deviation for both groups as 9.3mA based on 
previous studies using the acid induction VPH model. (175) Using a mean 
value of 83.4mA for the control group, and the within-subject standard 
deviation of 9.3mA in order to achieve 6mA difference between the two 
groups at 5% significant level and 80% power (beta of 0.8 p=0.05), the 
minimum sample size was calculated to be 30 by using the paired t-test. 
That means a total of 30 subjects will enter this paired designed study. 
The probability is 80% that the study will detect a treatment difference at 
a two-sided 5% significance level, if the true difference between the 
treatments is 5 units. This is based on an assumption that the standard 
deviation of the response variable is 9.33mA as in previous studies. On 
average only about 64% of recruited subjects who will enter the study will 
sensitise to acid, as such, it was necessary to recruit 47 subjects 
presuming a dropout rate of zero, and 53 subjects assuming a 10% drop 
out rate. 
 
For study 4, the primary endpoint was the utility of physiological 
manipulation of ANS in conjunction with atropine in oesophageal VPH in 
healthy volunteers who sensitise to acid with a ≥6mA difference between 
the two groups. Hitherto this has not been studied so it was impossible to 
estimate the size of any effect accurately, so it was based on previous 
studies using atropine blockade. (251) Calculation of sample size for 
placebo vs. atropine was used, with a 30% reduction in sensitisation from 
baseline with atropine or saline  (+/- 2 SDs) with a beta of 0.8 p=0.05, 
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giving n=7 in each treatment arm, and a sample size of 14 sensitisers. 
Based on previous studies using this model, a conservative estimated 
non-sensitiser rate of 40%, with a dropout rate of 10%, was used to back-
calculate a minimum-screening cohort of 30 subjects. 
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3 Effect of Psychophysiological Modulation on Acid Induced 
Oesophageal Hypersensitivity - Pilot Study  
  
3.1 Introduction 
Psychiatric comorbidity is common in FGID. It is widely observed that IBS 
patients have a greater degree of anxiety and depression than either 
healthy controls or patients with inflammatory bowel disease. (252) A 
similar finding is seen in other medical conditions like Non Cardiac Chest 
Pain (NCCP) and patients diagnosed with coronary artery disease. (253, 
254) The lack of clearly identifiable biological markers along with the 
aforementioned associations promotes the belief that these disorders are 
clinical manifestations of psychosomatic disturbance. Exploratory 
findings like the enhanced perceptual responses to experimental gut 
stimulation demonstrated in FGID patients, further strengthens the 
likelihood of this hypothesis. (152) Visceral pain hypersensitivity (VPH), 
clinically presents as hyperalgesia and allodynia, and occurs because of 
peripheral and central sensitisation, presently understood to result from 
the upregulation of nociceptive pathways. Given that both psychiatric 
comorbidity and VPH are common findings in FGID, an important 
question now being raised is how they interact in the pathophysiology of 
these disorders.  
 
Persisting IBS symptoms develop as a result of gastroenteritis in about 30% 
of individuals (Post-infectious IBS (PI-IBS)), suggests that there is a link 
between inflammation, gastrointestinal injury and subsequent sensory 
dysfunction. (40) Furthermore it has been observed that the likelihood of 
developing PI-IBS in patients who were hospitalised when they 
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experienced gastroenteritis is much higher in those patients also suffering 
with comorbid anxiety, suggesting that psychiatric factors may modulate 
this link, although the exact mechanisms remain unclear. (255) A 
preceding history of inflammation or injury leading to somatic and 
visceral pain syndromes is also commonly seen in a variety of medical 
conditions, and includes cases of PI-IBS (40), Post-Herpetic Neuralgia 
(256) and also NCCP where acid reflux is a common finding. (257) There 
however remains great individual variety in the susceptibility for 
developing these post insult chronic conditions, as for instance only 
about a third of patients with gastroenteritis go on to develop PI-IBS. (40) 
 
It is now clear that in the gastrointestinal tract inflammatory and immune 
mediators can facilitate peripheral afferent nociception (Peripheral 
Sensitisation) and subsequently upregulate nociception at or above 
spinal dorsal horn level (Central Sensitisation). (152) In “post insult” 
affected tissues, peripheral and central sensitisation manifests clinically 
with heightened sensitivity to experimental stimuli (hyperalgesia or 
allodynia). (152) This interface between gut lumen, sensory-neural 
pathways and the higher brain centres is closely regulated by the 
Autonomic Nervous System (ANS). (152) The degree of regulation 
suggests that altering ANS balance modulates bowel sensitivity, for 
example in healthy volunteers greater colonic sensitivity to balloon 
distension, has been shown by increasing sympathetic nervous system 
dominance. (153)  
 
In patients with gastro-oesophageal reflux disease experimental 
oesophageal acidification is associated with enhanced sympathetic 
dominance (154), while in NCCP patients reporting pain during acid 
infusion, a reduction in vagal activity was observed. (155) 
Sympathetically mediated mechanisms are implicated in several chronic 
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pain syndromes (258, 259) and are associated with diarrhoea 
predominant symptoms in FGID patients. (260) Both animal and human 
data support a vagally mediated inhibition of visceral nociception (181, 
261), and constipation predominant symptoms in FGID patients. (61, 262) 
These observations provide a mechanism whereby psychological 
abnormalities via their influence on the ANS, could be translated into 
differences in transit and pain discrimination leading to clinical 
syndromes observed. The potential role of autonomic dysfunction in 
FGIDs is made more plausible by the report from the Mayo Clinic of eight 
patients with acute autonomic neuropathies who presented with 
apparently typical IBS symptoms. (263) 
 
In the model of acid-induced oesophageal pain hypersensitivity, while 
most subjects demonstrate reproducible sensitisation to repeated 
infusions, a proportion do not sensitise at all. (53, 175, 191) In addition, 
there is inter-individual variability in the magnitude of sensitisation to the 
order of 23.8 ±12.8%(SD). (264) The reasons for this inter-individual 
variation in developing hypersensitivity remain unknown. Data presented 
by Sharma et al., (179, 185) suggested that psychological trait factors 
such as anxiety and neuroticism, and physiological (ANS) arousal states 
(HR, MBP and CVT) correlated with the degree of acid-induced 
oesophageal sensitisation in this model. What remains still unknown is to 
what degree the modulation of these psychophysiological factors via 
the ANS, can affect the degree of acid-induced oesophageal pain. The 
combined study of these factors as well as the effect of their modulation 
will further enhance our understanding and improve our ability to identify 
the phenotypes predisposed to or protected against pain hypersensitivity 
in this model, by means of more effective “psychophysiological 
profiling”. This in turn could have important implications for 
  
 
 
141 
 
understanding the development of visceral sensitisation in clinical states, 
and may also offer novel therapeutic possibilities. 
 
The aim of the study was thus to determine the effects of 
psychophysiological modulation of the ANS on acid-induced 
oesophageal pain hypersensitivity and to ascertain if inter-individual 
differences in the degree of sensitisation were predicted by inter-
individual differences to different ANS modulation types. It was 
hypothesised that sensitisation as expressed by the difference in average 
pain threshold (ΔPT) would be directly proportional to sympathetic 
nervous system activation (SNS: ∆SCR), and parasympathetic nervous 
system withdrawal (PNS: ∆CVT), as induced or amplified by different 
psychophysiological modulations. A secondary aim of the study was to 
expand on the data in order to determine whether psychological state 
and trait factors predicted the degree of sensitisation to acid in the 
model. 
 
3.2 Materials and Methods 
3.2.1 Ethics Committee Approval 
All protocols for this study were submitted and approved by the 
University Senate Ethics Committee, ‘East London and The City Research 
Ethics Committee - Alpha’ (ref: 09/H0704/71). See section 2.1(page 77). 
3.2.1 Subjects 
20 healthy asymptomatic adult male and female volunteers, aged 18 to 
50, were recruited by advertisement. Screening for acceptability for 
inclusion and exclusion criteria was completed as described in section 
2.2 (page 77).  
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3.2.2 Oesophageal Manometry 
For this study standardised oesophageal manometry (183) was 
performed in the first five subjects to determine the positions of the upper 
and lower oesophageal sphincter (UOS and LOS) from the nostril. As the 
LOS positions on these first five subjects were found to be accurate 
enough for the purpose of this study, only the ‘pH change’ pull through 
technique as described in section 2.3 (page 78), was used for the 
remaining 15 subjects. 
 
3.2.3 Other Methods of Measurement 
All other methods of measurement; Catheter Assembly (section 2.4, 
page 78), Oesophageal acid infusion (section 2.4, page 78), 
Oesophageal pH monitoring (section 2.6, page 80), Pain Threshold 
Measurements (section 2.8, page 82), Psychological assessment (section 
2.11, page 85), Measurement of the Autonomic Nervous System (section 
2.12, page 86) and Respiratory Monitoring (section 2.16, page 99), was 
performed as described in their specific sections. 
 
3.2.2 Methods of Psychophysiological Modulation 
For this study the Screening visit protocol (section 2.20.1, page 111), 
Deep breathing protocol (section 2.20.3, page 114) and Isometric “hand 
grip” exercise test protocol (section 2.20.5, page 118), was used as 
described in the specific sections, and illustrated in figure 3.1 below. The 
Psychological stress induction was achieved by using the “Dichotomous 
listening” psychological stress test protocol as described in section 2.20.6 
(page 119), but without the subsequent “standardised reading and 
mental arithmetic task” adaption, which was introduced for study 3.  
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Figure 55 Diagram illustrating the psychophysiological modulation protocol for (from top 
to bottom) the Screening visit: As this visit during study 1 was to serve as a baseline visit, 
no psychophysiological modulation was performed during the 30minitus acid infusion 
period (red bar). ‘Deep breathing’ visit: The subject was paced to perform 6 deep 
breaths on six occasions (purple figures) during the 30minitus acid infusion period (red 
bar). ‘Handgrip’ visit: The subjects were directed to complete three separate isometric 
handgrips sustained for 5mins (purple figures) during the 30minitus acid infusion period 
(red bar). ’Stress test’ visit: Subjects listened to a conflicting duel track sound recording 
(purple figures) during the 30minitus acid infusion period (red bar). Autonomic 
measurement (brown bars) was done before and during the acid infusion. Pain 
thresholds (blue bars) were done before and three times after acid infusion. PH-metry 
(green bar) was started 20mins before acid infusion, and stopped 30mins after acid 
infusion ended (see figure 41). 
 
3.2.3 Study Procedure, Experimental Design & Protocol 
The experimental study design was that of a prospective pseudo-
randomised three-tiered crossover double-blinded longitudinal cohort 
study. (Figure 56) The study procedure was followed as described in 
section 2.17 (page 99), i.e. using the ‘three research assistants’ method. 
The experimental protocol was used as described in section 2.20.5 (page 
118), with ‘time and events’ proceeding as outlined in figure 40 (page 
100). Specific modulation protocols were followed as discussed above in 
section 3.2.2.  
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Figure 56 Flowchart illustrating the final numeric outcome of participants in the pilot 
modulation study (study 1). The experimental study design was that of a prospective 
pseudo-randomised three-tiered crossover double-blinded longitudinal cohort study. 
[Sv: Screening Visit, ST: Stress Test, Db: Deep Breathing, Hg: Hand Grip.] 
 
3.2.4 Data Handling and Analysis 
Demographic, pain threshold and autonomic data were normally 
distributed hence data are presented as mean ± SD, with parametric 
analysis.  For the Isometric “hand grip” test protocol, ‘collection bin’ 
analysis (figure 66, page 152), and the “Dichotomous” psychological 
stress test, pain threshold ‘pre and post acid’ analysis (figure 60, page 
136). All statistical analysis was completed as described in section 2.21 
(page 120). 
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3.3 Results 
During acid infusion, pH fell to <2.0 in the distal oesophagus of all subjects 
but remained >6.0 in the proximal (unexposed) oesophagus. The most 
common symptom reported with acid infusion was nausea. Other 
sensations included a cold sensation in the chest region, feeling of 
hunger and / or heartburn. 
 
3.3.1 Demographic Data 
A total of 20 healthy volunteers were recruited and assessed for criteria 
eligibility. The majority (about 85%) of the subjects who responded to the 
adverts had a medical background (hospital staff or medical students), 
the rest were mostly students or research staff from a local university. The 
age range was from 18-41 years with a mean age of 28 ±5.87years. There 
were no obese or underweight subjects and the average body mass 
index (BMI) was 23.59 ±2.43kg/m2. The subjects were recruited from 
different ethnic backgrounds reflective of local ethnic diversity. The 
majority of subjects were Caucasians (76%) followed by Asians (12%), 
Africans (6%) and Chinese (6%). All were acid infusion naïve, and 88% 
sensitised to acid infusion. Both sensitisers and non-sensitisers to acid were 
recruited for study 1. 
 
During screening visit two subjects could not tolerate prolonged nasal 
intubation, even though intubations were successful, and a further 
subject threw up during acid infusion, contaminating the proximal 
oesophagus, and had to be excluded.  17 Subjects completed the 
screening visit protocol and were subsequently randomised into three 
groups for their second visits by means of a ‘pseudo-block-
randomisation’, as the different modulation types were initially started 
one at a time, until all three were ‘up-and-running’ and formal 
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randomisation could be instigated.  One more subject dropped out for 
their third visit, as he could not attend his final visit due to unexpected 
travel commitments. For the final analysis, 17 subjects (13 male) were 
included from the screening visit protocol, 12 subjects from the deep 
breathing protocol, 12 subjects from the isometric handgrip protocol, 
and seven subjects from the psychological stress protocol. (Figure 56) 
 
 
3.4.2 Pain Tolerance Threshold Data for Proximal Oesophagus 
 
The proximal oesophageal pain threshold (PT) data unexpectedly 
showed that all three modulations caused desensitisation, i.e. no 
decrease in the difference of mean pain threshold (Δ Avr PT) with regard 
to the that observed during the screening visit, across all post acid time 
points. Figure 57(A) & table B below illustrate the average absolute PT 
values. 
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Table 2  
Figure 57 (A&B) Absolute values for proximal oesophageal pain thresholds before (T0) 
and at T60, T90 and T120, post acid infusion, with  (blue) screening visit, (red) deep 
breathing, (green) stress induction and (orange) isometric exercise. (n-values as stated)	   
 
Two-way MANOVA analyses, comparing the screening visit’s mean ΔPT 
for the proximal oesophagus with that of the other modulations, across 
all time points and with regard to modulation type, showed a statistical 
difference for deep breathing and isometric exercise. (Figure 58(A)) In 
comparing average means of pre/post-acid PT differences (Δ Avr PT – 
‘degree of sensitivity’) between screening visit and modulations; no 
statistical difference was found for psychological stress modulation, 
however there was a clear statistical difference seen for both deep 
breathing and isometric exercise. (Figure 58(B)) There was also no 
statistical difference in the PT between the mean differences of deep 
breathing and psychological stress modulation. This suggests that the 
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psychological stress modulation and isometric exercise did not facilitate 
an increase in sensitisation to acid during the pilot study.  
 
Figure 58 A: Shows the difference in mean pain threshold  (ΔPT) in mA, for the proximal 
oesophagus between baseline and the three-time points (minutes) after acid infusion, 
for the different modulation types. B: Shows the difference in average means of pain 
threshold (Δ  Avr PT) in mA, for the proximal oesophagus between pre & post acid 
infusion, for the different modulation types. 
 
3.4.3 Pain Tolerance Threshold Data for Foot 
The foot pain threshold data showed that all three modulations caused 
no significant change with regard to the screening visit. There was thus 
no indication of any degree of sensitisation with regard to the somatic 
control (foot) demonstrated in this instance for both MANOVA analyses 
(Figure 59), and on average PT means comparison of pre/post-acid 
differences (Δ Avr PT, not illustrated). For all MANOVA analysis data stets 
were of similar in variance and found to be statistically matching.  
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Figure 59 Shows the difference in mean pain threshold (ΔPT) in mA, for the foot between 
baseline and the three-time points (minutes) after acid infusion, for the different 
modulation types. 
 
3.4.4 Autonomic Data 
The pre/post-acid change in ANS during the screening visits served as 
the ‘baseline’ with which other modulation-ANS changes were 
compared, and is illustrated below. (Figure 60(A) & table 3(B)) The 
changes observed for screening visit protocol demonstrated (Figure 
60(A) - shaded graph), is a post-acid increase in SNS activation (SCR & 
MBP), with a coinciding PNS withdrawal (CSB & CVT). The SNS is hence 
‘unopposed’ in this instance.  
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Table 3 
 
Figure 60 The comparison between the different ‘pre/post-acid infusion’ ANS changes 
between screening visit (shaded) and other modulation-types, are graphically 
illustrated in (A); with table (B) below showing the mean values of change & standard 
deviations for each specific protocol, and for the three modulations; there respective 
comparison & p-value significance with regards to the screening visit. [Abbreviations 
are as follows; SCR: skin conductance response, MBP: mean blood pressure, HR: heart 
rate, CSB: cardiac sensitivity to baroreflex, & CVT: cardio vagal tone.] 
-20 0 20 40 60
Screening Visit
Deep Breathing
Psychological Stress
Isometric Exercise
Autonomic change by Modulation
Units of change due to acid infusion
*" p=0.0149"
*"
**"
p=0.0166"
p=0.0015"
*" p=0.01479"
SCR$(mS)%
MBP$(mmHg)!
HR$(bpm)%
CSB$(ms/mmHg)%
CVT$(Lvs)%
Modulation Protocol ANS Measure Δ Avr SD Difference between means P value 
SCR 
(mS) 11.70 8.85 4.308 ± 3.164 0.3476 
 MBP (mmHg) 20.25 21.03 9.549 ± 5.804 0.1120 
 Isometric Exercise HR (bpm) 7.28 6.12 4.552 ± 1.796 0.0176 
 CSB (ms/mmHg) 0.96 3.95 1.599 ± 1.121 0.1655 
 CVT (Lvs) -0.26 3.51 0.3925 ± 1.015 0.7021 
SCR 
(mS) 10.98 9.00 3.591 ± 3.741 0.3476 
 MBP (mmHg) 17.13 7.59 6.427 ± 4.290 0.1490 
Psychological 
Stress  
HR 
(bpm) 1.00 2.34 -1.729 ± 1.515 0.2664 
 CSB (ms/mmHg) -0.40 1.06 0.252 ± 0.849 0.7696 
 CVT (Lvs) 1.42 4.80 2.080 ± 1.351 0.1385 
SCR 
(mS) 2.34 4.22 -5.052 ± 2.762 0.0794 
 MBP (mmHg) -1.98 14.50 -12.68 ± 4.819 0.0149 
Deep Breathing  HR (bpm) -2.62 10.47 -5.354 ± 2.762 0.1508 
 CSB (ms/mmHg) 1.71 2.43 2.335 ± 0.9034 0.0166 
 CVT (Lvs) 3.50 3.98 4.160 ± 1.151 0.0015 
SCR 
(mS) 7.39 8.07   
 MBP (mmHg) 10.71 9.45   
 Screening Visit HR (bpm) 2.73 3.41   
 CSB (ms/mmHg) -0.64 1.96   
 CVT (Lvs) -0.65 1.86   
A: 
B: 
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Immediately above  (Figure 60(A) - one above shaded graph) is seen the 
ANS changes as modulated by the deep breathing protocol. There is a 
distinct and significant difference in activation for this modulation 
compared to screening and all other visits, as there is a marked 
activation of the PNS, with a withdrawal of the SNS. The PNS increase is 
thus uniquely associated with a reduction in SNS activation. 
 
The changes observed during the psychological stress protocol (Figure 
60(A) - two above the shaded graph) showed that there was no 
significant difference in activation for this modulation compared to 
screening, except for an increase in the magnitude of SNS outflow. Of 
note is that there was also an increase in CVT, which could be indicative 
of PNS co-activation, and needs further clarification. Changes for the 
isometric exercise protocol (Figure 60(A)) demonstrated a similar ANS 
activation pattern as observed for screening. The main difference being 
a twofold increase in SNS outflow. Contrary to expectation, there is 
almost no change with regard to the PNS.  
 
In figure 58(A&B) it is shown that isometric exercise led to a 
desensitisation with a reduction in Δ Avr PT (post-acid sensitivity) when 
compared to screening visit, which was an unanticipated result, as the 
opposite response was intended. However of particular interest here is 
that this desensitisation is seemingly not associated with an increase in 
CVT (PNS) outflow, as observed during deep breathing. (Figure 60) To 
assess this apparent conflicting phenomenon further analysis of the CVT 
change during the acid infusion period was undertaken.  
 
CVT-data during the 30minute acid-infusion period was analysed in 
seven data ‘collection bins’ (each lasting approximately 4.5-minutes). 
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This was due to a technical limitation of the Neuroscope that only allows 
for a maximum period of 5 minutes of information to be analysed 
accurately at any given moment. 
 
Figure 61 A: Graph plotting the change for each individual data collection bin during 
the 30minute acid infusion period. B: Mann-Whitney test showing the comparison of the 
average difference between collection bins. 
 
The average of all seven bins was used for comparative analysis. (Figure 
61(A)) When the change for each individual bin is plotted (Figure 61(B)) 
the graph gradient of isometric exercise (orange) is similar to that of 
deep breathing (red), in comparison to screening visit (blue). In 
comparing average differences in CVT per collection bin, (Mann-
Whitney) t-test indicated a difference between screening visit and deep 
breathing, and no difference between deep breathing and isometric 
exercise. This finding suggests that the net activation of the isometric 
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exercise modulation is similar to that of the deep breathing for some of 
the time during acid infusion, and dissimilar in others causing an ‘overall-
cancellation’, and hence a neutral average for the infusion time in total, 
compared to screening visit, where the withdrawal increases with 
duration of infusion time.  
 
3.4.5 Psychological Profiling Data  
3.4.5.1 BFI questionnaire 
On the Big five Inventory (BFI) subjects were scored based on: 
1. Extraversion – (outgoing/energetic [100] vs. solitary/reserved [0]).  
2. Agreeableness – (friendly/compassionate [100] vs. cold/unkind 
[0]).  
3. Conscientiousness – (efficient/organised [100] vs. easy-
going/careless [0]).  
4. Neuroticism – (sensitive/nervous [100] vs. secure/confident [0]).  
5. Openness to experience – (inventive/curious [100] vs. 
consistent/cautious [0]). 10 
 
There is no maximum value subjects could achieve using the BFI 
questionnaire. Therefore the percentage of maximum possible 
(Cumulative Percentages) was used to interpret the data. Cumulative 
Percentages is a linear transformation of raw metric data, which is 
graded into a 0 to 100-percentile scale. Where 0 represents the minimum 
possible score and 100 represents the maximum possible score on the 
continuum between the opposites of the specific personality trait. 
Cumulative Percentage scores is a universal metric that is more intuitive 
than scale scores with idiosyncratic ranges. (265)(Figure 62) 
 
                                                      
10 For a more detailed description see explanatory note, appendix Three. 
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Figure 62 Big Five inventory (BFI) as percentage of maximum possible (Cumulative Percentages) 
scores in n=17 healthy volunteers across the five different personality domains.  
 
The personality domains of this cohort of healthy volunteers indicated 
that they were evenly grouped between introversion and extroversion. 
Their agreeableness was just below the 50th percentile, whereas their 
conscientiousness, neuroticism and openness were above the 50th, but 
below the 80th percentiles. There were no personality extremes detected 
(above the 80th, or below the 20th percentile – indicative of personality 
disorders). Neuroticism, a personality vulnerability factor, was the highest, 
with openness, a protective personality factor, the second highest. 
Based on the BFI average response the cohort as a whole could be 
described as a “semi-social, slightly reserved, organised, emotionally 
sensitive but curious and adventurous” group. This personality description 
would be expected from a cohort where the majority of individuals are in 
or are training to be in the caring professions (conscientious with 
emotional sensitivity (neuroticism)). It is further suggestive and consistent 
of the self-selection that occurs with advert recruitment, as only the 
individuals with a high degree of openness (curiosity and 
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adventurousness) will willingly volunteer for invasive experimentation as 
required by this study.  
3.4.5.2 Hospital Anxiety and Depression questionnaire 
On the Hospital Anxiety and Depression Score (HADS) the mean values 
for anxiety, 9.18 ±2.51(SD) and depression, 8.41 ±1.28(SD) were within the 
borderline range (HADS score of 8-10/21), but below the clinical 
‘caseness’ cut-off (HADS score of ≥11/21)(266), but 29% of subjects met 
the criteria for moderate anxiety and 6% for moderate depression. This is 
reflective of the efficacy of exclusion criteria used during recruitment, as 
none of the subjects attracted a formal psychiatric diagnosis and as 
such were not on any psychotropic medication. These individuals are 
examples of the more extreme end of a healthy cohort, with a high 
percentage being university students and are of interest as they are 
potentially representative of a large part of the patient group clinically 
seen. (200) Hence the cohort was slightly anxious, but still representative 
and consistent with expected means for age and gender of the general 
population. 8 
 
Analysis of the State and Trait Anxiety Inventory (STAI) indicated firstly that 
the cohort’s trait anxiety, 38.53 ±7.22(SD) is consistent with general 
population expectations (38.69 ±10.34(SD)). (267) A second finding was 
that the subjects’ state anxiety reduced with each subsequent visit 
(mean ∆STAI-S = -2.395 per visit), and is an example of exposure 
habituation. With regard to emotional attachment style, only 13% of 
subjects had significant attachment vulnerability as measured by the 
Vulnerable Attachment Style Questionnaire (VASQ), and due to the small 
sample size most probably represent a type II error. 
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3.4.6 Correlation Data  
 
During Screening visit a statistically significant positive correlation 
between the differences in PT and SCR was detected, r=0.505 (p=0.039). 
This implies that visceral sensitivity increases with the increase in 
sympathetic outflow. (Figure 63) 
 
  
Figure 63 The correlation between the difference in pain threshold (ΔPT) and skin 
conductance response (ΔSCR) during screening visit. 
 
Also seen during the screening visit was that the difference in SCR (ΔSCR) 
correlated positively with HADS-anxiety, r=0.491 (p=0.045), WAI-distress, 
r=0.528 (p=0.029) and TAS, r=0.4596 (p=0.012).11 This implies that an 
increase in sympathetic outflow correlates with anxiety, distress and the 
inability to read or understand subject’s subjective emotional state. For 
                                                      
11 Bonferroni correction was not used for these observations. 
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this study there was no significant correlation found with neuroticism for 
any of the visits. A strong negative correlation between the differences in 
PT and CVT was found during the Deep breathing protocol, r=-0.753 
(p=0.031). (Figure 64) Also seen was a strong negative correlation 
between the differences in PT and CSB, r=-0.817 (p=0.013), implying that 
an increase in both afferent and efferent branches of the para-
sympathetic nerves system is associated with a reduction in the degree 
of visceral sensitivity, and replicates previous findings using this model. 
(30) 
 
Figure 64 The correlation between the difference in pain threshold (ΔPT) and cardiac 
vagal tone (ΔCVT) during deep breathing visit. 
 
In comparing both the sympathetic and para-sympathetic activation, a 
divergent effect regarding their respective correlations with the average 
PT is observed during Deep breathing. Sympathetic activation as 
measured by the difference in SCR has a strong negative correlation, r=  
-0.766 (p=0.016), while para-sympathetic as measured by the differences 
in CVT, r= 0.787 (p=0.02) have strong positive correlations. Thus, the higher 
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the average PT, the higher the para-sympathetic activation and 
inversely, the bigger the degree of the sympathetic withdrawal.  
 
3.5 Summery of Key findings for study 1 (Modulation Pilot Study) 
3.5.1 Demographic Data: 
1. 85% of the subjects had a medical background. 
2. All subjects were acid infusion naïve, and 88% sensitised. 
3. The pilot study was at 60% power. 
3.5.1 Pain Tolerance Thresholds Data: 
1. The distal oesophageal pain threshold data showed all three 
modulations caused desensitisation, with regard to the Screening 
visit, across all time points. 
2. The foot pain threshold data showed all three modulations caused 
no significant change with regard to the Screening visit, across all 
time points. 
3. Deep breathing desensitised significantly at, -18.3 ±10.45mA 
p=0.0004, with p=0.0171 across all time points. 
4. Isometric exercise desensitised significantly at, -17.67 ±16.24mA, 
p=0.0031 with p=0.0014 across all time points. 
5. Psychological stress modulation did not significantly desensitise at, 
-2.286 ±5.648mA p=0.3255, with p=0.1187 across all time points. 
6. Non-sensitisers remained desensitised for all modulations. 
7. Non-sensitisers were markedly less vulnerable to the effects of stress 
induction p=0.0201. 
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 3.5.2 Autonomic Data: 
1. Screening visits demonstrated a post-acid increase in sympathetic 
outflow, with a para-sympathetic withdrawal. (SNS increase 
unopposed by PNS) 
2. Deep breathing protocol demonstrated a post-acid/modulation 
decrease in sympathetic outflow, with a statistically significant 
increase in para-sympathetic activation, CSB: 2.33 ±0.90ms/mmHg 
p=0.017, and CVT: 4.16 ±1.15Lvs p=0.002. (PNS increase with no SNS 
co-activation) 
3. During Psychological stress modulation there was no objective 
indication of ANS stress, with no significant difference in ANS 
regulation post-acid/modulation demonstrated. (SNS was 
increased with PNS co-activation) 
4. Isometric exercise protocol showed a difference in an increase in 
the magnitude of SNS outflow, with a statistical increase for HR, 
4.55 ±1.80bpm p=0.018. (Twofold increase in SNS, with ‘neutral’ 
PNS) 
5. Isometric exercise protocol, during the 30minute acid infusion 
period, showed that the degree of change per data collection bin 
was more similar to that of the Deep breathing, than to that of the 
Screening visit, and no statistical difference was detected 
between Deep breathing and Isometric exercise during data bin 
analysis, p=0.097. 
 
3.5.3 Psychological Questionnaire Data & Correlations: 
1. The lower the volunteers’ pain threshold (Avr PT, p=0.049), or the 
higher their degree of sensitivity (ΔPT, p=0.016); the more likely the 
subjects were to report the stimulus as more painful or unpleasant.  
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2. Neuroticism, a personality vulnerability factor was the highest, with 
openness, a protective factor the second highest. (BFI) 
3. The cohort’s mean personality profile indicated a “semi-social, 
slightly reserved, organised, emotionally sensitive but curious and 
adventurous” study group. (BFI) 
4. 29% of subjects met the criteria for moderate anxiety and 6% for 
moderate depression. (HADS) 
5. Subjects’ state anxiety reduced with each subsequent visit with a 
mean difference in score of 2.4 per visit. (STAI-S) 
6. Significant positive correlation between ∆PT and ∆SCR was 
detected, r=0.505 (p=0.039), during Screening visit. 
7. A strong negative correlation between the differences in ∆PT and 
∆SCR was found during the Deep breathing protocol, r=-0.753 
(p=0.031). 
8. The higher the average PT, the higher the para-sympathetic 
activation and inversely, the larger the degree of the sympathetic 
withdrawal, SCR, r=-0.766 (p=0.016), CVT, r= 0.787 (p=0.02) and 
CSB, r=0.717 (p=0.045). 
9. The higher the emotional valence, the lower the pain threshold, 
HADS anxiety, r=-0.900 (p=0.006), and depression, r=-0.809 
(p=0.028). 
10. There were no significant correlations found with neuroticism for 
any of the visits. 
 
3.6 Discussion 
This study replicates and further demonstrates the finding that 
oesophageal acidification in a validated model of human oesophageal 
pain hypersensitivity is associated with sympathetic nervous system 
activation, and parasympathetic withdrawal. (30) The data presented 
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further suggest that activity within the ANS during oesophageal 
acidification correlates with the degree of subsequent sensitisation. Using 
this model, previous studies have shown that the magnitude of 
sensitisation is variable between individuals with some failing to sensitise. 
(175, 191) The factors responsible for variability in sensitisation in the 
model were unknown; this study examined how this variability could be 
influenced by psychophysiological factors, and the preliminary data 
suggests that autonomic nervous system’s activity is associated with 
variability in sensitisation to acid infusion.  
 
The data presented showed that the initial hypothesis was confirmed 
stating that sensitisation as expressed by the difference in pain threshold 
(ΔPT) was directly proportional to SNS activation (∆SCR), and PNS 
withdrawal (∆CVT). Objectively, for the first time it was demonstrated that 
psychophysiological induced unopposed PNS activation successfully 
produced a subsequent statistically significant desensitisation in the 
acidified oesophagus.  Subjectively, the reporting of pain and discomfort 
was found to be proportional to the degree of hypersensitivity, and it was 
observed that subjects’ pain and discomfort during acidification was 
also reduced during positive PNS modulation.12 However, the SNS could 
not be further amplified by stress or exercise induction. Pain thresholds on 
the foot did not change significantly from baseline with acid infusion 
suggesting that hypervigilance was not the mechanism of the increased 
pain sensitivity in the oesophagus.  
 
This study also replicates, and independently verifies the previous finding 
that anxiety is a significant vulnerability factor, and that it increases the 
magnitude of acid-induced oesophageal pain hypersensitivity in healthy 
                                                      
12 For more information see appendix 4.1.    
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volunteers. (179, 211, 268)  Objective evidence is thus further provided to 
support the hypothesis that anxiety influences the degree of post-injury 
pain hypersensitivity in the human oesophagus. The data presented also 
highlighted the role and relationship between affective states (anxiety, 
depression and distress), ANS activation and the subsequent degree of 
visceral hypersensitivity. Even though this study failed to demonstrate a 
further increase in the degree of sensitisation by means of stress 
induction, it still confirmed that stress plays a role in the degree of visceral 
sensitisation.  
 
Supporting this, it has been reported clinically that increased comorbid 
anxiety scores significantly predict the diminished symptomatic response 
to PPI therapy in both endoscopy positive and negative cases. (269) This 
data suggests that anxiety both promotes the development of sensory 
dysfunction and hinders the resolution of aberrant sensory processes in 
response to therapy once dysfunction is established. A recent study by 
Rubenstein et al. (270) demonstrated that oesophageal sensation in 
patients with heartburn was correlated with the presence and degree of 
psychological dysfunction. Compared to healthy volunteers, patients 
with heartburn demonstrating VPH had lower sensory and pain thresholds 
to oesophageal balloon distension. However, when these patients 
underwent oesophageal acid perfusion, the presence of psychiatric 
factors such as anxiety was associated with increased pain intensity and 
discomfort suggesting that anxiety modulates visceral sensory 
processing.  
 
Regarding the psychological stress induction modulation; the data 
presented indicated that the use of dichotomous listening, a previously 
validated method to examine the impact of stress on visceral perception 
in IBS patients, (246-248) was unsuccessful in further increasing the 
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degree of hypersensitivity in the healthy volunteers above that which 
was already established during screening visit. Contrary to the initial 
hypothesis the modulation protocol produced a degree of 
desensitisation in the proximal oesophagus compared to the secondary 
hyperalgesia observed at screening visit. This observation is most likely 
due to the study not being at full power and producing a type II error, 
the changes seen were not of statistical significance, but remain 
important.  ANS regulatory markers indicated an increase in SNS and PNS 
outflow (increased SCR, MBP & CVT) that is suggestive and consistent 
with of autonomic co-activation.  
 
Paine et al. (271) found that the pain induced by balloon distension in 
the proximal oesophagus of healthy volunteers, evoked “fight-n-flight” 
responses with novel parasympathetic/sympathetic co-activation, and 
that the personality traits correlated with the slope of distal oesophageal 
pain-related CVT changes, where the more neurotic-introvert subjects 
had greater sensitivity. The data presented indicated that the cohort 
investigated in the current study measured highest for neuroticism on the 
BFI, and hence these findings may have a bearing on the observed ANS 
response. Porges et al. (70, 272) with the polyvagal theory demonstrated 
that in greater stress situations the more primitive vagal nucleus (dorsal 
motor nucleus - DMNX) contrary to expectation increases activation to 
produce greater PNS outflow to cause co-activation with the SNS. The 
branches of the vagus nerve serve different evolutionary stress responses 
in mammals: the more primitive branch (DMNX) elicits immobilisation 
behaviours (e.g., feigning death), whereas the more evolved branch 
from the nucleus Ambiguous is linked to social communication and self-
soothing behaviours. (See section 1.9.4, chapter 1, page 53) These 
functions follow a phylogenetic hierarchy, where the most primitive 
systems are activated only when the more evolved structures fail. The 
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experimental measurement of vagal tone has since become a novel 
index of stress vulnerability and reactivity and could be an objective 
indication of the stress induction protocol’s effect on SNS and PNS co-
activation which precluded any effect of SNS modulation on pain 
sensitivity. (273) 
 
The data presented showed no significant correlations found with 
neuroticism for any of the visits, even though it was a prominent 
personality factor in the cohort. Drabant et al. (274) reported that 
neuroticism mediated autonomic and neural responses during threat 
anticipation, where the intensity varyed as a function of the threat 
anticipated, and Coen et al. (275, 276) demonstrated that higher 
neuroticism is associated with engagement of brain regions responsible 
for emotional and cognitive appraisal during anticipation of pain but 
reduced activity in these regions during the actual experience of the 
pain. It could hence be that the main influence of the degree of 
neuroticism is not effectivly evaluated in the response to an isolated pain 
incident, as simulated by this model, but that it would be more reflective 
in situations of prolonged anticipation of pain.  
There is further the confounding factor of self-selection to consider that 
occurs with advert recruitment, as only the individuals with a high degree 
of openness (curiosity and adventurousness) will volunteer for invasive 
experimentation. Firstly the high degree of openness might not be 
representative of the clinical population, and secondly it is a protective 
factor when exposed to stress induction, and might influence results 
obtained. Another confounder is the fact that a high percentage of the 
subjects had a medical or research background, and hence are familiar 
with the laboratory environment or procedures. The reduced novelty has 
a negative impact on the anticipation, as is represented by the low 
baseline STAI anxiety scores measured. This then enhances the exposure 
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habituation observed as reflected by the subjects’ state anxiety 
reducing with each subsequent visit, and affects the degree of visceral 
sensitivity to repeated stimuli.	   Labus et al. (277) demonstrated 
normalisation of visceral hypersensitivity following repeated exposure to 
experimental visceral stimuli in IBS patients. (277)demonstrating that they 
experienced decreased discomfort and pain thresholds to visceral 
stimuli, including cognitive change in hypervigilance to gastrointestinal 
sensations, and to the context in which these visceral sensations and 
symptoms occurred. In addition Sharma, using this model demonstrated 
that the magnitude of acid-induced sensitisation is variable between 
visits and that sensitisers may show diminishing sensitisation with repeated 
studies. (30)	  
A final important factor to consider regarding the psychological stress 
induction modulation specifically, but applying equally to all modulation 
protocols used, is that previous studies showed that distraction reduces 
the degree of visceral pain sensitivity. (276, 278) In 1968 Melzack and 
Casey (279) described pain in terms of its three “dimensions”:  
I. Sensory- discriminative (location, intensity, quality, duration),  
II. Motivational- affective (emotional valence, suffering and urge to 
escape the suffering), and 
III. Cognitive- evaluative (contextual meaning and degree of 
attention/ focus).  
At the Screening visit the subject has no distraction during the period of 
acid infusion, and is fully focused on the visceral sensation, while during 
all subsequent visits during the same period they are in addition also 
engaged with one of the modulation protocols. In the case of stress 
induction, it could produce a reduction, while during the deep breathing 
protocol the effect could be additive.  
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In a similar study, Fass et al. used the dichotomous listening stress 
paradigm to assess the effect of distress on the perception of 
intraoesophageal acid in patients with gastro-oesophageal reflux 
disease, and found that it was effective in producing hypersensitivety 
only in patients, and could not reproduce visceral sensitisation in healthy 
controls. (280) This suggests that in the absence of a predisposing 
vulnerability the stress intensity produced by this paradigm is not of a 
magnitude to produce the intended effect required in healthy 
volunteers, and can explain the lack of sensitisation observed in our 
study. To overcome similar problems while assessing the effect of stress in 
Inflammatory Bowel Disease patients, Goodhand et al. (249) amended 
the protocol to include a standardised reading and mental arithmetic 
task to perform while listening to the dichotomous auditory recording. 
The inclusion of this amendment, along with the minimisation of acid 
exposure visits, and the addition of an active placebo to control for the 
effect of distraction, should be incorporated in future modulation studies.  
 
 Concerning the use of the Isometric handgrip exercise protocol as 
positive modulator of the sympathetic nervous system, the data 
presented was unexpected, as the anticipated response was that of an 
increase in sympathetic tone, associated with the withdrawal in 
parasympathetic tone. Previous studies used this method successfully to 
increase sympathetic tone. (162, 244, 245) Here however the stimulation 
paradigm was for a far shorter time duration and was effective as a 
positive SNS modulator. For my study however the isometric handgrip 
exercise was used over a 30-minute period during acid infusion. Each 
handgrip exercise period lasted for five minutes, and was repeated at 
least three times during the infusion period.  
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On post hoc ANS data analyses it became clear the when the isometric 
handgrip exercise was used repeatedly over a longer time period it 
exhibited different physiological properties. Closer laboratory observation 
revealed that towards the end of the 5-minute exercise period, as the 
muscle excursion becomes more evident, subjects, as part of the 
‘straining to maintain the grip’, would unconsciously hold their breath 
and effectively perform a prolonged Valsalva manoeuvre. When this 
manoeuvre is analysed using the Neuroscope, it becomes clearer that 
the Valsalva manoeuvre produces a short initial SNS increase and PNS 
withdrawal, but is then followed by a large PNS rebound increase, 
caused by the increased outflow from midbrain regulatory centres in 
response to the positive thoracic pressure stimulation of baro- and- 
chemoreceptor situated in the carotid sinus and aorta arch. (Figure 65) 
 
Figure 65 This diagram shows the Neuroscope ‘screenshot’ analysis of a subject 
performing two Valsalva manoeuvres. The red box highlights the coinciding decrease in 
CVT from baseline followed by a large rebound increase in PNS activity highlighted by 
the yellow oval. The graphs in the upper half of each panel show the blood pressure 
labelled BP (upper red graph: systolic, lower red graph: diastolic and yellow graph: 
MAP), and the RR-interval labelled RR (white graph). The graphs in the lower half of etch 
panel shows the CSB (green graph) and CVT (white graph) each labelled as such.  
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Neuroscope analysis of the isometric handgrip exercise revealed similar 
physiological responses to that observed during the Valsalva 
manoeuvre. (Figure 66) It thus clarifies why the resultant CVT change 
measured during the isometric handgrip protocol was neutral (-0.26 
±3.51Lvs, Figure 60), as the produced CVT withdrawal is effectively 
cancelled by the rebound PNS increase. Analysis of the data collection 
bins during the acid infusion period confirms this, as the net CVT change 
during the handgrip protocol was not significantly different from that 
which was observed during the deep breathing protocol, and would 
explain the significant subsequent oesophageal desensitisation 
observed. (Figure 61) The repeated use of the isometric handgrip 
exercise protocol over a longer time period inadvertently turned out to 
be similar to the deep breathing protocol at producing desensitisation in 
this model.   
 
Figure 66 This diagram shows the Neuroscope ‘screenshot’ analysis of a subject 
performing he Isometric handgrip exercise. The red box highlights the coinciding 
decrease in CVT from baseline followed by a large rebound increase in PNS activity 
highlighted by the yellow oval. The graphs in the upper half of each panel show the 
blood pressure labelled BP (upper red graph: systolic, lower red graph: diastolic and 
yellow graph: MAP), and the RR-interval labelled RR (white graph). The graphs in the 
lower half of etch panel shows the CSB (green graph) and CVT (white graph) each 
labelled as such.  
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The only feasible alternative to producing prolonged SNS increase 
associated with PNS withdrawal is the use of the tilt-table test (TTT), (281) 
which can be effective over time periods as long as 20 to 30 minutes.  Its 
costly, cumbersome equipment is associated with frequent dizziness and 
syncope, making its possible use for this study impractical given the 
present circumstances. Future investigators will have to find a more 
appropriate alternative physiological method to examine the effect of 
sympathetic increase on sensitisation in this model. 
  
Concerning the use of the Deep breathing protocol as positive 
modulator of the para-sympathetic nervous system, it would suffice to 
say at this stage that data presented was novel and encouraging, and 
will be fully discussed in the following chapter. The deep breathing 
modulation protocol successfully demonstrated the proof of concept 
that increasing parasympathetic outflow can produce visceral 
desensitisation in this model. Due to the desensitising effect of distraction 
(as discussed for the "dichotomous listening” protocol), Deep breathing 
as intervention should be tested against an active placebo. This should 
now be investigated further with a fully powered study. 
 
 Finally, in spite of all subjects being acid infusion naïve, 22% did not 
sensitise during acid infusion, and also failed to sensitise on subsequent 
visits, irrespective of modulation. They also demonstrated that acid-
induced autonomic responses are variable between visits. For these 
subjects the difference in degree of sensitisation between visits was not 
related to the degree of change in HR, CVT or CSB between visits. They 
had less sympathetic activation (SCR) compared to sensitisers, and 
scored less for neuroticism on the BFI. Their response remained consistent, 
and remains unclear and is suggestive that they may represent a distinct 
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phenotype with reduced susceptibility to injury-induced sensitisation in 
the model. As a previous study using this model demonstrated that stress 
induction increases the degree of secondary oesophageal hyperalgesia 
in sensitisers, (30)  it now remains to further investigate this in non-
sensitisers. 
	  
3.7 Conclusions 
 
As study 1 was a pilot study and not yet fully powered the emphasis was 
on identifying early trends to investigate more thoroughly in the 
subsequent studies, hence the following conclusions were made: 
1. The Isometric “handgrip” exercise test is not suitable for this 
investigation, as it produces both a parasympathetic withdrawal and 
rebound increase. The alternative “tilt-table” test is impractical in the 
circumstances, and future investigators will have to find a more 
appropriate method to examine the effect of sympathetic increase 
on sensitisation in this model. 
2. Due to subjects’ anxiety habituation as measured by the STAI, the 
decreased induction of acid induced sensitisation on subsequent 
visits and the "first-pass effect" of the screening visit, the amount of 
visits should be kept to a minimum. The screening visit should be 
discontinued, and randomisation should occur directly following 
recruitment. Recruitment should attempt to include a larger diversity 
of backgrounds to reduce subjects familiar with medical 
environment. 
3. As previous studies have already demonstrated that stress increases 
the degree of sensitisation in sensitisers using this model, the 
augmented Psychological stress protocol should be performed only 
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in non-sensitisers, as the effect on non-sensitisers has not been studied 
and remains unknown. 
4. The Deep breathing modulation successfully demonstrated the proof 
of concept that increasing parasympathetic outflow can produce 
visceral desensitisation in this model. Due to the desensitising effect of 
distraction (as discussed for the "dichotomous listening” protocol), 
deep breathing as intervention should be tested against an active 
placebo. This should be investigated further with a fully powered 
study. 
5. The inter-individual variability in the magnitude of sensitisation 
between sensitisers and non-sensitisers, as well as their vulnerability 
and protective factors remains unclear and as yet unexamined, and 
should now be further explored in a comparative study, that will 
allow the evaluation of ANS responses across a continuum of 
environmental stress for the different sensitisation groups. 
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4 Effect of Psychophysiological Modulation by Deep Breathing 
& Psychological Stress on Acid Induced Oesophageal 
Hypersensitivity    
  
4.1 Introduction 
Visceral pain in FGID is a major global cause of disability, healthcare 
seeking and a leading cause for loss of quality of life and patient 
morbidity. (23) Chronic visceral pain is a common condition for which 
patients seek care from various health-care providers. This type of pain 
causes much suffering and disability, but in spite of its ubiquity is still 
misunderstood and undertreated and tangible patient benefit remains 
limited. (282) Visceral pain shares many features with somatic pain, yet 
there are important differences in the pathophysiological mechanisms 
underlying visceral nociception, but these differences are not reflected 
in treatment approaches to date. (283) Few controlled clinical trials of 
psycho-behavioural interventions for pain relief in FGID exist in spite of 
frequent support for their importance as adjuncts to medical treatment. 
(284) 
 
Ashburn et al. (285) in a landmark discussion of the long-term care of 
patients suffering from chronic pain conditions, state that these patients 
often require adjustment of treatment with the aim of decreasing pain 
and suffering while improving physical and mental functioning, and they 
cite behavioural interventions including training in deep breathing 
amongst effective interventions in the management of this difficult to 
treat patient group. Similarly Syrjala et al. (286) researching in cancer 
related visceral pain, found that training of deep breathing, relaxation 
and guided imagery, reduced cancer treatment-related pain to such a 
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degree, that adding cognitive-behavioural skills to the breathing-
relaxation regimen did not further improve pain relief. Observations of 
this kind have led to the use of deep breathing in pain control becoming 
more widespread. Using data from the 2002 National Health Interview 
Survey (NHIS), conducted by the Centres for Disease Control and 
Prevention National Centre for Health Statistics, it was found that in 2002 
already 12% of patients in the USA used deep breathing exercise 
strategy in the treatment of chronic pain. (287) Deep breathing exercises 
now form a standard part of the non-pharmacological treatment for 
patients with chronic widespread pain and fibromyalgia. (288) 
 
With regard to pain control in the acute A&E setting, Downey et al. (289) 
found that the usefulness of deep breathing exercises was ineffective in 
reducing acute pain levels statistically; however noted that the majority 
of patients who received deep breathing education felt it was useful. 
The exercise was effective in increasing patients’ feelings of rapport and 
motivation to follow their doctors’ directives, both of which are key 
features in the effective management and treatment of chronic pain. 
 
Finally concerning the clinical use of deep breathing, Jerath et al. (290) 
described a specific variation of deep breathing (long pranayamic13 
breathing) in the treatment of autonomic nervous system and other 
related disorders. They described a physiological response characterised 
by the presence of decreased oxygen consumption, decreased heart 
rate, and decreased blood pressure, as well as increased theta wave 
amplitude in EEG recordings, with increased parasympathetic activity, 
accompanied by the psychological experience of alertness and 
reinvigoration. The exact mechanism of how deep breathing interacted 
                                                      
13 Prana (प्राण, prāṇa) is the Sanskrit word for breath or "life force". 
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with the nervous system affecting metabolism and autonomic nervous 
system changes remains to be clearly understood. This model however 
validated the hitherto poorly understood modulation effects of deep 
breathing as a topic requiring more research, especially in context of 
chronic visceral pain management. 
 
Similar autonomic findings to those described were observed during 
study 1 described in chapter three. Using the deep breathing protocol, it 
was demonstrated that increasing parasympathetic outflow could 
produce oesophageal pain desensitisation in a model of acid induced 
hypersensitivity. Study 1 was, however, a pilot study and not fully 
powered with the emphasis being on identifying early trends. Further 
investigation of this desensitising effect of deep breathing and the 
underlining mechanisms was therefore undertaken. Due to the 
desensitising effect of distraction as discussed in chapter three, deep 
breathing as intervention was now tested against an active placebo 
using a blinded crossover study design at full power. 
 
Also discussed in chapter three was the use of stress induction, and the 
role of the stress responses in oesophageal sensitisation. It is in this regard 
that Paine et al. (271) demonstrated that oesophageal intubation 
evoked "fight-flight" responses with heart rate and sympathetic (CSI, SC, 
MBP) activation and significant parasympathetic (CVT) withdrawal 
(p<0.05). Sharma et al. (185) went on to demonstrate that the degree of 
resulting oesophageal sensitisation to acid correlated with the degree of 
vagal withdrawal. Porges proposed vagal tone as a novel index of stress 
vulnerability and reactivity with potential applications in all branches of 
medicine. He further proposed a model emphasising the role of the 
parasympathetic nervous system and particularly the vagus nerve in 
mediating homeostasis and defining the degree of stress. (273) 
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Hausken et al. (291) investigated the effects of acute mental stress on 
gastric antral motility in 23 healthy volunteers and 25 patients with 
functional dyspepsia. They found that the sympathetic tone increased 
during stress in both groups. Vagal tone was however lower in the 
functional dyspepsia patient group than in the healthy controls (p < 
0.001). The lack of stress-related reduction of motility among patients with 
functional dyspepsia may, therefore, be a consequence of poor vagal 
tone, supporting Porges’s hypothesis where vagal tone acts as a novel 
index of stress vulnerability. 
 
Mayer et al. described that different types of stress play an important 
role in the onset and modulation of irritable bowel syndrome (IBS) 
symptoms. They demonstrated the physiological effects of psychological 
and physical stressors on gut function and brain-gut interactions, and 
highlighted that they are mediated by outputs of the emotional motor 
system in terms of autonomic, neuroendocrine, attentional, and pain 
modulatory responses. (110) Posserud et al. confirmed this by 
demonstrating that stress worsens IBS symptoms. They hypothesised that 
the stress effect might be explained by altered neuroendocrine and 
visceral sensory responses to stress in IBS patients, as they found that stress 
induced exaggeration of the neuroendocrine response and visceral 
perceptual alterations during and after the exposure to stress. This may 
explain some of the stress related gastrointestinal symptoms in IBS 
patients. (292) 
 
In study 1 the examination of the effect of stress was attempted in 
context of the acid induced oesophageal hypersensitivity model. 
Unfortunately the psychological "dichotomous listening” stress test was 
found to be ineffective most likely due to a lack in stress intensity, and 
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therefore requires augmentation as suggested by Goodhand et al. (249) 
The protocol was hence amended to also include a standardised 
reading and mental arithmetic task, to be completed during the 
"dichotomous listening” stress test.  
 
Study 1 demonstrated that in spite of all subjects being acid infusion 
naïve, 22% did not sensitise during acid infusion, and also failed to 
sensitise on subsequent visits, irrespective of modulation. For these 
subjects the difference in degree of sensitisation between visits was not 
related to the degree of change in HR, CVT or CSB between visits. They 
had less sympathetic activation (SCR) compared to sensitisers, and 
scored less for neuroticism on the BFI. It is possible that they may 
represent a distinct phenotype with reduced susceptibility to injury-
induced sensitisation in this model. A previous study using this model 
demonstrated that stress induction increases the degree of secondary 
oesophageal hyperalgesia in sensitisers, (30) but the response in non-
sensitisers remains still unclear. It was decided to focus further 
investigation in this area.  
	  
In study 1 it was noted that due to subjects’ anxiety habituation, there 
was a reduced induction of acid induced sensitisation on subsequent 
visits. Thus the amount of visits should be kept to a minimum. The 
screening visit was hence discontinued, and randomisation occurred 
directly following recruitment. Recruitment also attempted to include a 
larger diversity of volunteer backgrounds to reduce subjects familiar with 
the medical environment. The stress augmentation together with the 
minimised number of acid exposure visits, and the addition of an active 
placebo to control for the effect of distraction and personal interaction, 
was now used to examine the effects of stress induction in non-sensitising 
individuals during study 3. 
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The aim of this study was thus to determine the effects of 
psychophysiological modulation of the ANS by means of deep breathing 
(study 2), and psychological stress induction (study 3), on acid-induced 
oesophageal pain. Also to ascertain if inter-individual differences in the 
degree of sensitisation were predicted by inter-individual differences in 
psychological profile. In order to best achieve this aim, the study was 
divided into two parts, with study 2 focusing on the effect of PNS 
increase (SNS withdrawal) in individuals that sensitise to acid, and study 3 
focusing on the effects of PNS withdrawal (SNS increase) in individuals 
that do not sensitise to acid. It was hypothesised that sensitisation as 
expressed by the difference in average pain threshold (ΔPT) would be 
directly proportional to sympathetic nervous system activation (SNS: 
∆SCR), and parasympathetic nervous system withdrawal (PNS: ∆CVT), as 
induced or amplified by different psychophysiological modulations. A 
secondary aim of the study was to expand on the data in order to 
determine whether psychological state and trait factors predicted the 
degree of sensitisation to acid in the model. 
 
4.2 Materials and Methods 
 
4.2.1 Ethics Committee Approval 
All protocols for this study were submitted and approved by the 
University Senate Ethics Committee, ‘East London and The City Research 
Ethics Committee - Alpha’ (ref: 09/H0704/71). See section 2.1(page 77). 
4.2.1 Subjects 
55 healthy asymptomatic adult male and female volunteers, aged 18 to 
50, were recruited by advertisement. In an attempt to include a larger 
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diversity of backgrounds to reduce subjects familiar with the medical 
environment, adverts were placed in waiting areas open to the public. 
Adverts were also placed at a local university’s main campus where 
non-medical students attend. Pre-screening for inclusion and exclusion 
criteria was completed as described in section 2.2 (page 77).  
 
4.2.2 Location of the LOS  
 As in study 1 we had determined that the LOS position could be 
accurately identified using the pH pull through technique therefore this 
technique (as described in section 2.3 page 78), was used for the 
subjects in studies 2 & 3. 
 
4.2.3 Other Methods of Measurement 
All other methods of measurement; Catheter Assembly (section 2.4, 
page 78), Oesophageal acid infusion (section 2.4, page 78), 
Oesophageal pH monitoring (section 2.6, page 80), Pain Threshold 
Measurements (section 2.8, page 82), Psychological assessment (section 
2.11, page 85), Measurement of the Autonomic Nervous System (section 
2.12, page 86) and Respiratory Monitoring (section 2.16, page 99), was 
performed as described in their specific sections. 
 
4.2.2 Methods of Psychophysiological Modulation 
For study 2 & 3 the Sham breathing protocol (section 2.20.2, page 111) 
and Deep breathing protocol (section 2.20.3, page 114), was used as 
described in the specific sections, and illustrated in figure 4.1 below. 
During the Sham breathing protocol subjects were divided into two 
groups depending on the degree of sensitisation. If they sensitised, they 
completed study 2 (hypothesis testing study); if they did not sensitise, 
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they were diverted to study 3 (hypothesis generating study), where the 
psychological stress induction was achieved by using the augmented 
“Dichotomous listening” psychological stress test protocol as described in 
section 2.20.6 (page 119). During study 3 the “standardised reading and 
mental arithmetic task” was included. (249) 
 
 
 
Figure 67 Diagram illustrating the psychophysiological modulation protocol for (from top 
to bottom) the ‘Sham breathing’ visit: The subject was asked to count 6 breaths on six 
occasions (purple figures) during the 30minitus acid infusion period (red bar).  ‘Deep 
breathing’ visit: The subject was paced to perform 6 deep breaths on six occasions 
(purple figures) during the 30minitus acid infusion period (red bar). ’Stress test’ visit: 
Subjects listened to a conflicting duel track sound recording (purple figures) during the 
30minitus acid infusion period (red bar). During study 3, it was augmented to include a 
mental arithmetic task as well.  Autonomic measurement (brown bars) was done before 
and during the acid infusion. Pain thresholds (blue bars) were done before and three 
times after acid infusion. PH-metry (green bar) was started 20mins before acid infusion, 
and stopped 30mins after acid infusion ended (see figure 41). 
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4.2.3 Study Procedure, Experimental Design & Protocol 
The experimental study design was that of a prospective randomised 
placebo controlled two-tiered crossover double-blinded longitudinal 
cohort study. (Figure 67) The study procedure was followed as described 
in section 2.17 (page 99), i.e. using the ‘three research assistants’ 
method. The experimental protocol was used as described in section 
2.18 (page 101), with ‘time and events’ proceeding as outlined in figure 
2.12 (page 86). Specific modulation protocols were followed as 
discussed above in section 4.2.2. 
 
Figure 68 Flow diagram illustrating the final numeric outcome of participants in studies’ 2 
& 3. The experimental study design was that of a prospective randomised placebo 
controlled two-tiered crossover double-blinded longitudinal cohort study. [SB: Sham 
Breathing, ST: Stress Test, Db: Deep Breathing.] 
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4.2.4 Data Handling and Analysis 
Due to the methodological dissimilarities (differences in baseline 
protocol), data derived from study 1 was not pooled or used in the 
analysis of studies 2 or 3. Demographic, pain threshold and autonomic 
data were normally distributed hence data are presented as mean ± SD, 
with parametric analysis. The variability was computed for the main 
effects of each subject’s change in PT over time points (ΔPT & time). All 
statistical analysis was completed as described in section 2.21 (page 
120).  
 
4.3 Results 
During acid infusion, pH fell to <2.0 in the distal oesophagus of all subjects 
but remained >6.0 in the proximal (unexposed) oesophagus. The most 
common symptom reported with acid infusion was nausea. Other 
sensations included a cold sensation in the chest region, feeling of 
hunger and / or heartburn. 
 
4.3.1 Demographic Data for full cohort (studies 2 & 3) 
A total of 55 healthy volunteers (31, male) were recruited and assessed 
for criteria eligibility. In spite of changing our advertising strategy, the 
majority (about 60%) of the subjects who responded to the adverts still 
had a medical background (hospital staff or medical students), the rest 
were other students from a local university and general public. The age 
range was from 18-48 years with a mean age of 26 ±6.61years. There 
were no obese or underweight subjects with a mean body mass index 
(BMI) of 22.73 ±2.41kg/m2. The subjects were recruited from different 
ethnic backgrounds reflective of local ethnic diversity. The majority of 
subjects were Caucasians (63%) followed by Asians (29%) and Africans 
(4%). All were acid infusion naïve, and 63% sensitised to acid infusion. 
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Author’s note: 
To avoid confusion, parts of the results section will be presented separately in 
the following order: 
• Sections 4.3.2 to 4.3.7:  will deal with study 2, (sensitisers) and 
• Sections 4.3.8 to 4.4.11:  will focus on study 3 (non-sensitisers). 
Further results will once again pertain to the whole cohort. 
 
 
4.3.2 Demographic Data for study 2 (Deep Breathing in Sensitisers) 
 
 
Figure 69 Flow diagram illustrating the final numeric outcome of participants in study 2. 
The experimental study design was that of a prospective randomised placebo 
controlled two-tiered crossover double-blinded longitudinal cohort study.  [SB: Sham 
Breathing, Db: Deep Breathing.] 
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Form the full cohort of 55 healthy volunteers, 31 subjects (18, male) 
sensitised to acid infusion during the Sham breathing protocol visit, and 
were recruited to study 2. (Figure 69) The age range was from 18-48 years 
with a mean age of 26 ±6.28 years. There were no obese or underweight 
subjects and the average body mass index (BMI) was 22.87 ±2.66kg/m2. 
The subjects were recruited from different ethnic backgrounds reflective 
of local ethnic diversity. The majority of subjects were Caucasians (55%) 
followed by Asians (35%) and Africans (10%). All were acid infusion naïve. 
 
During their first randomisation visit, five subjects could not tolerate 
prolonged nasal intubation even though intubations were successful and 
were excluded. For the final analysis, 31 subjects (18 male) completed 
both the sham breathing and deep breathing protocols, as a further 
three subjects were unable to complete the study due to study 
unrelated reasons (one had a family emergency and the other two 
sudden unscheduled commitments). (Figure 69) 
 
4.3.3 Pain Tolerance Threshold Data of Proximal Oesophagus for 
study 2 
 
Absolute threshold data for the proximal oesophagus at (T0) and after 
acid infusions (T60, T90, T120) are shown in Figure 70(A) & table B below.  
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Table 4 
Figure 70 Absolute values for proximal oesophageal pain thresholds before (T0) and 
after (T60 T90 and T120) post-acid infusion with (red) sham and (blue) deep breathing.	   
 
The mean individual ‘pre/post-acid infusion’ changes in pain threshold 
(∆PT) for all subjects in the proximal oesophageal, during sham-&-deep 
breathing with the mean group value (SD) for each time point, are 
shown in figure 71.  
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Figure 71 Individual values of change (difference from baseline) for proximal 
oesophageal pain thresholds (∆PT) for time points T60, T90 and T120, before and after 
acid infusion with (A) sham and (B) deep breathing. 
  
Two-way MANOVA analyses, comparing the influence of effect for sham 
vs. deep breathing modulation’s mean ΔPT for the proximal oesophagus 
with that of modulation type, across all time points, showed a strong 
statistical significance with regard to deep breathing, contributing 
29.85% (p<0.0001). (Figure 72(A)) In the comparison of the pre/post-acid 
infusion differences in average means of pain threshold (Δ Avr PT) 
between sham breathing, a strong statistical difference was detected 
between the modulation types. (Figure 72(B)) Deep breathing almost 
abolished the development of acid-induced hypersensitivity in the 
proximal oesophagus. At 60 minutes, mean change in PT (C.I.) was -
13.2mA (-15.8 to -10.6) after sham breathing, compared to a very small 
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decrease of -1.4mA (-3.5 to +0.7) after deep breathing.	  This pattern was 
repeated at 90 and 120 minutes. Mixed effects regression showed a 
coefficient of effect for deep breathing of + 9.94 (CI 8.3-11.6), p= 0.0001. 
 
Figure 72 A: shows the difference in mean pain threshold  (ΔPT) in mA, for the proximal 
oesophagus between baseline and the three-time points (minutes) after acid infusion, 
for the different modulation types. B: Showing the difference in average means of pain 
threshold (Δ  Avr PT) in mA, for the proximal oesophagus between pre & post acid 
infusion, for the different modulation types. The two-tailed paired t test was statistically 
significant. 
 
4.3.4 Pain Tolerance Threshold Data of Foot for study 2 
 
The foot pain threshold data showed the deep breathing modulations 
caused no significant change with regards to sham breathing. There was 
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thus no indication of any degree of sensitisation with regard to the 
somatic control (foot) demonstrated in this instance for both MANOVA 
analyses (Figure 73), and on average PT means comparison of pre/post-
acid differences (Δ Avr PT, not illustrated). For all MANOVA analysis data 
sets were of similar in variance and found to be statistically matching.  
 
 
 
 
Figure 73 Shows the difference in mean pain threshold (ΔPT) in mA, for the foot between 
baseline and the three-time points (minutes) after acid infusion, for the different 
modulation types. 
 
 
4.3.5 Autonomic Data for study 2 
 
The ‘pre/during-acid’ infusion change in ANS for sham breathing served 
as ‘baseline’ to which deep breathing’s ANS changes were compared 
for p-value calculation, and is illustrated below.  (Figure 74(A) & table 
5(B)) 
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Table 5 
 
Figure 74 The comparison between the different ‘pre/post-acid infusion’ ANS changes 
between sham breathing (shaded) and deep breathing modulation-types, are 
graphically illustrated in (A); with table (B) below showing the mean values of change & 
standard deviations for each specific protocol, and for deep breathing’s comparison & 
p-value significance with regards to sham breathing. [Abbreviations are as follows; SCR: 
skin conductance response, MBP: mean blood pressure, HR: heart rate, CSB: cardiac 
sensitivity to baroreflex, & CVT: cardio vagal tone. 
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HR$(bpm)%
CSB$(ms/mmHg)%
CVT$(Lvs)%
**" p=0.0022"
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Deep Breathing  HR (bpm) 2.07 7.12 -1.13 ± 9.17 0.5168 
 CSB (ms/mmHg) -0.26 3.13 0.24 ± 3.81 0.7351 
 CVT (Lvs) 1.7 2.6 2.07 ± 5.12 0.041 
SCR 
(mS) 8.73 9.09   
 MBP (mmHg) 15.71 14.02   
 Sham Breathing HR (bpm) 2.47 4.78   
 CSB (ms/mmHg) 0.29 2.45   
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Sham breathing (shaded graph above, figure 74(A) & table (B)) 
demonstrated a post-acid increase in SNS activation, with a coinciding 
PNS withdrawal. The SNS is hence homeostatically ‘unopposed’ as a 
result of acid infusion. In contrast the deep breathing protocol showed 
the reverse, demonstrating a decrease in sympathetic outflow with an 
increase in parasympathetic activation, with statistically significant 
changes in SCR & CVT. (Figure 75(A&B)) Modulated deep breathing’s 
PNS increase is thus not associated with SNS co-activation.  
 
 
Figure 75 The comparison of the difference in ANS change between Sham breathing 
visit and Deep breathing, with (A) showing the change in SCR (SNS) and  (B) the change 
in CVT (PNS).  
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4.3.6 Psychological Profiling Data for study 2 
4.3.6.1 BFI questionnaire 
The BFI questionnaire, using cumulative percentages, was used to 
analyse and interpret the cohort’s personality domain data. The 
personality domains of this cohort of healthy volunteers indicated that 
they were evenly grouped between introversion and extroversion. (Figure 
76(B)) Their agreeableness was just below the 50th percentile, which is 
higher than observed during study 1. (Figure 76(A)) Their 
conscientiousness, neuroticism and openness were above the 50th, but 
below the 80th percentiles and similar to that of study 1. 
 
 
Figure 76 Big Five inventory (BFI) as percentage of maximum possible (Cumulative 
Percentages) scores in (A) study 1(n=1) and (B) studies 2&3 (n=49), across the five 
different personality domains. 
 
Their Openness was slightly higher than observed in the pilot study, 
reflecting the need for a greater sense of ‘adventure/risk-taking’ by the 
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general public (40%) in participating with an invasive medical study 
compared to study 1 (15%). There were no personality extremes 
detected (above the 80th, or below the 20th percentile – indicative of 
personality disorders). As in study 1, the mean Neuroticism score, a 
vulnerability factor, was the highest, with openness, a protective 
personality factor, the second highest. Based on the BFI average 
response the cohort as a whole could be described as a “semi-social, 
slightly reserved, organized, emotionally sensitive but curious and 
adventurous” group. This personality description is similar to that of the 
pilot study, as the participants were of a similar background, education 
and socio-economical status. It is consistent with the self-selection that 
occurs with advert recruitment in the same geographical site, as only the 
individuals with a high degree of openness (curiosity and 
adventurousness) and extroversion will volunteer for this type of study.  
 
4.3.6.2 Hospital Anxiety and Depression questionnaire 
On the Hospital Anxiety and Depression Score (HADS) the mean values 
for anxiety, 8.97 ±2.52(SD) and depression, 8.55 ±1.52(SD) were within the 
borderline range (HADS score of 8-10/21), but below the clinical 
‘caseness’ cut-off (HADS score of ≥11/21). (266) Only 16.1% of subjects 
met the criteria for moderate anxiety and 9.7% for moderate depression, 
which is below average expectation. This is reflective of the efficacy of 
exclusion criteria used during recruitment, as none of the subjects 
attracted a formal psychiatric diagnosis and as such were not on any 
psychotropic medication. These individuals are examples of the upper 
end of the normal range of a healthy cohort, with a high percentage 
being university students. Hence the sensitiser cohort was slightly anxious, 
but representative and consistent with expected means for age and 
gender of the general population.   
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4.3.6.3 State and Trait Anxiety Inventory questionnaire 
Analysis of the State and Trait Anxiety Inventory (STAI) indicated firstly that 
the cohort’s trait anxiety, 38.45 ±9.56(SD) is consistent with the 
expectations from a general population (38.69 ±10.34(SD)). (267) A 
second finding that was consistent with observations in study 1, was that 
the subjects’ state anxiety reduced on the subsequent visit (mean ∆STAI-
S = -3.81 ±9.43(SD) per visit), and is an example of exposure habituation.	  
There was no relationship between STAI-trait and T0 thresholds, nor with 
degree of acid sensitisation at subsequent time points (p= 0.84 – 0.89, 
linear regression). A significant negative correlation was found between 
STAI-trait and change in CVT during deep breathing, coeff. -1.05 (CI -0.54 
to +1.44), p= 0.004, but not sham breathing, coeff. 0.45 (CI -1.73 to -0.36), 
p= 0.36. 
 
4.3.6.4 Vulnerable Attachment Style Questionnaire 
With the Vulnerable Attachment Style Questionnaire (VASQ), 40% of 
subjects had significant attachment vulnerability, which is similar to the 
proportion among other non-patient samples (293, 294). Of these 
subjects with attachment vulnerability 67% of anxious-preoccupied, and 
33% of dismissive-avoidant types. The combined attachment vulnerability 
for the whole cohort (study 2&3) was 37%. (Figure 77) 
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Figure 77 The Vulnerable Attachment Style Questionnaire (VASQ) findings for study 2, 
showing the secure/insecure percentages with the pie graph, and a brake-down of the 
types of insecure attachment style on the adjacent bar chart. 
 
4.3.7 Correlation Data for study 2 
 
During sham breathing a negative correlation between the differences 
in PT and SCR (yellow graph, figure 78) was detected and a positive 
correlation with the difference in MBP (red graph, figure 78). There was 
no correlation with CVT (blue graph, figure 78).  
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Figure 78 The correlation between the difference in pain threshold (ΔPT) and skin 
conductance response (ΔSCR), blood pressure (∆MBP) and efferent PNS (∆CVT) during 
sham breathing. [Encircled: outlying point] 
 
This is potentially contradictory, as it implies that visceral sensitivity (∆PT) 
increases with the increase in sympathetic outflow, except for the 
positive correlation with MBP.  The ∆PT/∆MBP correlation was sensitive to 
the inclusion/exclusion of an outlying point. When the analysis was 
repeated after the exclusion of the outlier the strength of the correlation 
and the statistical significance disappeared, r=0.158 (p=0.402), and 
suggests no contradiction, but rather a probable chance finding.  
 
During deep breathing contrary to the above ‘sham breathing-
observation’ (yellow graph, figure 78), the SNS now had a weak non-
significant negative correlation with the mean pain threshold (SCR, 
yellow graph, figure 79), while the PNS had a significant positive 
correlation.  (CVT, blue graph, figure 79) 
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Figure 79 The correlation between the average pain threshold (Avr PT) and cardiac 
vagal tone (ΔCVT) during deep breathing visit.  
 
There was a moderate positive correlation between the degree of PNS 
activation (∆CVT) and BFI-conscientiousness score (red graph, figure 
80).14 Also observed during sham breathing, was a negative correlation 
with WAI-defensiveness (blue graph, figure 80).14 This is of interest, as it 
infers that the “more” conscientious and the “less” defensive the subject 
is, the higher the observed CVT activation; suggestive of a ‘generally 
more relaxed, prepared, non-threatened’ attitude being associated with 
a higher protective vagal tone. 
 
 
                                                      
14 Bonferroni correction was not used for these observations. 
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Figure 80 The correlations between the difference in cardiac vagal tone (ΔCVT), the 
personality trait Conscientiousness (BFI) and WAI-defensiveness score (WAI) during 
sham breathing protocol. 
 
4.3.8 Demographic Data for study 3 (Stress induction in Non-
sensitisers) 
 
From the full cohort of 55 healthy volunteers, 18 subjects (13, male) did 
not sensitise to acid infusion during the Sham breathing protocol visit, 
and were recruited to study 3. (Figure 81) The age range was from 19-45 
years with a mean age of 27 ±7.33 years. There were no obese or 
underweight subjects and the average body mass index (BMI) was 22.5 
±1.98kg/m2. The subjects were recruited from different ethnic 
backgrounds reflective of local ethnic diversity. The majority of subjects 
were Caucasians (78%) followed by Asians (17%) and Africans (5%). All 
were acid infusion naïve. 
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Figure 81 Flow diagram illustrating the final numeric outcome of participants in study 3. 
The experimental study design was that of a prospective randomised placebo 
controlled two-tiered crossover double-blinded longitudinal cohort study. [SB: Sham 
Breathing, St: Stress Test, Db: Deep Breathing.] 
 
During their first randomisation visit, five subjects could not tolerate 
prolonged nasal intubation even though intubations were successful and 
were excluded. For the final analysis, 18 subjects (13 male) completed 
the sham breathing protocol and only 16 the psychological stress 
induction protocol, as a further three subjects were unable to complete 
the study (due to study unrelated reasons, one had a family emergency 
and the other two, sudden unscheduled commitments). (Figure 81) Due 
to the sensitisation state ‘blinded’ randomisation, 8 non-sensitising 
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subjects completed the deep breathing protocol, before they could be 
identified and recruited to study 3. 
 
4.3.9 Pain Tolerance Threshold Data of Proximal Oesophagus for 
study 3 
 
4.3.9.1 Main modulation group 
Absolute threshold data for the proximal oesophagus at (T0) and post-
acid infusions (T60, T90, T120) for all modulation types are shown in Figure 
82(A&B). 
Table 6 
Figure 82 (A) Graph and (B) table, illustrating and listing absolute values for proximal 
oesophageal pain thresholds before (T0) and after (T60 T90 and T120) acid infusion with 
sham, deep breathing	  and stress induction protocols. 
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breathing and stress test, with the mean group value (SD) for each time 
point, are shown in figure 83 (A, B & C). During the stress test visit however 
25% (n=4) of subjects sensitised (i.e. mean ∆PT ≤-6mA) to acid infusion, 
and are indicated by means of the pink rectangles, in figure 83(C).  
 
 
Figure 83 Individual values of change for proximal oesophageal pain thresholds (∆PT) 
for time points T60, T90 and T120, following acid infusion with (A) sham breathing, n = 18  
(B) deep breathing, n = 8 and (C) Stress Test, n = 16. 
  
Two-way MANOVA analyses, comparing the influence of modulation 
type, across all time points, showed no statistical significance between 
modulations for the study group as a whole. (Figure 84(A)) 
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Figure 84 A: shows the difference in mean pain threshold  (ΔPT) in mA, for the proximal 
oesophagus between baseline and the three-time points (minutes) after acid infusion, 
for the different modulation types. B: Showing the difference in average means of pain 
threshold (Δ  Avr PT) in mA, for the proximal oesophagus between pre & post acid 
infusion, for the different modulation types. 
 
4.3.9.2 Sensitised stress-test modulation group 
Concerning the subjects that sensitised to acid infusion during the 
psychological stress induction visit, two-way MANOVA analyses indicated 
significance with regard to degree of sensitisation, contributing 25% of 
change over all time points (Figure 86(A)) and means comparison of the 
difference in pain threshold (∆PT) post-acid, also achieved significance. 
(Figure 86(B)) 
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Figure 85 A: shows the difference in mean pain threshold  (ΔPT) in mA, for the proximal 
oesophagus between sensitisation status and the three-time points (minutes) after acid 
infusion, for the stress induction modulation. B: Showing the difference in average 
means of pain threshold (Δ  Avr PT) in mA, for the proximal oesophagus between pre & 
post acid infusion, for the different modulation types.  
 
4.3.10 Pain Tolerance Threshold Data of Foot for study 3 
 
The foot pain threshold data showed that both deep breathing and 
stress induction modulations caused no significant change with regard to 
sham breathing. There was thus no indication of any degree of 
sensitisation with regard to the somatic control (foot) demonstrated in 
this instance for both MANOVA analyses (Figure 73), and on average PT 
means comparison of pre/post-acid differences (Δ Avr PT, not illustrated). 
For all MANOVA analysis data stets were of similar in variance and found 
to be statistically matching.  
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Figure 86 Shows the difference in mean pain threshold (ΔPT) in mA, for the foot between 
baseline and the three-time points (minutes) after acid infusion, for the different 
modulation types. B: shows the two-way MANOVA analysis tables across all time points 
for each individual modulation compared to sham breathing visit. 
 
3.4.11 Autonomic Data for study 3 
 
4.4.11.1 Sham breathing 
The ‘pre/during-acid’ infusion changes in ANS for the sham-breathing 
visit, served as ‘baseline’ to which deep breathing and stress induction’s 
modulated ANS-changes were compared; and are illustrated below in 
figure 87(A) & table 7(B). The changes observed during the sham 
breathing protocol demonstrated a post-acid increase in SNS activation, 
but in this group, as opposed to the sensitisers’ response in study 2 (Figure 
74(A&B)), there is still a degree of coinciding increased PNS activation 
observed. The SNS is hence still homeostatically ‘apposed’ to a degree, 
which is a novel finding not previously observed. (Shaded graph below, 
figure 87(A) & table 7(B). 
!! !! !! !! !! !!
Two-way MANOVA Foot (Alpha 0.05) 
            
    
Source of Variation % of total variation P value P value summary Significant?  
Interaction 1.314 0.7185 ns No  
Time 2.117 0.5402 ns No  
Deep breathing 1.289 0.2531 ns No  
       
ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 321.5 3 107.2 F (3, 96) = 0.4492 P = 0.7185 
Time 518.1 3 172.7 F (3, 96) = 0.7237 P = 0.5402 
Deep breathing 315.4 1 315.4 F (1, 96) = 1.322 P = 0.2531 
Residual 22907 96 238.6   
!! !
!! !
Source of Variation % of total variation P value P value summary Significant?  
Interaction 1.518 0.6724 ns No  
Time 2.133 0.5397 ns No  
Stress test 0.00481 0.9443 ns No  
       
ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 310.2 3 103.4 F (3, 96) = 0.5157 P = 0.6724 
Time 435.9 3 145.3 F (3, 96) = 0.7247 P = 0.5397 
Stress test 0.983 1 0.983 F (1, 96) = 0.004902 P = 0.9443 
Residual 19250 96 200.5   
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Table 7 
 
Figure 87 The comparison between the different ‘pre/post-acid infusion’ ANS changes 
between sham breathing (shaded), deep breathing and stress test modulation-types, 
are graphically illustrated in (A); with table (B) below showing the mean values of 
change & standard deviations for each specific protocol, and for deep breathing’s 
comparison & p-value significance with regards to sham breathing. [Abbreviations are 
as follows; SCR: skin conductance response, MBP: mean blood pressure, HR: heart rate, 
CSB: cardiac sensitivity to baroreflex, & CVT: cardio vagal tone.  
-50 0 50 100 150
Sham Breathing
Stress Test
Deep Breathing
Autonomic change by Modulation
Units of change due to acid infusion
SCR$(mS)%
MBP$(mmHg)!
HR$(bpm)%
CSB$(ms/mmHg)%
CVT$(Lvs)%
***"p=0.0006"
Modulation Protocol ANS Measure Δ Avr SD Difference between means P value 
SCR 
(mS) 5.28 6.74 1.07 ± 7.77 0.708 
 MBP (mmHg) 4.57 8.83 -10.2 ± 12.36 0.099 
 Deep Breathing HR (bpm) 3.58 8.86 2.63 ± 10.15 0.553 
 CSB (ms/mmHg) 0.2 1.75 0.117 ± 3.56 0.939 
 CVT (Lvs) 2.5 2.01 2.67 ± 2.70 0.0602 
SCR 
(mS) 6.17 4.31 -2.56± 11.64 0.3774 
 MBP (mmHg) 67.22 46.22 52.01 ± 48.34 0.0006 
Psychological 
Stress  
HR 
(bpm) 5.41 4.31 3.13 ± 7.08 0.097 
 CSB (ms/mmHg) -0.76 1.3 -0.94 ± 3.13 0.246 
 CVT (Lvs) -0.5 2.03 -1.13 ± 3.78 0.253 
SCR 
(mS) 8.73 9.09   
 MBP (mmHg) 15.71 14.02   
 Sham Breathing HR (bpm) 2.47 4.78   
 CSB (ms/mmHg) 0.29 2.45   
 CVT (Lvs) 0.53 2.83   
B: 
A: 
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4.4.11.2 Deep breathing 
The changes observed during the deep breathing protocol (figure 87(A) 
and table 7(B)), demonstrated no change post-acid/modulation in 
sympathetic outflow, but showing a further increase in the para-
sympathetic activation. Of note is that although the CVT showed a 
strong trend, there was no statistical difference to that observed during 
sham breathing. Interestingly the non-sensitisers’ PNS co-activation is 
consistent for both deep-and-sham breathing visits.  
 
4.4.11.3 Stress test 
The changes observed during the psychological stress test induction 
(figure 87(A) and table 7(B)), demonstrated a strong statistical significant 
post-acid/modulation increase in the MBP part of the sympathetic 
outflow, with a small withdrawal of para-sympathetic activation (a novel 
finding in non-sensitisers). Looking at the ANS response in the non-
sensitiser study group as a whole, in spite of the SNS increase and the 
slight PNS withdrawal (their only example of ANS non-co-activation), the 
modulation was not sufficient in producing an associated increase in 
post-acid sensitisation in the group, except in the 25% of individual 
subjects who sensitised (Figure 83), that we will turn to next. 
 
4.4.11.4 Sensitised vs. non-sensitised 
Comparing the ANS responses of subjects who sensitise vs. those that did 
not, as illustrated in figure 88(A&B) below. The changes observed during 
the psychological stress test induction demonstrated a significantly larger 
activation of the SNS (SCR - figure 89(A)) by the non-sensitisers, while the 
PNS (CVT - figure 89(B)) was not statistically significant. 
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Table 8 
 
 
Figure 88 The comparison between the different ‘pre/post-acid infusion’ ANS changes 
between the mean difference in ANS change between the group of subjects who 
sensitised and who did not, during the psychological stress protocol, are graphically 
illustrated in (A); with table (B) below showing the mean values of change & standard 
deviations for each specific protocol, and for deep breathing’s comparison & p-value 
significance with regards to sham breathing. [Abbreviations are as follows; SCR: skin 
conductance response, MBP: mean blood pressure, HR: heart rate, CSB: cardiac 
sensitivity to baroreflex, & CVT: cardio vagal tone.   
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Sham Breathing
Sensitised
Non-sensitised
Units of change due to acid infusion
Autonomic change by Stress Test Modulation
**" p=0.0015"
SCR$(mS)%
MBP$(mmHg)!
HR$(bpm)%
CSB$(ms/mmHg)%
CVT$(Lvs)%
t.se i3 $
(Stress%Test)%
e i3 $
(Stress%Test)%
Modulation Protocol ANS Measure Δ Avr SD Difference between means P value 
SCR 
(mS) 13.61 2.96 6.372 ± 1.626 0.0015 
 MBP (mmHg) 59.65 302.50 78.35 ± 155.5 0.6229 
 Not-sensitised HR (bpm) -64.58 10.63 -0.6818 ± 5.481 0.9029 
(Stress Test)  CSB (ms/mmHg) 0.16 2.33 -1.361 ± 1.321 0.3216 
 CVT (Lvs) -0.18 2.93 -0.6318 ± 1.585 0.6966 
SCR 
(mS) 7.24 2.23   
 MBP (mmHg) -18.70 49.73   
Sensitised  HR (bpm) -63.90 2.24   
 (Stress Test)  CSB (ms/mmHg) 1.53 2.03   
 CVT (Lvs) 0.45 1.85   
SCR 
(mS) 8.73 9.09   
 MBP (mmHg) 15.71 14.02   
 Sham Breathing HR (bpm) 2.47 4.78   
 CSB (ms/mmHg) 0.29 2.45   
 CVT (Lvs) 0.53 2.83   
A: 
B: 
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Of note are two potentially contradictory observations regarding the 
sensitised ‘non-sensitiser’ group’s observed ANS responses: 
(i) Opposite to the observations in study 2, here the sensitised 
‘non-sensitisers’ demonstrate no PNS withdrawal (possibly even 
a trend indicative of PNS increase), yet sensitised. In study 2, 
CVT had a positive correlation with increased pain threshold 
(Avr PT), and hence a higher CVT would be associated with 
desensitisation.  (Figure 79) 
(ii) Compared with the non-sensitised ‘non-sensitisers’ who were 
not able to maintain ANS co-activation, the sensitised group 
had a statistically significant lower degree of SCR activation, 
yet sensitised. In study 2, SCR correlated positively with 
increased pain sensitivity (∆PT), and hence a lower SCR would 
be associated with desensitisation. (Figure 78) 
 
 
Figure 89 The comparison of the difference in ANS change between the group of 
subjects who sensitised (pink) and who did not (green) during the psychological stress 
protocol with (A) showing the change in SCR (SNS) and  (B) the change in CVT (PNS).  
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4.4.12 Psychological Profiling Data for study 3 
 
4.4.12.1 BFI questionnaire 
The BFI questionnaire, using cumulative percentages15, was used to 
analyse and interpret the cohort’s personality domain data. A 
comparison of personality domains of the cohort of healthy volunteers 
between study 2 and 3, indicated that they were both evenly grouped 
between introversion and extroversion, with the sensitisers slightly more 
extrovert and higher for agreeableness and conscientiousness. (Figure 
4.24(B)) The non-sensitisers scored higher for neuroticism and openness. 
(Figure 4.24(A)) The respective profiles suggest that the sensitisers are 
more ‘out-going’ and ‘eager to please’, with the non-sensitisers more 
‘reserved and conservative’ yet ‘adventurous’. Both groups were similar 
in general personality, reflecting the confounder of self-selection for 
voluntary experimentation. 
 
Figure 90 Big Five inventory (BFI) as percentage of maximum possible (Cumulative 
Percentages) scores in (A) studies 3, non-sensitisers and (B) study 2, sensitisers, across 
the five different personality domains.  
                                                      
15 For a more detailed description see explanatory note, appendix thee, and chapter 
3, section 3.4.4, page 135). 
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4.4.12.2 Hospital Anxiety and Depression questionnaire 
On the Hospital Anxiety and Depression Score (HADS) the mean values 
for anxiety, 8.44 ±1.76(SD) and depression, 9.55 ±1.73(SD) were within  the 
borderline range (HADS score of 8-10/21), but below the clinical 
‘caseness’ cut-off (HADS score of ≥11/21). (266) Only 11.1% of subjects 
met the criteria for moderate anxiety and 16.7% for moderate 
depression, which is below average expectation. The sensitisers (study 2) 
scored less for depression (9.7%) and more for anxiety (16%). The 
opposite was observed for the non-sensitisers (study 3) (16.1% - anxiety & 
11.1% - depression). This could suggest that higher anxiety states 
(sensitisers) coincided with a greater awareness and sensitivity to 
influence from internal/external environmental stimulus, while not the 
case for depression (non-sensitisers). (295) 
 
4.4.12.3 State and Trait Anxiety Inventory questionnaire  
Analysis of the State and Trait Anxiety Inventory (STAI) indicated firstly that 
the cohort’s trait anxiety (STAI-T), 34.33 ±8.05(SD) is below general 
population expectations (38.69 ±10.34(SD)). (267) A second consistent 
finding was that the subjects’ state anxiety reduced with each 
subsequent visit, and is an example of exposure habituation. Between 
visit 1 and 2 state anxiety dropped by ∆-4.49, and between visit 1 and 3, 
by a further ∆-2.44. (mean ∆STAI-S = -3.47 ±5.19(SD) per visit) 
 
In comparing STAI-S analysis with regard to non-sensitised ‘non-sensitisers’ 
(non-sensitised-ns) vs. sensitised ‘non-sensitisers’ (sensitised-ns), the 
sensitised-ns had a lower trait anxiety, 29.00 ±2.16(SD) compared to the 
non-sensitised-ns: 35.17 ±8.20(SD), p=0.504; replicating this previously 
observed contradictory finding. (296) When the sensitised-ns & non-
sensitised-ns’s ‘anxiety habituation’ were compared, the sensitise-ns 
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habituated more, mean ∆STAI-S(S) = -2.25 per visit, than the non-
sensitisers-ns, mean ∆STAI-S(N) = -0.875 per visit. At the time of the third 
(stress induction) visit, the sensitised-ns’ STAI-S was 21.00 <0.00(SD), 
compared to the non-sensitisers-ns’ 30.33 ±4.72(SD), p=0.038. This finding 
could suggest “non-adaptive calm”, or coinciding conflicting 
emotional/arousal states, sighted by Gray and McNaughton. (66)  
 
4.4.12.4 Toronto Alexithymia Scale questionnaire 
In comparing the Toronto Alexithymia Scale (TAS-20) analysis with regard 
to the sensitised/non-sensitised-ns, the sensitised-ns had a significant 
higher TAS-20 score, 87.5 ±5.45(SD) compared to the non-sensitised-ns’ 
76.00 ±6.99(SD), p=0.010, replicating similar previous findings. (297-299) 
The “Difficulty describing feelings” TAS-20 sub-scale was specifically 
predictive as the non-sensitised-ns had a mean of 21.5 ±2.08(SD) 
compared to the non-sensitised-ns’ 17.00 ±2.52(SD), p=0.006.  
 
4.4.12.5 Vulnerable Attachment Style Questionnaire 
With the Vulnerable Attachment Style Questionnaire (VASQ) 33% of 
subjects had significant attachment vulnerability, which is lower than 
expected for a non-patient population (293), of which 67% was of 
anxious-preoccupied, and 33% of dismissive-avoidant types. The 
percentage of significant attachment vulnerability for the non-sensitisers 
(study 3 - 33%) was less than for the sensitisers (study 2 - 40%), as well as 
less for the cohort as a whole (studies 2&3 - 37%). (Figure 91) 
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Figure 91 The Vulnerable Attachment Style Questionnaire (VASQ) findings for study 3, 
showing the secure/insecure percentages with the pie graph, and a brake-down of the 
types of insecure attachment style on the adjacent bar chart. 
 
In comparing the VASQ analysis with regard to the sensitised/non-
sensitised-ns sub-group, the sensitised-ns had significant higher 
attachment vulnerability VASQ percentage of 50%, which is also higher 
to the proportion when compared to other non-patient samples. The 
non-sensitised-ns’ 33%, on the contrary was lower than expected for a 
non-patient population. (293, 294) (Figure 92) The non-sensitised-ns’ 
vulnerability was consistent with that of the cohort (33%), but the 
sensitised-ns were 17% higher (50%). 
 
 
 
 
 
secure& anxious–preoccupied& dismissive–avoidant&
Study&3:&A7achment&Style&Vulnerability&
66%# 33%#
67%&
33%&
  
 
 
211 
 
 
 
Figure 92 The Vulnerable Attachment Style Questionnaire (VASQ) findings, showing the 
secure/insecure percentages with the pie graph, and a brake-down of the types of 
insecure attachment style on the adjacent bar chart. 
 
 
4.4.13 Correlation Data for study 3 
 
During sham breathing visit a positive correlation between pain threshold  
(Avr PT) and CVT was detected, r=0.518 (p=0.032), i.e. the higher the 
CVT, the higher the PT. This replicates the finding that visceral pain 
threshold increases with the increase in para-sympathetic outflow. (132, 
133) (Figure 93) 
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Figure 93 The correlation between the average pain threshold (Avr PT) and cardiac 
vagal tone (ΔCVT) during sham breathing visit.  
 
During psychological stress induction visit a positive correlation between 
the degree of pain sensitivity (∆PT) and SCR was detected, r=0.063 
(p=0.030). This indicates that visceral pain sensitivity increases with the 
increase in sympathetic outflow during stress. (Figure 94) 
 
Figure 94 The correlation between the difference in pain threshold (ΔPT) and cardiac 
vagal tone (ΔCVT) during deep breathing visit. 
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4.5 Discussion 
The results of study 2 provide evidence that visceral pain hypersensitivity, 
induced in the proximal oesophagus by acid infusion in the distal 
oesophagus, is prevented by deep breathing through its action on the 
increasing PNS tone.  
 
Hitherto, the mechanisms by which deep breathing increases PNS tone 
have been incompletely understood. (300-302) It has been hypothesised 
that deep breathing increased PNS tone through its action on increasing 
afferent baroreflex signalling via the vagus nerve. (228) This enhances 
neuronal activity in the nucleus tractus solitarius (NTS), located in the 
caudal medulla, resulting in excitation of pathways leading to the 
nucleus ambiguous (NA), a structure within the medulla responsible for 
increasing efferent vagal tone, i.e. CVT. To date, to the best of my 
knowledge, this physiological reflex arc has not been demonstrated with 
a direct, rather than proxy, measure of CVT in humans. These results 
therefore provide evidence that deep breathing manoeuvres do cause 
a demonstrable objective rise in CVT and thus PNS tone, which could 
represent a physiological mechanism of action of many complementary 
therapies in which deep breathing is emphasised. (57, 303) 
  
It has been in excess of 20 years since the role of vagal afferents, where 
the effects of vagotomy, with or without supplementary vagal nerve 
stimulation (VNS), in modulating pain in animal models were first 
reported. (304) For instance, Chen et al. have presented evidence to 
support the hypothesis that vagal afferents modulate sensorimotor 
responses to visceral pain emanating from the GI tract per se. (305) In this 
study, the authors’ measured visceromotor responses (VMR) to graded 
colorectal distension (CRD) following electrical VNS, or topical 
application of lidocaine to the vagus nerve, following subdiaphragmatic 
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vagotomy in conscious rats. In both of these scenarios, a reduction of 
VMR to increasing CRD was noted thus indicating enhancement of PT.   
 
Study 2 was devised to translate these findings into a human model of 
visceral pain in order to evaluate the importance of physiologically 
manipulating PNS tone in the development of central sensitisation. 
Central sensitisation is considered to be an important component of the 
endogenous pain regulatory system, whose dysfunction is considered to 
play a role in the maintenance of chronic visceral pain, through its 
functional and dynamic interaction with the ANS. (306, 307) For the first 
time in a model of human visceral hypersensitivity it has been 
demonstrated that deep breathing increases PNS tone and prevents the 
development of central sensitisation. However thus far, objective 
experimental evidence for the effectiveness of deep breathing in 
management of visceral pain is lacking. Nevertheless, both common 
personal experience and a number of studies have postulated its 
efficacy in ameliorating both acute and chronic somatic pain. In the 
context of chronic somatic pain syndromes, deep breathing has been 
observed to reduce pain and increase daily functioning in patients with 
fibromyalgia. (308) Similarly in acute somatic pain, what parent has not 
soothed their child, following a grazed knee for argument, with the 
suggestion of “taking deep breaths,” presumably conferring a degree of 
analgesia from the said injury. Somewhat more objectively, Friesner et al., 
have demonstrated breathing induced analgesia, when comparing 
deep breathing with natural breathing, during thoracic drain removal, 
although this study did not control for distraction. (309) More recently, 
Chalaye et al. resolved this confounding, evaluating basic HRV variables 
and thermal PT during deep breathing and distraction. (310) In healthy 
subjects, deep breathing increased proxy measures of vagal activity and 
resulted in elevated PT, and whilst distraction produced similar relative 
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analgesia it was not accompanied by changes in autonomic tone. In 
the context of this data, it would be important to study the effect of co-
administered atropine and deep breathing on sensitisation. This could 
potentially examine and contrast the contribution and importance of the 
neurobiological pathways that underlie deep breathing induced PNS 
analgesia, with the degree of associated distraction which arguably 
accompanies all paced breathing techniques, and could highlight their 
possible difference. Distraction is a manifold phenomenon; the analgesia 
that was observed could plausibly be due to the observed reduction in 
anxiety. 
 
Anxiety at the time of GI injury or inflammation increases the risk of 
developing chronic visceral hyperalgesia and symptoms. (41) Sharma et 
al. recently examined whether anxiety influences acid-induced 
hyperalgesia in a cohort of healthy subjects. (311) In this study the 
investigators demonstrated that acute anxiety induction, through 
autobiographical recall of adverse life events, caused an increase in 
sympathetic nervous system tone, with concomitant PNS withdrawal, 
and an increase in acid-induced oesophageal hyperalgesia. Thus 
anxiety may therefore facilitate the development of central sensitisation 
in the oesophagus presumably in combination with modulatory 
influences of the ANS.   Study 2 evaluated trait anxiety measures and saw 
a small negative effect on CVT but not PT. In combination therefore, 
both short (state) and long (trait) term anxiety measures influence ANS 
tone in response to acid-infusion although the former may confer 
hyperalgesia possibly through the acute withdrawal of PNS tone 
influencing the process of central sensitisation. 
 
Whilst this study was not designed to describe the precise 
neurobiological mechanisms by which increasing PNS tone imparts an 
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analgesic effect, data derived from VNS studies have facilitated 
important insights to be garnered. It maybe surmised that such 
mechanisms may be manifest at three levels from the periphery to 
central neurotransmission and supraspinal areas. Firstly, in the periphery, it 
has been shown that VNS may have a dual effect with seemingly 
inhibitory and excitatory effects below and above C3 respectively, 
raising the possibility that neurones arising from the propriospinal tracts of 
higher cervical segments may confer anti-nociception in more distal 
segments. (312, 313) Secondly, a plethora of neurotransmitter systems 
have been implicated in vagal mediated anti-nociception including 
serotonin, noradrenaline and opioids. (314) For example, opioid 
antagonism, which would be expected to cause hyperalgesia, has been 
shown to not influence PT following functional vagotomy thereby 
suggesting a role for opioidergic pathways in vagal mediated anti-
nociception. (315) Vagal afferents signalling also influences the allostatic 
hypothalamic-pituitary-adrenal axis through indirect activation of the 
parabrachial nucleus through the modification of adrenocorticotrophic 
hormone, corticosterone and adrenaline, themselves arbitrators of 
inflammation and nociception. (316, 317) Finally, within the brainstem, 
the NTS forms part of the central autonomic network (CAN), itself 
encompassing a network of highly interconnected pain inhibition relays 
in association with the periaqueductal grey, lateral parabrachial nucleus 
and the ventrolateral medulla. (318) Experimental evidence, largely 
derived from animal studies utilising local aesthetic blockage of the 
constituent areas of the CAN, support the notion that these structures are 
the main substrates for vagal induced analgesia. (319, 320) Moreover, in 
humans, following short-term transcutaneous VNS, functional 
neuroimaging shows changes in activity in areas of the visceral pain 
neuromatrix, such as the limbic brain areas, including the amygdala, 
hippocampus and parahippocampal gyrus. (321)  
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There are a number of important therapeutic implications of study 2’s 
findings. An immediately attractive suggestion is whether the direct 
measurement of CVT during deep breathing techniques may facilitate 
the objective interrogation of the success of such measures in changing 
PNS tone but also inducing analgesia. Furthermore, interventional 
manipulation of PNS tone could be used to identify patients with visceral 
hypersensitivity as sequelae of central sensitisation per se. For instance, if 
it were possible to show that hyperalgesia was lessened following 
administration of a technique that increased PNS tone, it would provide 
evidence for central sensitisation as the underlying cause. In contrast, 
failure to respond would suggest a different mechanism such as 
hypervigilance. Such characterisation would also allow appropriate 
individualisation of management to the underlying mechanism, such as 
cognitive behavioural treatments in those with hypervigilance and 
pharmacotherapy in those with central sensitisation. Equally, it is possible 
that episodic utilisation of deep breathing techniques during acute 
inflammatory episodes, such as during gastro-oesophageal reflux events, 
may produce both symptomatic relief and prevention of central 
sensitisation, hyperalgesia and chronicity of symptoms that are seen in 
EO. Finally with regard to study 2, transcutaneous electrical VNS 
stimulation has been shown to increase somatic PT and reduce pain 
ratings, in the absence of any demonstrable cardiovascular side effects, 
and therefore this novel non-invasive technology may offer a treatment 
option in the prevention of central sensitisation and with it, chronic pain, 
in patients with FGID. (322) 
 
With the consideration of study 3’s results evidence is provided that 
explains and clarifies the hitherto poorly understood multifactorial ANS 
regulatory mechanisms of visceral pain hypersensitivity in non-sensitising 
subjects. This group has never been studied using this model before, and 
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it is with the inclusion of their ANS response to acid that allows us for the 
first time to observe and compare the ANS response of healthy subjects 
across the complete spectrum of visceral hypersensitivity reactions as 
induced by this model.  
 
In study 2 it has been demonstrated how increase in PNS activation (and 
SNS withdrawal) is associated with reversal of hypersensitisation, but it is 
only when compared with the responses of the non-sensitisers that a 
deeper understanding can be reached. The most striking observation is 
the contradictory finding that in non-sensitisers under stressful conditions 
an increase in PNS (CVT) is associated with sensitisation and activation of 
SNS (SCR) is now associated with non-sensitisation. This is an example of 
what has now come to be known as the “Vagal Paradox”. (8) It is only 
with the incorporation of ‘polyvagal’ and ‘attachment’ theory that a 
more full and coherent discussion of the observed results can be given as 
hypothesis.  
 
The Polyvagal theory is proposed by Porges et al. (8, 215, 292) and has 
gained great acceptance as it is increasingly supported by laboratory 
findings. From a psychological perspective, it provides an understanding 
of visceral self-regulation and sensory modulation. A phylogenetic 
approach is proposed to explain the vagal paradox in terms of the 
medullary source nuclei of the dorsal motor nucleus (DMNX) and nucleus 
ambiguous (NA). The term polyvagal is used as it distinguishes between 
the two main branches of the vagus nerve: 
1: The primitive unmyelinated “Vegetative Vagus”; which originates in 
the DMNX, and is associated with passive reflexive regulation of visceral 
functions, and mediates the most primitive ‘freeze’ stress response, which 
is part of the reptilian response system. 
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2: The new-myelinated “Mammalian Vagus”; which originates in the 
medullary source of the NA. The ventral vagal complex (including NA) is 
related to processes associated with attention, motion, emotion and 
communication, and mediates the most recent evolutionary 
‘communication system’ stress response that regulates heart (RSA) and 
bronchi to promote calm and self-soothing physiological states. 
 
Physiological states support different classes of behaviour. Vagal 
withdrawal, for instance, would support mobilisation behaviours of ‘fight-
n-flight’. Vagal activation would (via NA) support spontaneous ‘social 
engagement’ behaviours by means of structural links between brainstem 
nuclei and the striated muscles of the face and the smooth muscles of 
the viscera. (99) This is known as neuroception, and is the mechanism 
with which defence strategies are triggered. Neuroception, as a process, 
determines whether specific features in the environment elicit specific 
physiological states that would support either ‘fight-flight’ or ‘social 
engagement’ behaviours. It involves areas of the temporal cortex that 
decode biological movement and detect the intentionality of social 
interactions and would distinguish them between situations that are 
‘safe’ or ‘threatening’. (118) Porges proposes that the evolution of the 
ANS provides an organising principle to interpret the adaptive 
significance of affective processes. It thus links the evolution and 
structure of the ANS to affective experience, emotional expression, facial 
gestures, vocal communication and contingent social behaviour-and-
interaction. Hence a plausible explanation of socio-emotional, 
communication dysfunctions and visceral disregulation and sensitisation 
is potentially provided.  
 
Three phylogenetic stages of vertebrate ANS development are 
proposed (Table 9). Each stage is associated with a distinct ANS 
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subsystem that is retained and expressed by mammals.16 These ANS 
subsystems are phylogenetically ordered and behaviourally linked to (III) 
social communication (NA), (II) mobilisation (Spinal cord) and (I) 
immobilisation (DMNX). The three subsystems can be conceptualised as 
dynamic, providing adaptive responses to progressively safe, dangerous, 
or life threatening events and contexts. 
 
 
Table 9 The Phylogenetic stages of Polyvagal Theory’s stress activation responses.  
                                 [Duplicated from Porges, 2007 (8)] 
 
Functionally, when the environment is perceived as ‘safe’, the visceral 
state is regulated in an efficient manner to promote growth and 
restoration (e.g., visceral homeostasis), but when the environment is 
                                                      
16 They respond to challenges in a phylogenetically-determined hierarchy consistent 
with the Jacksonian principle of dissolution. Jackson proposed that in the brain, higher 
(i.e., phylogenetically newer) neural circuits inhibited lower (i.e., phylogenetically older) 
neural circuits and “when the higher are suddenly rendered functionless, the lower rise 
in activity” and describe the sequence of ANS response strategies to challenges. (John 
Hughlings Jackson (1835-1911) – known as “The Father of English Neurology”.) 
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perceived as ‘threatening’, two more primitive neural circuits to regulate 
defensive strategies (i.e., fight-flight and freeze behaviours) are retained. 
Social behaviour-and-communication and visceral homeostasis states 
are incompatible with the neurophysiological states and behaviours 
promoted by the two neural circuits that support defence strategies. 
Thus, via evolution the human nervous system retains all three neural 
circuits of ANS activation, which are in a phylogenetically organised 
hierarchy. In this hierarchy of adaptive responses, the newest circuit is 
used first (III), and if that circuit fails to provide safety the older circuits (II 
and I) are recruited sequentially. 
  
Bearing the aforementioned in mind, if the ANS responses observed in 
studies 2 and 3 are considered with the deep breathing visit representing 
arguably a safe/nurturing environment with a high degree of 
interpersonal interaction he sham breathing visit with some interaction, 
as representing a neutral environment, and the stress test that of a 
threatening/stressful environment, as summarised in table 10, one will 
then have a continuum of ANS responses of various subject vulnerability 
phenotypes across progressively increasing environmental stress states.  
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Table 10 An ‘Executive schematic summery’ of the results for study 2&3.   
 
Using the subject group’s sensitisation status the ANS responses can now 
be contrasted and better understood with the ANS activation phase as 
proposed by Porges et al. across different stress environments. In Figure 
95 it will become clear how the sensitisers PNS (∆CVT) activation 
represents a U-shape, where the vagal is both adaptive, and 
maladaptive, depending on the specific lower vagal motor neuron 
activated, which then leads to subsequent sensitisation in phases II and I, 
and desensitisation during phase III. The non-sensitisers on the other hand 
demonstrate an S-shaped curve, which does not lead to 
hypersensitisation in any of the phases. During the deep breathing visit, 
both groups demonstrate similar increases in CVT, consistent with phase 
III’s NA activation (the “mammalian vagus”). It is during the sham-
breathing visit that differences in the groups become clearer, with the 
sensitisers demonstrating a greater degree of vagal withdrawal 
compared to the non-sensitisers, consistent with phase II. Similarly during 
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phase I, the subjects that did not sensitise had lower activation than 
those that sensitised, consistent with phase I’s DMNX activation (the 
“vegetative vagus”). 
 
Figure 95 Illustrates the changes in Cardiac Vagal Tone (CVT) of the Parasympathetic 
nervous system (PNS) across three different environmental stress conditions ranging 
from ‘supportive/safe’ (left) as experienced during the deep breathing-experimental 
modulation procedure, threw ‘neutral’ (middle) as experienced during the sham 
breathing-experimental modulation procedure, to ‘demanding/threatening’ (right) as 
experienced during the stress test-experimental modulation procedure. This gives rise to 
three distinct different activation patterns as described by S. Porges (100) and illustrated 
by the roman numerals: III, II & I, coinciding with different vagal lower motor neuron 
activation, illustrated above as ranging from left, mainly Nucleus Ambiguus (NA) to the 
Dorsal motor neuron nucleus of the vagus (DMNX) on the right. In the foreground is a 
schematic representation of the changes in stress responses as observed during studies 
2 & 3, for the sensitisers (pink graph), and the non-sensitisers (green graph) to acid 
infusion induced oesophageal pain hypersensitivity (OPH).  
 
Similarly in Figure 96 the differences in SNS (∆SCR) are illustrated during 
the same stress activation phases as in table 9 for the differing subject 
sensitisation status groups. Once again during phase III (deep breathing 
visit), both groups demonstrated low SNS activation/withdrawal. During 
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phase II (sham breathing visit) there is SNS activation to a degree where 
the between group differences are noted, but not statistically significant. 
It is during phase I that a clear difference can be detected, with the 
non-sensitisers able to mount an appropriate sympathetic response, 
compared to much lower activation by the subject group that sensitised 
(stress test). 
 
 
Figure 96 Illustrates the changes in sudomotor activation of the Skin Conduction 
Response (SCR) under control of the Sympathetic nervous system (SNS) across three 
different environmental stress conditions ranging from ‘supportive/safe’ (left) as 
experienced during the deep breathing-experimental modulation procedure, threw 
‘neutral’ (middle) as experienced during the sham breathing-experimental modulation 
procedure, to ‘demanding/threatening’ (right) as experienced during the stress test-
experimental modulation procedure. This gives rise to three distinct different activation 
patterns as described by S. Porges (100) and illustrated by the roman numerals: III, II & I, 
coinciding with change in primary autonomic nervous system (ANS) activation, 
illustrated above as ranging from left, mainly Vagal (also known as the ‘vagal brake’ to 
unimpeded sympathetic activation on the right. In the foreground is a schematic 
representation of the changes in stress responses as observed during studies 2 & 3, for 
the sensitisers (pink graph), and the non-sensitisers (green graph) to acid infusion 
induced oesophageal pain hypersensitivity (OPH). 
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It is with the incorporation of attachment theory that the psychological 
underpinnings of the above observed ANS responses potentially become 
clearer and possibly more understandable. 
 
In the extreme, the true freeze response (phase I) is dangerous to 
mammals as the high tone immobility response of the DMNX vagal 
system is lethal in mammals. Whereas high tone from the NA-vagal 
system (phase III) may be beneficial in adaptive significance of 
mammalian affective processes including courting, sexual arousal, 
copulation, and the establishment of enduring social bonds 
(attachment). In the development of enduring pair-bonds the 
mammalian vagus communicates safety and trust, via oxytocin and 
vasopressin, between the hypothalamus and the medullary source 
nuclei of the viscera vagus. (323) 
 
The higher cognitive processes of the prefrontal cortex calm the stress 
response and establish effective social connections by using facial 
muscles, establishing eye contact, modulating tone of voice and 
listening to others (attachment behaviour). This increases the influence of 
the myelinated vagus, which is calming and decreases the stress 
response and is metabolically more efficient. (324) 
 
The vagus is asymmetrical with the left and right sides performing 
different tasks, with the right vagus most active in cardiovascular 
regulation. Primary emotions are related to autonomic functioning since 
they are often survival related, and hence they must be integrated into 
cardiopulmonary regulation. Emotions have a right limbic bias, as does 
the brainstem medullary structures controlling visceral function. Only 
when the environment is perceived as “safe” is there cortical regulation 
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of the visceral pathways, because while under threat, cortical control of 
brainstem structures would compromise the individual’s ability to mobilise 
(phase II). Therefore when stressed or in danger, cortical control of 
brainstem is “inhibited” and the brainstem structures are “disinhibited” to 
allow the SNS to efficiently increase metabolic output (phase I). 
 
Vagal stimulation releases noradrenaline into the amygdala 
strengthening memory storage and regulates arousal, memory and 
affective responses to emotionally laden stimuli. This is the mechanism by 
which peripheral adrenaline released during the fight-flight response, 
activates noradrenaline release in the limbic system strengthening 
memory of certain events. Since adrenalin cannot cross the blood brain 
barrier it activates the vagus nerve, which in turn stimulates neurons in 
the NTS. Visceral organ vagal afferents from the head, neck, thorax, and 
abdomen relay information to the NTS, that in turn release noradrenaline 
into the memory processing areas of the amygdala and hippocampus. 
(325) This activates long-term memory storage of emotionally laden 
events.  It is these long term stored limbic memories of “emotionally 
laden events”, that give rise to one’s inner-concept of a “secure-base”, 
that forms the discriminating factor in the observed inter-individual 
variation of the degree of cortical control of brainstem structures 
controlling the individual’s ability to mount an appropriate mobilisation 
response. Therefore when stressed or in danger, the inhibitory cortical 
control of the brainstem is modulated by the limbic memory storage and 
brainstem structures, that then affect the degree of SNS “disinhibition” 
that is allowed to increase metabolic output in response to an 
environmental stress stimuli (phase I). 
 
Craig et al. (326) explains how emotions arise from feelings in our organs 
and gut. The feelings are sent via the vagus nerve to the Anterior Insular 
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Cortex (AIC) in the brain. The AIC captures feelings over time and stores 
them as snapshots of feelings. This is our “working emotional memory”. 
These feelings are massaged and integrated with the social exchange to 
give us both an emotional response to the world around us as well as a 
safety-driven response strategy (e.g. an adult attachment style). Almost 
any activity will involve the combined interaction of the various safety 
strategies. The bottom line of which is that one is constantly adjusting to 
meet the challenges posed by the world. The results of studies 2 and 3 
give one a look at how this potentially works.  
 
Safety, as an inner sensation, not a mind-based concept, is the feeling of 
“inner-security” that Bowlby and Ainsworth et al. called one’s "secure-
base," and one’s “fundamental need of attachment to others, for 
healthy physical and emotional/mental, functioning.” (119, 327, 328) 
Attachment theory describes the dynamics of long-term relationships 
between humans. Its most important tenet is that an infant needs to 
develop a relationship with at least one primary caregiver for social and 
emotional development to occur normally. It explains how much the 
parents’ relationship with the child influences development. Attachment 
theory is an interdisciplinary study encompassing the fields of 
psychological, evolutionary, and ethological theory. Ainsworth et al. 
(329) introduced and reinforced the basic concept of the "secure base" 
and developed a theory of a number of attachment patterns in infants: 
secure attachment, avoidant attachment and anxious attachment, that 
later was expanded to include a fourth type,17 and applied it to adults. 
 
“Feeling safe within” and “having a secure-base”, is now increasingly 
understood as being as vital to one’s physical, emotional and mental 
                                                      
17 The Disorganised attachment. 
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health, as oxygen is for one’s on-going survival. It is known that feeling 
unsafe within or not having a secure-base ‘autonomically’ triggers our 
ancient freeze/flight/fight defences, through the above-mentioned 
process of "neuroception", and thus produces these individuals more 
vulnerable. It has been previously reported that when one does not feel 
‘safe within’, or has no ‘secure-sense-of self’, the resulting tension is then 
observable in the changes seen in visceral responses. Depressing this 
neural system has several behavioural consequences including flat 
affect, aprosody, difficulty in phoneme recognition, articulation 
problems, auditory hypersensitivity, and behavioural state regulation 
issues. (330) Although these symptoms are nonspecific regarding 
differential psychiatric or behavioural diagnosis, they are shared by 
many children with developmental disorders. 
 
With the above-mentioned in mind, when one considers the 
‘vulnerability phenotype’ column of table 10, the most vulnerable 
subjects (subjects sensitising at sham breathing) had a 40% vulnerability 
score, as opposed to the ‘resistant phenotype’-groups (subjects who did 
not sensitise at sham breathing) 33%, on VASQ. Of the resistant 
phenotype group, those subjects who sensitised under stress had a 50% 
VASQ vulnerability. The tentative results with regard to the adult 
attachment style indicate that it was predictive of the sensitisation 
response status. This finding could represent a replication of that made 
by Meredith et al. (22) and Davies et al. (331) working in similar fields of 
chronic pain disorders, and can aid in a better understanding of the 
context of underlining ANS effects in analgesia.  
 
The main weakness of this part of the study was the small sample size 
(type II error), and that attachment was assessed using a brief, self-report 
measure. The assessment of attachment therefore reflects individuals’ 
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subjective perceptions of their close relationships, which may be 
vulnerable to reporting bias. Whilst other more comprehensive 
assessments of attachment, delivered by self-rated questionnaire or 
interview, were available, these were considered too lengthy for 
inclusion in the laboratory setting of this study. 
 
Closely related to attachment is the significance of alexithymia in 
affording a degree of vulnerability to individuals in study 3. If a subject is 
able to ‘understand’, or ‘make sense’ of their inner emotional and/or 
visceral – states, i.e. neuroception, the individual is able to ‘cortically’ 
mediate the resulting ANS response more effectively, as described 
above, and in so doing maintain a higher visceral PT. Nyklícek et al. (298) 
looking at 41 healthy volunteers, found that alexithymia was associated 
with low tolerance to experimental pain stimuli, a finding that Ahlberg et 
al. (297) replicated looking at 750 subjects in connection with 
temporomandibular pain disorder. Dealing with alexithymia and 
attachment issues has now become the object of a major field of 
research known as “interpersonal neurobiology”, where Siegel et al. are 
developing novel therapeutic interventions dealing with these 
complicated interdisciplinary patients. A concept known as “mindsight” 
has been coined to address alexithymia and disregulation 
therapeutically. (332)  
 
Finally, with regard to study 3 there remains the issue around anxiety. 
Here the observed contradiction where the non-sensitising subjects had 
a higher state anxiety when compared to those who sensitised 
previously, goes against findings in study 1 and heretofore experiences 
using this model by Sharma et al. (311) This is however not without  
precedent, as Thibodeau et al. (296) found looking at 95 nonclinical 
participants (55% women) that anxiety sensitivity was associated with an 
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increased pain tolerance, “a novel finding needing further examination.” 
(296) Here pain was induced by using heat and cold stimuli, 
administered by a Medoc Pathway Pain and Sensory Evaluation System. 
This arguably represents a stressful experience in healthy volunteers 
(possibly a resistant group), and it would be interesting to see if the results 
remained consistent when repeated in patients (a vulnerable group). 
With the understanding gleamed from the ‘phase I protective’ SNS 
activation (figure 96) a possible reinterpretation consistent with the 
present findings would suggest that anxiety in this context represents an 
appropriate ‘adaptive’ response from a more resistant phenotype, and 
just like the PNS could represent a ‘double edged sword’, where, 
depending on the context. Activation can be both ‘protective’ and 
‘harmful’. This hypothesis is strengthened by the observation that the 
non-sensitising group’s trait anxiety was lower than that of the sensitising 
group. The finding would be consistent with a more resistant sub-group. 
Further, Holtmann et al. (333) found that when acute psychological stress 
was  induced in 14 healthy subjects and compared with endogenously 
stimulated gastric acid output, there was a great individual variability in 
gastric acid response to acute mental stress, and that this variability may 
be “attributed to differences in personality traits.” (333) They go on to 
describe inter individual differences in blood pressure and heart rate 
responses, suggesting personality (in their case, impulsivity) mediated 
differences in cortical control of ANS responses, as described above, 
effecting gastric acid secretion.  
 
Hence the application and reinterpretation of previously contradicting 
findings could possibly become more understandable and clinically 
applicable. This would suggest that for clinicians to reach greater clinical 
efficacy in future, they would have to have a working knowledge of a 
patient’s vulnerability phenotype, in order to best match to most 
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effective treatment regimen. Characterisation would also allow 
appropriate individualisation of management to the underlying 
mechanism. The results from studies 2 and 3 for the first time give us an 
explanation of underlying neural mechanisms for the observed spectrum 
in phenotype vulnerability, but further study is necessary to clarify this. 
  
4.6 Conclusions 
In conclusion, studies 2 and 3’s findings represent the first human study 
addressing the pivotal role of the ANS in mediating visceral pain 
hypersensitivity as induced in the proximal oesophagus by acid infusion 
in the distal oesophagus. Study 2 provides evidence for how sensitisation 
can be prevented by deep breathing through its action on the 
increasing PNS tone, and study 3 demonstrates the paradoxes with 
regard to ANS regulation across a continuum of environmental stress 
levels. It also highlights the need for a deeper understanding of the 
vulnerability phenotypes involved. 
 
Studies 2’s results represent a novel human intervention study addressing 
the key role of the PNS in mediating visceral pain hypersensitivity. It has 
now been shown that the induction of acid-induced hypersensitivity is 
altered by physiological influencing PNS tone. This finding strongly 
indicates that the PNS plays a central role in the development of central 
sensitisation. Further study is now needed to investigate the potential of 
therapeutically manipulating PNS tone in the management of visceral 
pain.  
 
It is now important to study the effect of co-administered atropine and 
deep breathing on sensitisation. This could potentially examine and 
contrast the contribution and importance of the neurobiological 
  
 
 
232 
 
pathways that underlie deep breathing induced PNS analgesia. The 
degree of associated distraction that accompanies all paced breathing 
techniques could be examined and potentially highlight their 
therapeutic difference and impact. Distraction is a manifold 
phenomenon; the analgesia that was observed in study 2 could plausibly 
be due to the observed reduction in anxiety. The results should also be 
validated by means of an unrelated cohort in another study centre.  
 
Studies 3’s results provide evidence that explain and clarify the hitherto 
poorly understood multifactorial ANS regulatory mechanisms of visceral 
pain hypersensitivity in non-sensitising subjects. This group has never been 
studied using this model before, and it is with the inclusion of their ANS 
response to acid that allows us for the first time to observe and compare 
the ANS response of healthy subjects across the complete spectrum of 
visceral hypersensitivity reactions as induced by this model.  
 
With the simultaneous examination of all three parts of the 
biopsychosocial triumvirate, an important synthesis could be made 
between developmental psychology, neurobiology and 
gastroenterology. This allows us to reinterpret previously conflicting results 
with more clarity and potentially greater therapeutic advantages.  With 
the incorporation of attachment and polyvagal theory, study 3’s results 
demonstrate the paradoxes surrounding ANS regulation with regard to 
central sensitisation across a continuum of environmental stressors. It also 
highlights the need for a deeper understanding of the vulnerability 
phenotypes involved, and further study is now warranted to clearly 
define the psychological, physiological and genetic markers of the 
vulnerability phenotypes. Future investigation is also needed to examine 
the potential of therapeutically manipulating ANS tone (e.g. 
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psychologically / pharmacologically) in the management of chronic 
visceral pain syndromes.  
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5 Effect of Psychopharmacological Modulation with Atropine 
on Acid Induced Oesophageal Hypersensitivity - Study 4 
(Atropine challenge pilot study)  
  
5.1 Introduction 
Visceral pain is a complex phenomenon with sensory-discriminative, 
affective-motivational and cognitive-evaluative components. (334) In 
study 2 it was demonstrated that during deep breathing there is an 
increase in CVT such that oesophageal acid infusion failed to cause 
sensitisation. This observation supports the hypothesis that withdrawal of 
parasympathetic tone is associated with sensitisation whereas an 
increase is protective and reduces sensitisation. This data supports the 
notion that the parasympathetic nervous system may have anti-
hyperalgesic properties in the human viscera, and that anxiety may 
predispose to greater post-injury gut sensitisation through the withdrawal 
of vagal tone. Conversely, it has been demonstrated that increasing CVT 
through deep breathing reduces sensitisation in the viscera. However, 
the exact mechanism of how this decrease in sensitisation occurs is not 
clear despite evidence pointing to the ‘up’ modulation of the 
parasympathetic nervous system as the likely cause for the anti-
hyperalgesia.  
 
It is important to study the effect of co-administered atropine and deep 
breathing on sensitisation. If potential amelioration of the degree and 
development of visceral hyperalgesia is due to deep breathing induced 
PNS, this should be negated with pharmacologically reduced PNS tone 
by an anti-cholinergic. This could potentially examine and contrast the 
contribution and importance of the neurobiological pathways that 
underlie deep breathing induced PNS analgesia. The degree of 
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associated distraction that accompanies all paced breathing 
techniques as in study 2, should be clarified. Distraction is a manifold 
phenomenon; the analgesia that was observed in study 2 could plausibly 
be due to the observed reduction in anxiety. Study 2’s results should also 
be validated by means of an unrelated cohort in another study centre. 
 
The proposed study aims to clarify this phenomenon, as well as elaborate 
on the conditions of desensitisation with the addition of a means of PNS 
anti-cholinergic blocking with atropine sulphate, administered 
intravenously. Atropine is used, as it is an established form of blocking 
vagal tone in similar experimental studies. The resulting re-sensitisation of 
volunteers that previously desensitised with the deep breathing 
modulation protocol during oesophageal acidification will be conclusive 
in establishing the role of the PNS in deep breathing induced 
desensitisation. 
 
It is thus hypothesised that the physiological deep breathing induced 
PNS desensitisation will be inhibited with the anticholinergic atropine, 
causing a re-sensitisation in oesophageal pain hypersensitivity through 
the unopposed effect of the sympathetic nervous system. 
 
5.2 Materials and Methods 
5.2.1 Ethics Committee Approval 
All protocols for this study were submitted and approved by the 
Research Ethics Committee of North Jutland, Denmark (ref: N-
20120065vII).  See section 2.1 (page 77). 
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5.2.1 Subjects 
32 healthy asymptomatic adult male and female volunteers, aged 18 to 
50, were recruited by advertisement. Screening for acceptability for 
inclusion and exclusion criteria was completed as described in section 
2.2 (page 77).  
 
5.2.2 Oesophageal Manometry 
For this study standardised oesophageal manometry (183) was 
performed in the first five subjects of study 1 to determine the positions of 
the upper and lower oesophageal sphincter (UOS and LOS) from the 
nostril. As the LOS positions on these first five subjects were found to be 
accurate enough for the purpose of this study, only the ‘pH change’ pull 
back technique as described in section 2.3 (page 78), was used for the 
remaining 15 subjects. 
 
5.2.3 Psychological Assessment 
For study 4, only Spielberger – Trait and State Anxiety Inventory STAI was 
used. (section 2.11, page 85) The Trait questionnaire was completed 
during the screening visit, wiles the State questionnaire, was completed 
at the start and end of visit 2 (V1) and visit 3 (v2), as study 4’s endpoint 
analysis did not require more extensive psychological examination.  
 
5.2.4 Other Methods of Measurement 
All other methods of measurement; Catheter Assembly (section 2.4, 
page 78), Oesophageal acid infusion (section 2.4, page 78), 
Oesophageal pH monitoring (section 2.6, page 80), Pain Threshold 
Measurements (section 2.8, page 82). Measurement of the Autonomic 
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Nervous System (section 2.1, page 86) and Respiratory Monitoring 
(section 2.16, page 99) was performed as described in their specific 
sections, except that the skin conductance response could not be 
measured, as required equipment was not available in the Danish 
research site. Screening visit protocol was followed for the first visit, and 
all non-sensitisers were excluded.  For the following two visits the exact 
same protocol was followed as for the deep breathing modulation, used 
in study 2, with the exception of the administering of placebo (0.9% 
normal saline solution), or atropine, as described in chapter 2 (section 
2.20.4, page 115) and illustrated in figure 97 below.  
 
 
 
 
Figure 97 Diagram illustrating the psychophysiological modulation protocol for the 
atropine-placebo study. The subject was paced to perform 6 deep breaths on six 
occasions (purple figures) during the 30minitus acid infusion period (red bar) on all 
visits. Atropine or placebo was administered 5mins before the start of acid infusion. 
Autonomic measurement (brown bars) was done before and during the acid infusion. 
Pain thresholds (blue bars) were done before and three times after acid infusion. PH-
metry (green bar) was started 20mins before acid infusion, and stopped 30mins after 
acid infusion ended (see figure 41). 
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5.2.5 Study Procedure, Experimental Design & Protocol 
The experimental study design was that of a prospective randomised 
two-tiered double-blinded longitudinal crossover cohort study. (Figure 
98) The study procedure was followed as described in section 2.17 (page 
99), i.e. using the ‘three research assistants’ method. The experimental 
protocol was used as described in section 2.18 (page 101), with ‘time 
and events’ proceeding as outlined in figure 41 (page 102), with 
amendments as mentioned in section 5.2.3.  
 
  
Figure 98 Flow diagram illustrating the final numeric outcome of participants in study 4. 
The experimental study design was that of a prospective randomised two-tiered 
double-blinded longitudinal crossover cohort study. Sv: Screening visit, P: Deep 
breathing & placebo, A: Deep Breathing & atropine. 
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5.2.6 Data Handling, sample size and Analysis 
Demographic, pain threshold and autonomic data were normally 
distributed hence data are presented as mean ± SD, with parametric 
analysis. The variability was computed for the main effects of each 
subject’s change in PT over time points (ΔPT & time). All statistical analysis 
was completed as described in section 2.21 (page 120). 
 
 
5.3 Results 
 
During acid infusion, pH fell to <2.0 in the distal oesophagus of all subjects 
but remained >6.0 in the proximal (unexposed) oesophagus. The most 
common symptom reported with acid infusion was nausea. Other 
sensations included a cold sensation in the chest region, feeling of 
hunger and / or heartburn. 
 
5.3.1 Demographic Data: 
A total of 32 healthy volunteers were recruited and assessed for criteria 
eligibility. The healthy volunteers were recruited through an already 
established database at the Aalborg University Hospital, Denmark. All 
had normal medical assessments comprising of medical and surgical 
history with physical examination, heart rate (HR) and blood pressure (BP) 
recording, baseline electrocardiograph (ECG) and routine 
haematological and biochemical laboratory tests. The age range was 
from 21-49 years with a mean age of 28 ±9.11years. There were no obese 
or underweight subjects and the average body mass index (BMI) was 
23.10 ±2.75kg/m2. All subjects were recruited from a European (Danish) 
ethnic backgrounds All subjects were acid infusion naïve, with 59% 
  
 
 
240 
 
sensitising to acid infusion, allowing 19 subjects to be approached for 
phase two of the study. Three subjects withdrew from the study due to 
logistical limitations, and two withdrew consent following their 
experience during the screening visit. 
 
14 Subjects were randomised into two groups for their second visits. To 
randomise subjects without bias, www.randomisation.com (an approved 
statistical randomisation software package) was used. Subjects were 
randomised in groups of n=5. For the final analysis 14 subjects (6 male) 
were included. Due to technical problems with equipment, only 13 
subjects’ autonomic data could be analysed. (Figure 68) 
 
5.3.2 Pain Tolerance Threshold Data of Proximal Oesophagus and 
Foot 
Absolute threshold data for the proximal oesophagus at (T0) and after 
acid infusions (T60, T90, T120) are shown in Figure 99(A) & table 11(B) 
below.  
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Table 11 
Figure 99 (A&B) Absolute values for proximal oesophageal pain thresholds before (T0) 
and after (T60 T90 and T120) acid infusion with  (blue) Screening visit, (red) Deep 
breathing & placebo and (green) Deep breathing & atropine (n = 14)	   
 
The mean individual ‘pre/post-acid infusion’ changes in pain threshold 
(∆PT) for all subjects in the proximal oesophageal, during screening visit, 
deep breathing and placebo, and deep breathing and atropine with 
the mean group value (SD) for each time point, are shown in Figure 
100(A, B and C). Deep breathing and placebo significantly reduced the 
development of acid-induced hypersensitivity in the proximal 
oesophagus compared to screening visit. With deep breathing and 
atropine there was a greater degree of acid-induced hypersensitivity, 
but not to the degree observed during screening visit. 
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Figure 100 Individual values of change for proximal oesophageal pain thresholds (∆PT) 
for time points T60, T90 and T120, following acid infusion with (A) screening visit, (B) deep 
breathing & placebo, and (C) deep breathing & atropine. 	   
  
Two-way MANOVA analyses, comparing the influence of effect for 
‘Deep breathing and placebo’ and ‘Deep breathing and atropine’ vs. 
screening visit modulation’s mean ΔPT for the proximal oesophagus with 
that of modulation type, across all time points. A strong statistical 
significance with regard to deep breathing and placebo, for 
‘interaction’ (p=0.01) and ‘time points’, contributing 18.33% at p<0.0001, 
was observed. (Red graph, Figure 101(A)) Regarding deep breathing 
and atropine, there was not a statistical difference for ‘interaction’ 
(p=0.215), but significance was achieved to a lesser degree across ‘time 
points’, contributing 3.91% at p<0.0119. (Green graph, Figure 101(A)) 
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In the comparison of the pre and post acid differences in average 
means of pain threshold (Δ Avr PT) for the proximal oesophagus between 
the screening visit and the two modulations, a statistical difference was 
found with regard to screening visit vs. deep breathing and placebo, 
where the between group difference was ∆11.8 ±13.03mA, p=0.0048. For 
screening visit vs. deep breathing and atropine there was not a statistical 
between group difference, ∆7.24 ±13.06mA, p=0.058. The between 
modulation group difference was not significant, ∆-4.6 ±9.50mA, p=0.094, 
using two-tailed paired t-testing. (Figure 101(B))  
 
 
Figure 101 A: shows the difference in mean pain threshold  (ΔPT) in mA, for the proximal 
oesophagus between baseline and the three-time points (minutes) after acid infusion, 
for the different modulation types. B: Shows the difference in average means of pain 
threshold (Δ  Avr PT) in mA, for the proximal oesophagus between pre & post acid 
infusion, for the different modulation types.  
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all time points and modulation type; as well as with regard to means 
comparison analysis. 
5.3.3 Autonomic Data 
 
The ‘pre/during-acid’ infusion change in ANS for deep breathing and 
placebo protocol served as the ‘baseline’ to which deep breathing and 
atropine’s ANS changes were compared, and are illustrated below in 
figure 102(A) & table 12(B). 
 
 
Table 12 
 
Figure 102 The comparison between the difference in ANS change between Deep 
breathing & Placebo (A) and Deep breathing & Atropine (B).  In the tables below (A&B) 
are the mean values of changes (SD & SEM), along with each measure’s units and n 
numbers. Table B, includes the change in means between modulation types with there 
p value significance. 
-20 -10 0 10 20 30
Placebo + DB
Atropine + DB
Autonomic change by Modulation
Units of change due to acid infusion
MBP$(mmHg)!
HR$(bpm)(
CSB$(ms/mmHg)(
CVT$(Lvs)(
***" p=0.0002"
***"
***"
p=0.0003"
p=0.0002"
Modulation Protocol ANS Measure Δ Avr SD Difference between means P value 
 MBP (mmHg) 6.7 13.55 -0.71 ± 2.19 0.7871 
Atropine +  HR (bpm) 9.19 11.09 14.82 ± 7.08 0.0002 
Deep Breathing  CSB (ms/mmHg) -2.05 2.29 -3.43 ± 0.99 0.0003 
CVT 
(Lvs) -3.12 3.33 -5.46 ± 1.54 0.0002 
 MBP (mmHg) 7.41 11.36   
 Placebo + HR (bpm) -5.63 4.013   
Deep Breathing  CSB (ms/mmHg) 1.38 1.298   
CVT 
(Lvs) 2.34 1.79   
A: 
B: 
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The changes observed for Deep breathing and placebo protocol 
demonstrated a post-acid decrease in SNS activation, with coinciding 
PNS activation, consistent with the observations in study 2. (Chapter 4, 
Figure 74 (un-shaded graph), page 171) The PNS is hence iatrogenically 
‘induced’ by the behavioural modulation, and unimpeded by the 
placebo. (Figure 103, shaded graph) 
 
The changes observed during the Deep breathing and atropine protocol 
demonstrated a post-acid/modulation significant increase in the HR 
component of the sympathetic outflow, and PNS withdrawal. (Figure 102, 
un-shaded graph) When compared the difference in SNS was statistically 
a highly significant decrease in para-sympathetic activation. (Figure 102 
and Figure 103) Looking at the ANS comparison, there is a distinct and 
significant difference in activation between placebo and atropine, 
where there is a marked deactivation of the PNS, with some SNS 
activation. 
 
 
Figure 103 The comparison of the difference in CVT change between Deep breathing & 
placebo (Red) and Deep breathing & atropine (Blue).  
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5.3.4 Psychological Questionnaire Data 
The Danish (study 4) cohort’s trait anxiety, 25.79 ±5.90(SD, STAI-T) 
measured much lower than the British cohort, (study 2: 38.45 ±9.56(SD)) 
and expectations for similar studies. (267) 
  
Analysis of the State Anxiety Inventory (STAI-S) demonstrated very little 
variation between visits placebo-or-atropine modulation arm or for pre-
and-post modulation measures. This observation combined with the low 
Trait measure would suggest a psychological robust study group. The self-
selection byes that occur with advert recruitment for voluntary invasive 
experimentation is also a likely contributing factor. 
 
5.4 Summery of Key findings for study 4 
 
5.4.1 Demographic Data: 
1. 100% of the subjects were European. 
2. All subjects were acid infusion naïve, and 59% sensitised. 
 
5.4.2 Pain Tolerance Thresholds Data: 
1. Deep breathing & placebo desensitised significantly at, ∆11.8 
±13.03mA p=0.0048, compared to Screening visit, with p<0.0001 
across all time points. (MANOVA) 
2. The distal oesophageal pain threshold data showed Deep 
breathing & placebo modulation arm caused desensitisation, with 
regard to the Screening visit, across all time points.  
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3. Deep breathing and atropine desensitised at, ∆7.24 ±13.06mA 
p=0.058, compared to Screening visit, with p=0.0119 across all time 
points. (MANOVA) 
4. The desensitisation as a result of Deep breathing and placebo 
modulation was significantly reduced during the Deep breathing  
and atropine modulation arm.  
5. The foot pain threshold data showed no significant change or 
difference with regards to visit and observations. 
 
 5.4.3 Autonomic Data: 
1. Deep breathing and placebo modulation arm demonstrated a 
post-acid reduction in sympathetic outflow, with para-sympathetic 
activation consistent with study 2.  
2. The changes observed for Deep breathing and placebo protocol 
were; MBP: 7.41 ±11.36mmHg, HR: -5.63 ±4.013bpm, CSB: 1.38 
±1.298ms/mmHg, and CVT: 2.34 ±1.790Lvs. 
3. Deep breathing and atropine modulation arm demonstrated an 
increase in the HR component of the sympathetic outflow, and 
PNS withdrawal. 
4. The changes observed for Deep breathing and atropine protocol 
were; MBP: 6.70 ±13.55mmHg, HR: 9.19 ±11.09bpm, CSB: -2.05 
±2.29ms/mmHg, and CVT: -3.12 ±3.33Lvs. 
5. Comparison of between arm difference in SNS was, MBP: ∆-0.71 
±2.19mmHg p=0.787, HR: ∆14.82 ±7.08bpm p=0.0002, with a 
statistically highly significant decrease in para-sympathetic 
activation of; CSB: ∆-3.43 ±0.99ms/mmHg p=0.0003, and CVT: ∆-
5.46 ±1.54Lvs p=0.0002. 
6. The between arm comparisons of ANS responses, indicated a 
marked PNS deactivation, with some SNS activation. 
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5.4.4 Psychological Questionnaire Data 
1. The Danish (study 4) cohort’s trait anxiety, 25.79 ±5.90(SD, STAI-T) 
measured much lower than the British cohort, (study 2: 38.45 
±9.56(SD)) and expectations for similar studies.  
2. State Anxiety Inventory (STAI-S) demonstrated very little variation 
between visits, placebo-or-atropine modulation or for pre-and-
post modulation measures. 
 
 
5.5 Discussion 
The results of study 4 provide evidence that visceral pain hypersensitivity, 
induced in the proximal oesophagus by acid infusion in the distal 
oesophagus, is prevented by deep breathing through its action on the 
increasing PNS tone. The analgesic effect of deep breathing is partially 
reversed by addition of an anti-cholinergic demonstrating that 
development of oesophageal pain hypersensitivity, through central 
sensitisation, is influenced by the PNS. 
 
The first phase of study 4 was to exclude non-sensitisers following 
screening visit. Previous literature quotes that up to 30% of healthy 
volunteers will not sensitise to acid. (175) In this study using the model of 
acid induced oesophageal hypersensitivity it has been demonstrated 
that this result was replicated: such that 19 out of 32 (i.e.: 41%) of healthy 
volunteers did not sensitise to acid infusion. Enhanced sympathetic 
dominance to oesophageal acid infusion has been documented in 
patients with gastro-oesophageal reflux disease. (GORD) (154) It can 
therefore be speculated that in this model the difference between these 
two groups lies in their capacity to maintain or withdraw 
parasympathetic tone during acid infusion at this specific stress response 
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level. Withdrawal of parasympathetic tone indicates a pro-nociceptive 
state in the sensitisers, in phase II of the ‘stress response’, as discussed in 
chapter 4.  On the other hand, the lack of parasympathetic tone 
withdrawal in non-sensitisers is indicative of an anti-nociceptive state.  
 
Following studies 2 and 3, it is now more understandable why some 
subjects do not sensitise to acid infusion, as this is due to both peripheral 
and central factors as previously discussed. Concerning peripheral 
factors that are implicated in oesophageal hypersensitivity in GORD 
however, it has been suggested that sub mucosal nerves become 
exposed to acid through dilated intercellular spaces. Support for this 
phenomenon has been demonstrated by Sifrim et al. (335) whereby they 
verified that a 30 minute oesophageal acid infusion in healthy volunteers, 
(in a manner alike to this study), leads to dilated intercellular spaces both 
at the site of acid infusion in the distal oesophagus as well as in the 
unexposed proximal oesophagus. Non-sensitisers may therefore have 
greater resistance to the dilation of intercellular spaces, which does not 
allow their sub-mucosal nerves to become exposed to the acid. Hence, 
by sensing less acid, they do not withdraw parasympathetic tone after 
acid infusion to the same degree as sensitisers. This theory however 
cannot be confirmed by the present data, as the scope of this research 
was not to study the mucosal response to acid. What is definite however, 
is that the subjective response to acid between both sensitisers and non-
sensitisers was similar and therefore any differences regarding the 
exposure of the sub-mucosal nerves to the acid is unlikely to play a 
significant role in the present study context. 
 
Pain perception can also be influenced by central factors such as 
certain personality traits and psychological states like anxiety, as 
previously discussed. Past studies looking into such phenomena using this 
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experimental model showed that anxiety increases oesophageal 
hypersensitivity in subjects in the condition of anxiety being artificially 
induced. (336) Another study also demonstrated that healthy subjects 
with neurotic and introvert personality traits tended to sensitise more to 
painful oesophageal stimulation. (271) In the current study however, any 
significant difference in the levels of anxiety (STAI-trait) and the baseline 
(T0) levels of pain was not observed. The only significant relationship 
found between STAI-trait and change in CVT was during placebo and 
deep breathing (which was then abolished by atropine). The results 
therefore seem to suggest that psychological factors are not exclusively 
responsible for the differential response to acid infusion in this cohort.  
 
Figure 104 This diagram shows 3 x deep breathing cycles (numbered in blue) of an 
healthy volunteer’s NeuroScope™ ‘screenshot’. The subject received 0.5mg Atropine IV 
between breath cycle 1 & 2 (green dashed line). The graphs in the upper half of the 
panel show the blood pressure labelled BP (upper red graph: systolic, lower red graph: 
diastolic and yellow graph: MAP), and the RR-interval labelled RR (white graph). The 
graphs in the lower half of the panel shows the CSB (green graph) and CVT (white 
graph) each labelled as such. The first yellow oval (left) highlights the RSA changes in 
the BP & RR, brought about by six consecutive breaths of the deep breathing protocol 
before the administration of the atropine. The red box below highlights the coinciding 
increase in CSB & CVT from baseline. Compared to this the second yellow oval (right) 
highlights reduced RSA changes in the BP & RR, indicating that even though the subject 
was doing six consecutive breaths of the deep breathing protocol the brainstem outflow 
is now reduced. The RSA, CSB & CVT is noticeably diminished by the second breath 
cycle, and almost totally unresponsive by the third. The red box on the right highlights 
the total block of the coinciding CSB & CVT response by atropine. 
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Since anxiety is associated to an extent with dysfunction in the 
autonomic nervous system and the Hypothalamic-Pituitary-Adrenal axis, 
further study of these systems may provide more objective markers of 
psychological arousal and distress rather than the questionnaire based 
scoring tools used in this study, possibly by including the study of subject 
group’s genetic predisposition. In conclusion, the results may explain 
inter-individual susceptibility to injury-induced sensitisation. Nevertheless, 
the factors that predict non-sensitisation to acid in this model still remain 
unclear at present. 
 
The main objective of this study was however to study the anti-
hyperalgesic effects of the PNS in modulating the response to 
sensitisation through acid infusion. Use of the deep breathing protocol 
was to increase the CVT while use of atropine was used in a sense to 
‘knock-out’ any effects of the deep breathing. The protocol was based 
on the theory that you can stimulate the vasomotor centre (and NA), 
which maintains the body’s autonomic tone. Physiological stimuli such as 
paced forced deep inspiration and expiration selectively exaggerates 
the normal sinus arrhythmia controlled by parasympathetic output of the 
brain stem vasomotor centre leading to a slowing of the heart rate. This 
experiment has successfully shown that during deep breathing while on 
placebo there is indeed an increase in cardio vagal tone and evidence 
of this can be clearly seen on the Neuroscope™ (Figure 106) while the 
subject underwent the deep breathing protocol of 6 breaths per minute. 
Conversely, once atropine was administered, the drug successfully 
reduced the activity of the parasympathetic nervous system and likewise 
the cardio vagal tone dropped significantly.  
 
Atropine has a half-life of about two hours, but the data is 
notwithstanding a degree of circumspection, particularly with respect to 
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the relatively small sample size, although comparable to other studies of 
this type. However, it has demonstrated a degree of internal validity in 
that deep breathing reproducibly increased CVT and alleviated the 
development of central sensitisation in two unrelated cohorts across two 
study centres. Additionally, there are inherent limitations to all human 
pharmacological studies of atropine as its human pharmacodynamics 
are dose dependent with low dose (c. 2µg/kg IV) and high (>15µg/kg IV) 
where atropine is considered to be vagotonic and vagolytic 
respectively. (243) In study 4, largely due to regulatory concerns over 
cardiovascular safety, a standard dose of 0.5mg of atropine was chosen, 
which equates to approximately 7µg/kg. Given that only a partial 
sensitisation was observed in the atropine/deep breathing group, it is 
possible that the dose that was chosen was vagotonic rather than 
vagolytic. Therefore it may be possible by increasing the dose of 
atropine to vagolytic concentrations, i.e. in excess of 15µg/kg, that a 
complete blockade of the PNS effect of deep breathing may occur 
thereby allowing re-sensitisation to take place. Ultimately, whether such 
findings will translate to larger healthy populations and to clinical cohorts, 
as yet remains uncertain.  
 
Having determined that physiological modulation of the ANS through 
deep breathing does promote parasympathetic activity, next it had to 
be resolved whether or not the magnitude of acid-induced 
oesophageal hyperalgesia could be reduced through promoting 
activation of the parasympathetic nervous system. The results show that 
there was a slight fall in thresholds with placebo despite deep breathing. 
Despite subjects executing the deep breathing protocol the PT did not 
rise to baseline levels even after 90min post acid infusion. Secondly, 
when atropine was administered to block the rise in CVT, the sensitisation 
was significantly more pronounced with a greater drop in PT compared 
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to placebo intervention. This observation supports the hypothesis that 
parasympathetic tone withdrawal plays a key role, and is associated 
with sensitisation while an increase in parasympathetic tone is protective 
and reduces sensitisation at this phase of the stress response. 
 
To further verify the effect of deep breathing on the PT the same 
subjects’ data from visit 2 and 3 was compared with the data obtained 
at screening visit. It was found that subjects sensitised the most at 
screening visit where they didn’t perform any deep breathing. There was 
a statistically significant difference between the average PT of screening 
visit and placebo and deep breathing groups which can allow us to 
conclude that in the context of this model by increasing the 
parasympathetic autonomic nerve tone, oesophageal pain 
hypersensitivity could be reduced. Of note is the fact that when 
comparing the difference between the change in PT between screening 
visit and placebo and atropine groups across all time points, the fall in PT 
was smaller for the atropine group. Although this difference is not 
statistically significant on ANOVA analysis, potential explanations for why 
this occurred could be offered. Deep breathing may also exert its anti-
hyperalgesic effect through distracting subjects from experiencing pain. 
A theory by McCaul and Malott (337) states that “an individual must 
attend to a painful stimulus in order for it to be perceived as painful”. 
Therefore, when subjects are distracted, their perception of pain will also 
be decreased.  
 
The methodology used in this study was based on a validated model of 
acid infusion developed by Sarkar et al. (311) However, the model has 
limitations, as it does not fully replicate pathophysiology of GORD. This 
model uses hydrochloric acid to simulate heartburn/reflux, but clinically 
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there are other components, such as enzymes and bile salts that make 
up oesophageal refluxate, which could contribute to development of 
pathology and VPH symptomology. Another potential drawback of using 
this model in healthy volunteers is that it is uncertain whether patients 
suffering from GORD will respond in the same way. Since it is unknown 
how similar these two groups are, as the cohort in question had a below 
average expectation trait anxiety when compared to similar studies 
(297-299), it would thus be unwise to generalise results obtained, and 
further study in this regard is warranted. Finally, even though comparable 
results were found between the different research centres, successful 
deep breathing is experimenter dependent as a more experienced 
experimenter may cause a bigger effect size. 
 
3.6 Conclusions 
In conclusion, study 4’s findings represent the first human studies 
addressing the pivotal role of the PNS in mediating visceral pain 
hypersensitivity. It has been shown that the induction of acid-induced 
hypersensitivity in the proximal oesophagus in a human model of visceral 
hypersensitivity is altered by physiological and pharmacologically 
influencing PNS tone. These findings strongly indicate that the PNS plays a 
central role in the development of central sensitisation. Further study is 
now required to investigate the potential of therapeutically manipulating 
PNS tone in the management of chronic visceral pain syndromes.  
 
Study 4 is the first human study to assess the role of parasympathetic 
nervous antagonism using atropine in modulating acid induced 
oesophageal pain hypersensitivity. Future directions could look into 
whether diminished vagal activity does exist in patients with GORD, 
which might explain whether it does contribute to clinical oesophageal 
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acid sensitivity. Since the results have demonstrated that there is an 
autonomic response noted with acid infusion, it would be of value to test 
this in patients with GORD to determine whether there is greater 
sympathetic dominance in this patient group.  
 
Despite laudable progress in gastrointestinal neuroscience research 
directed towards describing the culpable mechanisms that account for 
development of visceral pain, in conjunction with considerable 
investment in drug development, translation into tangible improvements 
in patient outcomes have remained poor. (51, 338) Moreover, given that 
the contemporary pharmacological armamentarium has limited 
efficacy, and in some cases marked concerns regarding safety (339), it 
comes as no surprise that the multidisciplinary approach utilising a 
number of psychosocial and psychophysiological treatments have been 
used in the treatment of visceral pain. (340, 341) The results of study 4 
could also be applied clinically by using the deep breathing intervention 
in patients undergoing biofeedback training for pain-related diseases. 
Deep breathing techniques may be used in a variety of chronic pain 
states, which are characterised by clear limitations in drug treatment, 
and can be tailored to the individual needs of each patient. 
Furthermore, since the modulation is physiological rather than 
pharmacological, the treatment is not associated with any negative 
health side effects. However, further research must also address the 
limitation that a decrease in experimental pain perception due to deep 
breathing does not necessarily mean a significant alleviation of a 
patient’s clinical pain. This knowledge gap should now be addressed, 
possibly by including the study of subject groups’ genetic predisposition 
and its contributing role in offering protection against the development 
of clinical hypersensitisation conditions. 
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6 Evidence of a role for GTP cyclohydrolase-1 in Acid Induced 
Oesophageal Hypersensitivity - Study 5 (Psychogenetic Pilot 
Study) 
 
6.1 Introduction 
The enzymatic conversion of guanosine triphosphate (GTP) to neopterin 
by GTP cyclohydrolase-1 (GCH-1) is a rate-limiting step in the de novo 
synthesis of tetrahydrobiopterin (BH4) (Figure 105), a co-factor for the 
production of monoamines and nitric oxide. (342) BH4 production is 
normally tightly controlled, however following tissue or neuronal injury 
expression of GCH-1 is enhanced leading to increased production of 
BH4, which in turn facilitates the activation of sensory nerves. (343, 344) 
For example intraplantar injection of BH4 causes mechanical 
hyperalgesia in rodents and triggers calcium transients in isolated DRGs. 
(344) Furthermore substantial reduction in pain behaviours can be seen 
following treatment with the selective GCH-1 inhibitor, 2,4-diamino-6-
hydroxypyrimidine (DAHP) or knock down of GCH-1 with small hair pin 
RNA in animals. (344, 345) 
 
Figure 105 Biosynthetic pathway for the de novo synthesis of BH4.      
                 (Adapted from Costigan, 2012) (342) 
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Importantly these preclinical observations are supported by genomic 
studies which have identified the presence of a GCH-1 haplotype in 
patients and volunteers that is associated with reduced BH4 production 
and reduced pain. This haplotype was originally found to be associated 
with lower post-operative pain scores following discectomy (344) and 
lower pain scores and higher pain thresholds following sensitisation in 
healthy volunteers. (344, 346, 347) Further studies in patients have 
continued to support a role for GCH-1 in pain processing, demonstrating 
an association between the pain protective GCH-1 haplotype and 
reduced analgesic requirement or delayed opioid use in chronic pain 
states or cancer patients, (348, 349) in addition to improved pain scores 
and outcomes following surgical treatment of degenerative disc disease. 
(350) (Figure 106) Little research has been conducted on the role of 
GCH-1 in visceral pain, one study has demonstrated a modest increase 
in the prevalence of the haplotype within a subgroup of patients with 
pancreatitis, (351) however the importance of this finding is unclear.  
 
The goal of this study was to further investigate the role of GCH-1 in 
visceral pain. The role of the GCH-1 gene in mediating visceral analgesia 
was indicated in a previous preliminary GCH-1 inhibitor study of a rodent 
model of visceral pain. This study was performed via collaboration 
between Dr David Bulmer, currently a lecturer at the Wingate Institute, 
Queen Mary University of London, and Professor Beverley Greenwood-
Van Meerveld from Oklahoma University as part of a Glaxo-Smith Kline 
sponsored study.  
 
Briefly this study examined the role for GCH-1 in visceral pain by eliciting 
the effects of the selective GCH-1 inhibitor DAHP, on spontaneous pain 
behaviours elicited by colorectal injection of a chemical irritant (3% 
mustard oil), in male Sprague Dawley rats. In the rodent visceral pain 
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model, experimental pre-treatment with DAHP produced a substantial, 
and dose related inhibition of pain behaviours at doses from 10 to 
180mg/kg i.p. p<0.05. The data generated in these studies suggested 
that GCH-1 played an important role in visceral pain processing and 
required further investigation in a healthy volunteer model of visceral 
pain. 
 
Based on the results of the above study it is possible to speculate that the 
difference in the genotype could also further explain the inter-individual 
differences in pain response, observed in the human model of visceral 
pain. Our aim was to evaluate the possible contribution of the GCH-1 
pain protective haplotype to visceral pain processing in healthy 
volunteers characterised for baseline oesophageal pain thresholds, 
sensitisation to oesophageal acidification, and psychological states of 
depression and anxiety. Our initial hypothesis being that the prevalence 
of the pain protective GCH-1 haplotype would be greatest in subjects 
who did not sensitise to acid injury by comparison with subjects that were 
sensitive to acid injury. As was seen in study 4, further research is needed 
to address the limitation found, where the decrease observed in 
experimental pain perception due to the “deep breathing increased 
CVT” component does not fully equate to a complete alleviation of a 
patient’s clinical pain or the degree of sensitisation. Study 5 is a start in 
attempting to address this knowledge gap by including the examination 
of subject groups’ psycho-genetic predisposition and its contributing role 
in offering protection against the development of clinical 
hypersensitisation conditions and its associated psychiatric sequelae. 
(Figure 106) 
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Figure 106 Illustration of the central psycho-genetic predisposing role of BH4 and its contribution 
in offering protection against the development of clinical hypersensitisation conditions  & its 
resulting mental health sequelae “Tetrahydrobiopterin pathway, with the rate-limiting enzyme GTP 
cyclohydrolase 1, and its functional clinical implications. GTP cyclohydrolase expression and/or 
activity are up regulated during inflammation, mast cell stimulation, following ischemic stroke or 
peripheral nerve injury leading to increased BH4 production. Excess BH4 in peripheral sensory 
neurons following axonal injury contributes to the manifestation of neuropathic pain. This is 
mediated in part by increasing calcium influx and nitric oxide production. Inhibition of GCH1 
activity or reduced GCH1 upregulation reduces pain in various models. In blood vessels BH4 is 
required to produce nitric oxide by endothelial NOS (eNOS). Relative BH4 deficiency leads to an 
uncoupling of oxidation–reduction steps performed by eNOS resulting in increased production of 
reactive oxygen species, instead of nitric oxide, that contribute to endothelial dysfunction. 
Increasing endothelial BH4 improves vascular functions, particularly in diabetes models. In the 
brain BH4 is required for the production of dopamine and serotonin. BH4 deficiency due to loss-
of-function mutations of GCH1 lead to DOPA-responsive dystonia, a Parkinson-like neurologic 
disease, or to atypical phenylketonuria. On the other hand, excess BH4 in the striatum contributes 
to the dying of dopaminergic neurons probably mediated by enhanced calcium influx and 
disturbance of the redox balance. Similarly, excess BH4 after stroke due to GCH1 upregulation 
contributes to neuronal death.                                                                  [Abbreviations: GTP, 
guanosine triphosphate; GCH1, GTP cyclohydrolase 1; PTPS, 6-pyruvoyl tetrahydropterin synthase; 
SPR, sepiapterin synthase; QDPR, quinoid dihydropteridine reductase; PCD, pterin-4a-
carbinolamine dehydratase; BH4, tetrahydrobiopterin; BH2, dihydrobiopterin; nNOS, neuronal 
nitric oxide synthase; iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide 
synthase; NO, nitric oxide; PheH, phenylalanine hydroxylase; PheA, phenylalanine; TyrH, tyrosine 
hydroxylase; DA, dopamine; NA, noradrenaline; 5-HT, serotonin; TrpH, tryptophan hydroxylase; 
ONOO, peroxynitrite; BP, blood pressure; CAD, cardiovascular disease.”]                                                                            
Quoted and adapted from Doering (2008) (352) 
Clinical'
Hypersensi.sa.on'
Condi.ons'
Chronic'enduring'
Mental'Health'
Condi.ons'
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6.2 Materials and Methods 
 
6.2.1 Oesophageal pain testing 
Based on a clear reduction in visceral pain behaviours seen in the animal 
model following pre-treatment with DAHP, we went on to evaluate the 
potential contribution of the pain protective GCH-1 haplotype to visceral 
pain thresholds and depression and anxiety scores in healthy volunteers 
who were subjected to psychological profiling and oesophageal pain 
testing using a previously well validated model of acid induced central 
sensitisation. (184-190) The study was approved by the ‘East London and 
The City Research Ethics Committee - Alpha’ (ref: 09/H0704/71) and all 
subjects provided written informed consent prior to the start of the 
experiments.  
 
6.2.2 Protocol  
Volunteers underwent oesophageal pain testing during two visits 
separated by 2-4 weeks as part of a cross over design interventional 
study. (Sham breathing visit protocol – Study 2 & 3, see section 2.20.2, 
page 111) Volunteers were randomly assigned to an intervention prior to 
oesophageal acidification on either their first or second visit. Only data 
generated prior to intervention or on the non-interventional visit was used 
for this study. In addition during the first visit volunteers underwent 
psychological profiling with hospital-based depression and anxiety 
based questionnaires following which blood samples were taken for 
genomic analysis and frozen down.  
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6.2.3 Other Methods of Measurement 
All other methods of measurement; Catheter Assembly18 (section 2.4, 
page 78), Oesophageal acid infusion (section 2.4, page 78), 
Oesophageal pH monitoring (section 2.6, page 80), Pain Threshold 
Measurements (section 2.8, page 82), Psychological assessment (section 
2.11, page 85) and Measurement of the Autonomic Nervous System19 
(section 2.12, page 86) was performed as described in their specific 
sections. 
 
6.2.4 Genotyping and pain phenotyping 
GCH-1 haplotype was examined in blood samples in 38 healthy 
volunteers from the original study cohort of 72 which could be classified 
as sensitisers (n=19, mean age 27yrs; 11 females) or non-sensitisers (n=19, 
mean age 27yrs; 11 females) based on changes in their proximal 
oesophageal pain threshold to electrical stimulation following 
acidification of the distal oesophagus during their non-interventional visit. 
For the purposes of this study non sensitisers were characterised by a 
decrease in pain threshold no greater than 5mA or an increase in pain 
threshold following acidification (mean post acid increase of 2.4 
±1.4mA), and sensitisers were characterized by a decrease in pain 
threshold of 15mA or greater (change mean post acid decrease of 22.6 
±2.0mA). (Figure 107) The remaining subjects had a change in pain 
threshold >5 and<15mA following acidification and were not genotyped. 
20 
 
                                                      
18 For a more detailed description see appendix one. 
19 For a more detailed description see appendix one. 
20 For a more detailed description appendix four. 
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Figure 107 Human acid infusion study showing ∆ pain threshold following acidification 
with (white) non-sensitisers (mean post acid increase of 2.4 ±1.4mA), and (black) 
sensitisers (mean change mean post acid decrease of 22.6 ±2.0mA). 
 
 
Blood samples from these subjects were thawed, genomic DNA 
extracted and genotyped for the previously described pain protective 
GCH-1 haplotype using a 3 SNP screening strategy devised by Lotsch et 
al. (2007), which identifies the haplotype with 100% accuracy. Taqman 
assay kits were used to genotype for the three SNPs (dbSNP 
rs8007267G>A in the 50 untranslated region, rs3783641A>T in intron 1, and 
rs10483639C>G in the 30 untranslated region spanning the entire GCH1 
gene range) in a 384 well format using 5ng genomic DNA from each 
patient, total reaction volume 5µl. CGH haplotypes were reconstructed 
using Haploview. (353) 21 
  
                                                      
21 For a more detailed description appendix four 
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6.2.5 Data analysis 
Subjects were stratified by GCH-1 haplotype into those possessing at 
least one allele for the pain protective haplotype (X) or not (O). In 
addition subject’s pain phenotype was also determined from the 
change in pain threshold post acid infusion by calculating the mean 
value of the pain thresholds 30, 60 and 90 min post acid infusion and 
subtracting the pre-acid pain threshold. Subjects were stratified into 
sensitisers and non-sensitisers based on this value as described above. 
Baseline oesophageal pain thresholds on first and second visits, the 
change in pain threshold between first and second visits, depression and 
anxiety scores were then compared between subjects grouped by 
haplotype, pain phenotype and a combination of haplotype and pain 
phenotype using Student’s t-test or one way ANOVA as appropriate, 
significance set at p<0.05. Additionally the prevalence of GCH-1 
haplotype was compared between sensitisers and non-sensitisers using 
Fisher’s exact test. All data is expressed as mean ±SEM unless otherwise 
stated. 
 
 
6.3 Results 
6.3.1 Prevalence of the pain protective GCH-1 haplotype (X):  
The allelic frequency of the pain protective haplotype was 0.18 (14/62) 
across all 38 subjects genotyped, which was comparable with reported 
values in the literature. This resulted in the presence of n=12 volunteers 
heterozygous (O/X) for the haplotype and n=1 individual homozygous 
(X/X) for the haplotype. No difference was seen in the prevalence of the 
pain protective haplotype between subjects classified as sensitisers 
compared with non-sensitisers. (Figure 108) 
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Figure 108 Pain thresholds and haplotype/phenotype. (n=12) volunteers heterozygous 
(O/X & homozygous (X/X) for the haplotype. No difference was seen in the prevalence 
of the pain protective haplotype sensitisers & non-sensitisers. 
 
6.3.1 Characterisation of oesophageal pain thresholds by GCH-1 
haplotype: 
Across all 38 subjects baseline oesophageal pain thresholds were greater 
on the second visit compared with the first (e.g. 44.6 ± 3.3mA vs. 57.1 ± 
3.9mA first vs. second visit p<0.001). However no significant difference 
was seen in pain thresholds based on the presence or absence of the 
pain protective haplotype during either visit (e.g. first visit 44.9 ±4.2(SEM) 
vs. 44.0 ±5.6(SEM) p=0.90; second visit 55.8 ±4.7(SEM) vs. 59.5 ±7.2(SEM) 
p=0.66; (O) n=25 vs. (X) n=13 respectively), and no difference in the 
change in threshold between visits was seen based on haplotype (e.g. 
11.8 ±2.0mA vs. 16.4 ±5.2mA p=0.33 (O) vs. (X). Similarly no significant 
difference was seen in baseline oesophageal pain thresholds if subjects 
were stratified based on both haplotype and pain phenotype, although 
a trend towards a greater pain threshold was seen on the second visit in 
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sensitisers who possessed the pain protective haplotype compared with 
sensitisers who did not (e.g. 77.6 ±6.2mA vs. 60.6 ±6.1mA p=0.087; (X) n=7 
vs. (O) n=12). (Figure 109)  
 
 
 
Figure 109 Baseline oesophageal pain thresholds. Comparing first & second visits. PT’s 
were greater on the second visit compared with the first (77.6 ±6.2mA vs. 60.6 ±6.1mA 
p=0.087; (X) n=7 vs. (O) n=12) 
 
Analysis of the change in pain threshold between visits did however 
reveal a significantly greater increase in threshold for sensitisers that 
possessed the haplotype compared with sensitisers who did not and 
both subgroups of non-sensitisers (e.g. 26.6 ±6.2mA (X) sensitiser n=7 
p=0.012 vs. 10.1 ± 2.4mA (O) sensitiser n=12 vs. 4.5 ± 5.9mA (X) non-
sensitiser n=6 vs. 13.6 ± 3.1mA (O) non-sensitiser n=12). (Figure 110) 
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Figure 110 Analysis of the change in pain threshold between visits and pain protective 
haplotype. 
 
6.3.2 Characterisation of depression and anxiety scores by GCH-1 
haplotype: 
No difference was observed in depression or anxiety scores based on 
haplotype (depression 9.0 ±0.3(SEM) vs. 8.3 ±0.5(SEM) p=0.23; anxiety 8.6 
±0.5(SEM) vs. 9.4 ±0.7(SEM) p=0.37; (O) vs. (X) respectively). However in a 
comparable manner to pain thresholds, analysis of depression scores 
based on pain phenotype and genotype revealed that depression 
scores were significantly lower in sensitisers, ∆2.11 ±0.62(SEM), p=0.008 
(Figure 111) who possessed the pain protective haplotype compared to 
sensitisers who did not or both subgroups of non-sensitisers (e.g. 
depression score of 7.1 ±0.5(SEM) (X) sensitisers p=0.03 vs. 9.3 ±0.4(SEM) 
(O) sensitisers vs. 9.7 ± 0.7(SEM) (X) non sensitisers vs. 8.8 ±0.5mA (O) non-
sensitisers). (Figure 112) No difference was observed in anxiety scores 
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when subjects were grouped by pain phenotype and haplotype. (Figure 
113) 
 
 
 
Figure 111 Analysis of the sensitisers’ HADS – Anxiety & Depression scores and haplotype 
/phenotype. 
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Figure 112 Analysis of HADS - Depression scores and haplotype/phenotype. 
 
 
Figure 113 Analysis of HADS - Anxiety scores and haplotype/phenotype. 
 
 
 
  
 
 
269 
 
6.4 Discussion 
With this study we have generated data that supports a role for GCH-1 in 
visceral pain processing. We found a significant increase in pain 
thresholds on repeat pain testing in a subgroup of subjects who 
demonstrated robust central sensitisation to oesophageal injury and 
possessed the pain protective GCH-1 haplotype. 
 
Utilising a visceral model of central sensitisation by acidifying the distal 
oesophagus and examining pain thresholds within the proximal 
oesophagus. This restricts our observations to the resultant secondary 
hyperalgesia elicited in response to the central sensitisation produced by 
injury of the distal oesophagus. (354) Additionally by measuring pain 
thresholds with electrical stimulation we further restrict our observations to 
central changes by bypassing the contribution of stimulus transduction 
mechanisms to the activation of nociceptors within the proximal 
oesophagus. Two pain phenotypes are typically seen following 
oesophageal acidification, subjects who sensitise and present lower pain 
thresholds following injury (sensitisers), and subjects who do not sensitise 
and retain comparable pain thresholds following injury (non-sensitisers). 
Data from human studies has shown that pain thresholds following 
sensitisation of the skin in healthy volunteers were increased in subjects 
who possessed the GCH-1 pain protective haplotype consistent with a 
role for GCH-1 in inflammatory pain. (344, 346, 347) We therefore 
hypothesised that subjects with this GCH-1 haplotype may also have a 
reduced response to acid injury of the oesophagus. The prevalence of 
the pain protective haplotype would therefore be more in non-sensitisers 
compared with sensitisers. 
 
The data generated in the current study did not however support this 
hypothesis. The prevalence of the pain protective haplotype was 
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comparable between sensitisers and non-sensitisers. Furthermore 
baseline pain thresholds were also comparable between subjects with 
the pain protective haplotype and those without. However if pain 
thresholds were examined by pain phenotype and genotype we did find 
a trend towards increased pain thresholds on the second visit between 
sensitisers who possessed the pain protective haplotype and sensitisers 
who did not possess the haplotype. Furthermore a substantial increase in 
baseline pain thresholds was seen between first and second visits in these 
sensitisers who possessed the pain protective haplotype which was 
significantly greater than sensitisers who did not possess the haplotype 
and non-sensitisers regardless of whether they possessed the haplotype 
or not. Interestingly a similar pattern was found when depression scores 
were examined with the exception that depression scores were 
significantly lower in subjects possessing the pain protective haplotype 
and who sensitised to oesophageal acidification compared with the 
other groups. 
 
 Further studies are now needed to confirm the validity of our initial 
findings. The difference in pain thresholds and depression scores within 
subjects grouped by GCH-1 haplotype and pain phenotype suggests the 
two findings may be related. For example subjects with lower depression 
scores may adapt more quickly to the prospect of a repeat pain test 
and hence show increased pain thresholds. However it is not clear why 
we have only found these differences in a subgroup of subjects who 
possessed the pain protective GCH-1 haplotype and develop secondary 
hyperalgesia to injury as opposed to all subjects with the haplotype.  
 
One explanation for our changes is that subjects who sensitise following 
acid injury to the oesophagus have an on going contribution by GCH-1 
to their baseline pain thresholds which is reduced in people with the pain 
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protective haplotype and hence results in their higher pain thresholds. By 
contrast in subjects who don’t sensitise to injury there is little or no GCH-1 
contribution to baseline pain thresholds and so baseline pain thresholds 
are unaffected by the presence or absence of the pain protective GCH-
1 haplotype. Precisely what this might be is unclear, however the lower 
depression scores observed in the same subgroup of subjects who 
sensitise and possess the pain protective haplotype suggests that a link 
to emotional states may be important. This can be expected because of 
the polygenic nature of hypersensitisation conditions and its resulting 
mental health effects, which are additionally shaped by psychological 
and environmental pressures. (355, 356) With modest phenotypic 
consequences such as for pain, variants in other genes are likely to 
contribute to the phenotype to a similar extent, sometimes with opposite 
or cancelling out effects as proposed by Lötsch et al. (357). This might 
also be a reason for non-reproductions of genetic associations in 
polygenically controlled symptoms, as observed in this study for the pain-
protection by GCH1 variants. (358, 359) 
 
 
6.5 Conclusion 
The goal of this study was to further investigate the role of GCH-1 in 
visceral pain. The role of the GCH-1 gene in mediating visceral analgesia 
was indicated in a previous GCH-1 inhibitor study of a rodent model of 
visceral pain. The difference in the genotype could also further explain 
the inter-individual differences in pain response, observed in the human 
model of visceral pain. Our aim was to evaluate the possible contribution 
of the GCH-1 pain protective haplotype to visceral pain processing in 
healthy volunteers, with the hope of replicating its pain protection. 
Although we did not find a clear association between the GCH-1 pain 
protective haplotype and sensitisation of the acidified oesophagus, a 
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modest psychological effect was observed with regard to depression 
scores, highlighting the difficulties of research of polygenic conditions 
affecting hypersensitisation. Study 5 represents a start in attempting to 
address the knowledge gap with regard to the psycho-genetic 
predisposition and its contributing role in offering protection. Further 
research is now needed to address the existing limitations in our 
understanding of the development of clinical hypersensitisation 
conditions and its associated psychiatric sequelae. 
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7 Summary and General Discussion  
 
The aim of my research programme in essence was to ascertain what 
the determinants and ANS mechanisms were for predicting the inter-
individual differences with regard to the vulnerability of developing acid-
induced oesophageal pain hypersensitivity (OPH), and to determine if 
modulation of these ANS mechanisms could influence the degree of 
acid-induced OPH.  
 
7.1 Introduction and study rational 
Studying the factors that influence the development of post-injury 
visceral pain hypersensitivity is important, as I was aware that clinically 
the majority of individuals recover after an episode of visceral 
inflammation or injury, but a proportion go on to develop a functional 
gastrointestinal disorder with demonstrable visceral pain hypersensitivity 
(VPH). (41) This suggests phenotypic differences in the way individuals 
respond to and recover from injurious stimuli in the viscera. Reviewing 
preliminary research, I became aware of the inter-individual variability in 
magnitude of sensitisation to acid in the model. The factors underlying 
why some individuals developed greater sensitisation compared to 
others, and why some failed to sensitise at all, were not known. It was 
clear that understanding these factors might help understand the 
mechanism of injury-induced visceral pain hypersensitivity. Furthermore, 
identifying biological differences between individuals that predicted 
their tendency to sensitise to acid in the model might help identify 
phenotypic traits that predispose to or protect against injury-induced 
visceral sensitisation. This in turn might identify new targets for therapeutic 
developments. To achieve my aim I performed a number of studies in 
healthy human volunteers (chapters 3-6) using a previously well-
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validated model of acid-induced OPH. (177, 184-190) Autonomic 
nervous system activity during infusion was measured continuously in real 
time with novel technology that derived markers of selective 
sympathetic and parasympathetic activity. 
 
7.2 Summary of what I have demonstrated 
 
7.2.1 Chapter 3 (study 1 – pilot study) 
As study 1 was a pilot study and not fully powered the emphasis was on 
identifying early trends that would be investigated more thoroughly in 
the subsequent studies, and to test the suitability of the various 
psychophysiological modulations proposed in this model. It was 
hypothesised that sensitisation as expressed by the difference in average 
pain threshold (ΔPT) would be directly proportional to sympathetic 
nervous system activation (SNS: ∆SCR), and parasympathetic nervous 
system withdrawal (PNS: ∆CVT), as induced or amplified by different 
psychophysiological modulations. The secondary aim of the study was to 
expand on the data in order to determine what psychological state and 
trait factors predicted the degree of sensitisation to acid in the model. 
 
I found that in spite of all subjects being acid infusion naïve, 22% did not 
sensitise during acid infusion, and also failed to sensitise on subsequent 
visits, irrespective of modulation. These non-sensitisers demonstrated 
variable acid-induced autonomic responses between the different 
experiments. For these subjects the degree of sensitisation between visits 
was not related to the degree of change in HR, CVT or CSB. They had 
less sympathetic activation (SCR) compared to sensitisers, and scored 
less for neuroticism on the BFI. Overall their response pattern suggested 
that they might represent a distinct phenotype with reduced 
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susceptibility to injury-induced sensitisation in this model. As a previous 
study using this model demonstrated that stress induction increases the 
degree of secondary oesophageal hyperalgesia in sensitisers, (30)  it now 
remained to further investigate this phenomena, to ascertain if this could 
be replicated in the non-sensitiser group. 
 
The following conclusions were reached as a result of study 1:	  
1. The Isometric “handgrip” exercise test was not suitable for trying to 
increase sympathetic tone, as it produced both an initial 
parasympathetic withdrawal and then rebound increase.  
2. Due to subjects’ anxiety habituation with potential for decreasing 
induction of acid induced sensitisation on subsequent visits, the 
number of visits should be kept to a minimum. The screening visit was 
hence discontinued, and randomisation occurred directly following 
recruitment.  
3. The Deep breathing modulation was successful in producing visceral 
desensitisation in this model. But due to non-specific factors 
associated with deep breathing it was decided to test it against an 
active placebo.  
4. The inter-individual variability in the magnitude of sensitisation 
between sensitisers and non-sensitisers should now be further 
explored in a comparative study that will allow the evaluation of ANS 
responses across a spectrum of experimental stressors. 
 
7.2.2 Chapter 4 (study 2 - deep breathing in sensitisers & study 3 – 
stress induction in non-sensitisers)  
The results from studies 2 and 3 represented the first human studies 
addressing the pivotal role of the ANS in mediating VPH using this model 
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of OPH. Study 2 (fully powered hypothesis testing study) provided 
evidence for how sensitisation can be prevented by deep breathing 
through its action on increasing NA mediated - PNS tone, and study 3 
(hypothesis generating pilot study) demonstrated the mechanistic 
paradoxes with regards to ANS regulation across a continuum of 
experimental stress levels. 
 
7.2.2.1 Chapter 4 (study 2 - deep breathing in sensitisers) 
Study 2’s results represent a novel human intervention study addressing 
the key role of the Nucleus Ambiguus (NA) mediated - PNS in regulating 
visceral pain hypersensitivity. It demonstrated how acid-induced 
hypersensitivity could be abolished by physiologically increasing PNS 
tone. This finding strongly indicates that the PNS plays a central role in the 
development of central sensitisation. It was now important to study the 
effect of co-administered atropine and deep breathing on sensitisation. 
This could potentially examine and contrast the contribution and 
importance of the neurobiological pathways that underlie deep 
breathing induced PNS analgesia. As the placebo response is a manifold 
phenomenon, the analgesia that was observed in study 2 could plausibly 
be due to the observed reduction in anxiety. Also study 2’s results 
needed to be independently validated by means of an unrelated 
cohort in another study centre.  
 
7.2.2.2 Chapter 4 (study 3 – stress induction in non-sensitisers) 
The factors associated with failure to sensitise in the model were poorly 
understood; it has been noted that around 1 in 5 subjects display this. 
(175) Previous studies that were performed to pharmacologically 
modulate hyperalgesia using this model and help understand the 
receptor mechanisms of central sensitisation excluded non-sensitisers to 
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participation. (179, 180, 185) As such it was not known why they failed to 
sensitise and whether they sensitised on subsequent studies. Therefore, 
their selective study during repeated acid exposures was necessary to 
examine the consistency of response. 
 
Study 3’s results provided novel evidence that explain and clarify for the 
first time the hitherto poorly understood multifactorial ANS regulatory 
mechanisms of visceral pain hypersensitivity in subjects who fail to 
sensitise to acid infusion. With the coinciding ‘real time’ examination of 
all three parts of the biopsychosocial model in this study, it allowed for an 
important novel synthesis to be made between developmental 
psychology, neurobiology and gastroenterology. This allowed us to 
reinterpret previously conflicting results with more clarity and potentially 
greater therapeutic advantages.  With the incorporation of attachment 
and polyvagal theory, study 3’s results demonstrated the paradoxes 
surrounding ANS regulation with regard to central sensitisation as 
influenced by differing environmental stress assessments. It also 
highlighted the need for a deeper understanding of the vulnerability 
phenotypes involved. 
 
7.2.3 Chapter 5 (study 4 - placebo controlled /atropine challenge 
study)  
Study 4 (hypothesis testing study) was the first human study to assess the 
role of parasympathetic nervous system antagonism using atropine in 
modulating acid induced OPH, and it independently validated study 2’s 
results by means of an unrelated cohort in another study centre. 
 
In study 4, it was observed that in both arms of the study there was 
modulation of the induced hyperalgesia. Thus In the atropine arm, where 
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CVT’s effect was antagonised, a degree of desensitisation also occurred 
in comparison to the sensitisation that was observed in the screening visit. 
In other words, factors other than the increase in CVT were involved in 
reducing visceral sensitisation. This could be due to the ‘non specific’ 
therapeutic elements of the behavioural intervention, but also that of 
‘placebo effect’ induced as a result of the subjects being aware of an 
intervention. The placebo arm of the study resulted in subjects receiving 
the un-atropinised increase in CVT (i.e. the active treatment).  
  
However because in study 4 the ‘placebo arm’s paced deep breathing’ 
had efficacy over and above the effects of the atropine’s ‘antagonised’ 
deep breathing arm’s response, in spite of also being exposed to the 
nonspecific therapeutic elements of distraction and increased 
interpersonal interaction while being “paced”, this strongly suggested 
that the activation and increase of the NA mediated CVT by the deep 
breathing’s RSA added additional reduction in acid induced sensitisation 
and hyperalgesia of the spinal dorsal horn mediated central sensitisation 
per se, and thus could potentially provide additional ‘direct’ clinical 
efficacy in symptom reduction due to VPH. These findings thus confirmed 
that the PNS plays a central role in the development of central 
sensitisation.  
 
7.2.4 Chapter 6  (study 5 – psycho-genetic pilot study) 
The goal of this study (hypotheses generating pilot study) was to further 
investigate the role of GCH-1 in visceral pain. The role of the GCH-1 gene 
in mediating visceral analgesia was indicated in a previous GCH-1 
inhibitor study of a rodent model of visceral pain. The difference in the 
genotype could also further explain the inter-individual differences in 
pain response, observed in the human model of visceral pain. My aim 
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was to evaluate the possible contribution of the GCH-1 pain protective 
haplotype to visceral pain processing in healthy volunteers, with the 
hope of replicating its pain protection. Although we did not find a clear 
association between the GCH-1 pain protective haplotype and 
sensitisation of the acidified oesophagus, a modest psychological effect 
was observed with regard to depression scores, highlighting the 
difficulties of research of polygenic conditions affecting 
hypersensitisation. Study 5 represents a start in attempting to address the 
knowledge gap with regard to the psychogenetic predisposition and its 
contributing role in offering protection. Psychogenetic-
neurogastroenterology is presently in its infancy, and further research of 
this kind is clearly indicated.  
  
7.3 Psychophysiological Mechanisms in acid induced OPH 
The studies presented in this thesis have demonstrated that acid-induced 
oesophageal pain hypersensitivity can be modulated by a number of 
psychophysiological factors. The mechanisms underlying how 
sensitisation develops after acid exposure in the model are now better 
understood and indicate that it is a combination of peripheral and 
central factors.  
 
7.3.1 Psychophysiological Mechanisms in Sensitisers and non 
sensitisers 
In sensitisers acid infusion may activate acid-sensing receptors such as 
TRPV1 and ASIC resulting in increased primary afferent activity. The 
increased nociceptor barrage onto spinal dorsal horn neurones may 
activate a number of receptors, including NMDA receptors, resulting in 
the development of central sensitisation, further enhancing nociception. 
The magnitude and duration of central sensitisation that develop are 
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modulated by supraspinal pain inhibitory and facilitatory systems that in 
turn are influenced by cognitive factors such as psychological state, 
adult attachment vulnerability, alexithymia scores, attention & arousal 
levels and anticipation. 
 
In non-sensitisers the mechanisms in the model remain speculative. A 
failure of sensitisation once again could be due to peripheral or central 
effects. Non-sensitisers may have enhanced mucosal barrier function in 
response to injurious stimuli, which might result in reduced nociceptive 
inputs to the spinal cord. As a result, the magnitude of central 
sensitisation that develops in response to peripheral insults may be 
attenuated. Alternatively, these individuals may have enhanced 
supraspinal inhibitory processes that either reduce the magnitude of 
injury-induced central sensitisation at dorsal horn level, or inhibit the 
transfer of nociceptive inputs to cortical centres where pain is evaluated, 
and will be further considered below in contexts of supraspinal ANS stress 
response mediation. It might be possible to test the involvement of 
endogenous opioid systems in these individuals by determining whether 
naloxone induces hyperalgesia after acid in these individuals. 
 
My work has however provided novel insights into how the ANS may 
differentially modulate the response to oesophageal acidification in 
sensitisers and non-sensitisers. In the following section I provide an 
interpretation of my results in sensitisers versus non-sensitisers within the 
conceptual framework provided by Porges poly vagal theory described 
in detail in sections 1.9.4, (page 53); section 2.12.4 (page 91) & chapter 
4, table 9, (page 201). 
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7.4 Novel ANS responses in the context of environmental stress  
Stress and anxiety have been associated with the onset and severity of 
symptoms in functional gastrointestinal disorders; in particular, life events 
associated with stress and anxiety at the time of gastroenteritis increases 
the likelihood of developing symptoms of IBS. (255) 
 
7.4.1 Parasympathetic nervous system (PNS) stress response 
In a safe (supportive) environment (deep breathing) both sensitisers 
(Figure 114, pink graph) and non-sensitisers (green graph) increase PNS 
activation, due to paced breathing - NA activation (240)  
 
Figure 114 Illustrates the changes in Cardiac Vagal Tone (CVT) of the Parasympathetic 
nervous system (PNS) across three different environmental stress conditions ranging 
from ‘supportive/safe’ (left) as experienced during the deep breathing-experimental 
modulation procedure, threw ‘neutral’ (middle) as experienced during the sham 
breathing-experimental modulation procedure, to ‘demanding/threatening’ (right) as 
experienced during the stress test-experimental modulation procedure. This gives rise to 
three distinct different activation patterns as described by S. Porges (100) and illustrated 
by the roman numerals: III, II & I, coinciding with different vagal lower motor neuron 
activation, illustrated above as ranging from left, mainly Nucleus Ambiguus (NA) to the 
Dorsal motor neuron nucleus of the vagus (DMNX) on the right. In the foreground is a 
schematic representation of the changes in stress responses as observed during studies 
2 & 3, for the sensitisers (pink graph), and the non-sensitisers (green graph) to acid 
infusion induced oesophageal pain hypersensitivity (OPH).     
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(Porges-Stage III (see table 9, chapter 4, page 201)) that desensitises 
visceral pain thresholds in both groups. In a neutral (sham breathing), 
though challenging (experimental) environment (Porges-Stage II) non-
sensitisers are able to maintain the ‘protective’ vagal tone, while the 
sensitisers withdraw their ‘protective’ NA tone. In a stressful 
(demanding/threatening) environment (Porges-Stage I), the sensitisers 
increase their ‘damaging’ vagal tone (with SNS co- activation) (134-137), 
most likely due to DMNX activation (108), while the non-sensitisers do not. 
 
7.4.2 Sympathetic nervous system (SNS) stress response 
 In a safe (supportive) environment both sensitisers (Figure 115, pink 
graph) and non-sensitisers (green graph) have low activation, most likely 
due to the regulating “vagal-brake” (143) (via - NA activation; Porges-
Stage III (see table 9, chapter 4, page 201)), which is more efficient and 
neuro-chemically “cost-effective” in maintaining homeostasis. (138) In a 
neutral, though challenging (experimental) environment i.e. during sham 
breathing (Porges-Stage II) both the sensitisers and non-sensitisers 
increase SNS tone by the withdrawal of the external constraint due to the 
opposing “vagal-brake”, but the non-sensitisers are better at mobilising 
SNS tone. In a stressful (demanding/threatening) environment, the non-
sensitisers are more able to significantly increase their SNS tone in 
comparison with the sensitisers. The sensitisers are most likely unable to 
match this due to their DMNX co-activation (Porges-Stage I) that is 
impeding a more appropriate adaptive increased SNS response. (108) 
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Figure 115 Illustrates the changes in sudomotor activation of the Skin Conduction 
Response (SCR) under control of the Sympathetic nervous system (SNS) across three 
different environmental stress conditions ranging from ‘supportive/safe’ (left) as 
experienced during the deep breathing-experimental modulation procedure, threw 
‘neutral’ (middle) as experienced during the sham breathing-experimental modulation 
procedure, to ‘demanding/threatening’ (right) as experienced during the stress test-
experimental modulation procedure. This gives rise to three distinct different activation 
patterns as described by S. Porges (100) and illustrated by the roman numerals: III, II & I, 
coinciding with change in primary autonomic nervous system (ANS) activation, 
illustrated above as ranging from left, mainly Vagal (also known as the ‘vagal brake’ to 
unimpeded sympathetic activation on the right. In the foreground is a schematic 
representation of the changes in stress responses as observed during studies 2 & 3, for 
the sensitisers (pink graph), and the non-sensitisers (green graph) to acid infusion 
induced oesophageal pain hypersensitivity (OPH).      
 
7.5 The central role of stress and anxiety in the development of 
sensitisation in this model of OPH 
In chapter 3, 4 and 5, it was demonstrated that acid infusion was 
associated with an increase in subjective anxiety levels, and during acid 
infusion there was an associated increase in sympathetic and reduction 
in parasympathetic activity during screening/sham breathing (Porges-
stage II) in those subjects that sensitised to acid. This suggests that 
psychological factors can modulate the perception of pain directly at 
the level of the viscera. In addition it is inferred that anxiety at the time of 
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injury may have an additive effect on nociception that predisposes 
some individuals to chronic sensory dysfunction. 
 
In chapter 5 - study 3, the novel observation where stress induction was 
associated with greater acid-induced sensitisation in certain individuals 
that previously did not sensitise to acid, replicates findings seen in 
sensitising subjects of previous studies using this model. (175, 179, 194) It is 
difficult to know how stress and anxiety has this effect as it can both 
modulate peripheral mucosal barrier function and permeability, (360) 
and have a variety of central effects. Stress induction may induce 
activity in certain brain regions such as the ACC that may in turn 
enhance pain perception. (361) Stress induction may also influence 
nociception through the modulation of supraspinal pain inhibitory and 
facilitatory systems, or exert effects through the associated reduction in 
vagal tone as demonstrated during screening/sham breathing acid 
infusion (Porges-stage II) of this study.  
 
In this thesis the sensitising group were found to be generally more 
anxious, alexithymic, with greater adult attachment vulnerability markers, 
than the non-sensitising group. This would suggest that the non-sensitising 
group were emotionally more coherently integrated, enabling them to 
make more ‘emotional’ sense of both exteroceptive (psychosocial) and 
interoceptive (biological) stressors, and were possibly more capable of 
prefrontal cortex mediated inhibition (e.g. via GABA, oxytocin and 
vasopressin) of subcortical structures, resulting in subsequent greater 
adaptive abilities to remain in phase III of the stress and anxiety response 
for longer (sham breathing), and when called for (stress test) could 
mount a better (un-impeded) mobilisation (phase I) response, but by 
means of better mentalisation processes could be able to “self sooth” 
more effectively resulting in shorter time intervals before returning to the 
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baseline  phase III homeostatic regulation, resulting in less oesophageal 
pain hypersensitivity. Further research is now needed to address the 
existing limitations in our understanding of the role of pervasive supra 
spinal stress regulation in the development of clinical hypersensitisation 
conditions and to replicate and confirm present findings and posited 
theories regarding the stress/anxiety regulation as suggested above by 
using larger cohorts. 
 
 
7.6 A proposed consilient model incorporating observed ANS 
stress responses: 
 
Drawing from a number of models discussed in this thesis, one can come 
closer to a “unity of knowledge”, as E.O. Wilson has used the term (6) 
with regard to the greater implications and impact on our current 
aetiological understanding of FGID and medically unexplained 
symptoms. Currently in patients with FGID, visceral pain hypersensitivity 
(VPH) is thought to be an important mechanism in the development of 
chronic pain, (43) however the factors that predict the development of 
chronic pain due to VPH in these patients after inflammation or injury to 
the GI tract is not well understood. The precise physiological mechanisms 
for inter-individual differences in the differing degrees of VPH after gut 
inflammation or injury are difficult to identify. In addition to the severity of 
the external stressor, factors such as psychological state and trait, 
genotype, early life experiences and physiological factors such as the 
biomechanical properties of the gut are all important. To clarify some of 
these aspects, a proposed consilient view would start with our present 
FGID conceptualisation of bio-psycho-social, but now to extend it with 
the addition of the hitherto poorly understood physiological ANS stress 
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regulatory mechanisms, as suggested by the results obtained in this 
thesis:  
 
Looking at figure 116, one could start at the ‘over-lap’ of sociological 
(Figure 121 - purple, upper-right) with the psychological (Figure 121 - 
orange, upper-left) domains. The most common precipitating factors are 
(A) life events, (35) with concomitant on-going (i) psychological and (ii) 
physical stress; (24) and chronic medical (B) symptoms. As clinically it is 
observed that pain is one of the most common presenting complaints, 
irrespective of it being explained or unexplained, (89) followed by 
dysfunction and distress. These two factors (A&B) lead to (C) 
exteroceptive and (D) interoceptive stress respectively, affecting (purple 
arrow) the psychological domain of the patient, with its resulting 
activation of the “emotional motor system” (EMS).  
 
 
Figure 116 A proposed holistic, hierarchical, integrated conceptual-working model, 
incorporating the dynamic interplay of the observed ANS responses with four domains 
of centrally sensitised patients. Illustrated here is the effect of the Sociological domain 
on that of the Psychological. For the full conceptual-model, of which this is a part, see 
figure 121.               (For abbreviations and explanation see accompanying text.) 
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Looking at figure 117 (and Figure 121 - orange, upper-left), 
Psychologically predisposing factors of mental state/trait, adult 
attachment type, and ‘mentalisation status’ (362) (e.g. degree of 
alexithymia or “emotional intelligence”(363)) is here of immediate 
import. This is affected by the patient’s (1) genotype, and its expression 
by environmental factors. For instance heritability-twin studies in IBS, 
found that social learning contributed an equal or even greater 
influence than genetic heredity alone. (17) Regarding (2) early life 
influences, a co-morbid, or concomitant psychiatric diagnosis, history of 
abuse (mental/physical) or abandonment/neglect, and previous 
trauma, are of particular note. These vulnerability factors affect the level 
of (3) vigilance (e.g. hyper-vigilance, anticipatory anxiety & 
catastrophisation), which affect the ‘cognitive-evaluative’, and degree 
of (4) arousal (emotional valance) - ‘affective-motivational’ dimensions 
of the pain neuromatrix as proposed by Melzac et al. (77, 78), and hence 
causing greater activation of the (5) “emotional motor system” (EMS) as 
proposed by Drossman et al. (109). This then induces more involvement 
from the subcortical structures e.g. (6) amygdala (mediating 
emotions),(122) (7) periaqueductal grey (PAG) (mediating defence: 
avidness/approach response behaviours), (8) hypothalamus 
(homeostasis) and (9) facial/laryngeal- “visceral” responses (99, 
100)(mediating inter-personal communication). It is at the activation of 
the sub-cortical level that the psychological aspect eventually affects 
the brainstem structures (orange arrow), which then triggers the ANS 
response of the physiological domain.  
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Figure 117 A proposed conceptual-working model, incorporating the dynamic interplay 
of the observed ANS responses with four domains of centrally sensitised patients. 
Illustrated here is the effect of the Psychological domain on that of the Physiological. For 
the full conceptual-model, of which this is a part, see figure 7.8.     (For abbreviations 
and explanation see accompanying text.) 
 
Now considering the involvement of the Physiological ANS response 
domain (Figure 118 and figure 119 - blue bottom left), the basic Cardio 
Vagal Control (CVC) reflex cycle as proposed by Julu et al. (219) needs 
first to be illustrated. The (10) Nucleus Tractus Solitarius (NTS) (green 
triangle) regulates the cardio vagal motor (CVM) centre (purple half-
moon) that also has efferent nerve inputs from the (12) Nucleus 
Ambiguus (NA) that innervate the sinoatrial node of the heart in the 
modulation of the heart rate (HR). This then has a regulatory feedback 
loop, via changes in the blood pressure (BP) on the baroreceptors which 
then connect back to the NTS, and influences the beat-to-beat 
fluctuations as seen by monitoring heart rate variability (HRV).(10) To 
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opposing effects of the  (13) SNS spinal cord afferents, but further 
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from the (14) Dorsal Motor Nucleus (DMNX) of the vagus.  The CVC/SNS’s 
regulatory effect on the HR is thus best understood across a spectrum of 
responses, with differing degrees of activation from (12) NA, (13) SNS and 
the (14) DMNX, and this complicated interplay is best understood by the 
‘Dynamic Systems Approach’ (2-D & 3-D) – autonomic space 
conceptualisation as proposed by Berntson et al.(139) (See chapter 1, 
section 1.9.3, page 51) Finally the ANS response works in concert with the 
(11) HPA/Immune - response, (not here discussed) giving rise to the 
patient’s eventual clinical presentation by a multiplicity of means, but of 
particular note for this model is that of sensory modulation, via the 
regulation of spinal dorsal horn neurones, activating a number of 
receptors, including NMDA receptors, resulting in the development of 
central sensitisation, that affects the degree of nociception. 
 
With this understood, one can see how the psychological domain via the 
activation of the subcortical structures innervate the brain stem ANS 
response. It is here that the observations as discussed with figures 114 & 
115 come into effect. Depending on the psychological environmental 
threat assessment, one will find differing variations of PNS/SNS activation 
as proposed by Porges et al.(8, 100, 118). In a ‘Safe’ environmental 
threat assessment, the main regulation is via the (12) NA (III), during ‘Un-
safe’ assessments, the (13) SNS (II) is increasingly more activated with a 
coinciding withdrawal of NA activity, enabling “fight-or-flight” in the short 
term, and increase in anxiety in the long.  When deemed to be in a ‘Life-
threatening’ situation, the (14) DMNX (I) co-activation increases, to 
facilitate the “deer in the headlights” freeze response in acute situations, 
but an impeding ‘avoidant-denial’ type procrastination behaviour in the 
long term.  This implies that in the majority of FGID cases there would be 
an abnormal autonomic substrate, but merely as a part of the 
mechanism of the underlining disorder, and not as a primary aetiology. 
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This then through sensory modulation, has a bearing on the persons (15) 
Sensitisation status, which then can develop to have clinical significance 
(blue arrow).  
 
 
Figure 118 A proposed conceptual-working model, incorporating the dynamic interplay 
of the observed ANS responses with four domains of centrally sensitised patients. 
Illustrated here is the effect of the Physiological domain on that of the Clinical. For the 
full conceptual-model, of which this is a part, see figure 7.8.           (For abbreviations 
and explanation see accompanying text.) 
 
In considering the Clinical (Bio) domain (Figure 119 and figure 121 - 
green, bottom right), as mentioned above the sensory modulation 
affects the (15) Sensitisation status, that explains the physiological 
mechanism for the observed inter-individual differences in the differing 
degrees of (16) Visceral Pain Hypersensitivity (VPH) that is clinically 
observed by the (17) GI pathophysiological symptoms. (16) VPH 
contributes towards the (17) GI pathophysiological symptoms observed, 
giving rise to pain, dysfunction and patient distress. (43) Due to resulting 
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referrals ensue, which is followed inevitably by investigations and special 
(more invasive/expensive) investigations e.g. colonoscopy; gastroscopy 
etc. and finally medications are started. This can have a profound effect 
on patients, especially when more sinister diagnoses like neoplasms need 
to be excluded, affecting the patient’s social domain (green arrow).  
 
 
Figure 119 A proposed conceptual-working model, incorporating the dynamic interplay 
of the observed ANS responses with four domains of centrally sensitised patients. 
Illustrated here is the effect of the Clinical domain on that of the Sociological. For the full 
conceptual-model, of which this is a part, see figure 7.8.          (For abbreviations and 
explanation see accompanying text.) 
 
Finally in considering the Sociological (Figure 120 and figure 121 - purple, 
upper-right) domain, the effect of chronic medical symptoms is seen in 
poor quality of life (QoL), (14) commonly due to sleep disturbance, low 
energy/libido, social withdrawal and varying degrees of anhedonia and 
dyshedonia. (45) As a result of this in many cases there are accounts of 
increased sick leave (poor productivity), with increasing ‘tension/stress’ 
at the work place because of this. In extreme instances this leads to the 
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complicated process of ‘dismissal on medical grounds’ and 
disheartening negotiations associated with the turbulent process of 
securing state funded ‘Disability Living Allowance’ and its 
accompanying stigma. ‘Learnt helplessness’ and deskilling 
externalisation of the individual’s locus of control is also seen in cases, 
(14) which then contribute to poor interpersonal relationships, with 
increased strain and dependence on the individuals’ families and/or 
caregivers (‘carers fatigue’), which due to mounting desperation can 
lead to an increase in consultation behaviour, and resulting poor doctor-
patient relations. (15) Patients’ (19) adaptive or maladaptive behaviours 
are influenced to a great extent by the actual, or perceived sociological 
environment which can range from ‘safe’ to ‘life threatening’, 
determining in turn how they cope with and deal with inevitable (A) life 
events (35) and its subsequent demand on the psychological domain 
(purple arrow), bringing one full circle to where the discussion began.  
 
 
Figure 120 A proposed conceptual-working model, incorporating the dynamic interplay 
of the observed ANS responses with four domains of centrally sensitised patients. 
Illustrated here is the effect of the Sociological domain on that of the Psychological. For 
the full conceptual-model, of which this is a part, see figure 7.8.     (For abbreviations 
and explanation see accompanying text.) 
SNS 
Spinal cord 
Sociological(
Physiological(
!"""""Mental"state/trait"
!  A.achment"type"
!  Mentalisa4on"status"
VPH(
Cortex: 
Sub-Cortex: 
Brain-Stem: 
!  Safe"
!  Un!safe"
!  Life"threatening"
III!"NA"(Safe)"
II!""SNS"(Un!safe)"
I!"""DMNX"(Life"threatening)"
!  Pain"
!  Dysfunc4on"
!  Distress"
!  Medical"
consulta4on"
!  Inves4ga4ons"
!  Medica4ons"
!"""""Psychiatric"diagnosis"
!  Abuse/Abandoned"
!  Trauma"
!  Poor"QoL"
!  Poor"Produc4vity"
!  Learnt"Helplessness"
!  Consulta4on"Behaviour"
1:#
2:#
5:#
6:# 7:# 8:# 9:#
10:# 12:#############(III)#
13:###################(II)#
14:##(I)#
11:###########
15:###########
16:###########
17:###########
18:###########
+(HPA/Immune7
response(
+"
+"
Impact"
Clinical(
Psychological(
Symptoms(
19:###########
4:#
A:#
3:#
  
 
 
293 
 
A consilient view would entail the “weaving together” of all the 
constituent parts and their respective models as highlighted throughout 
the discussion, into  one united perspective as illustrated in figure 121 
below. It is then that (i) the ANS responses observed’s true context and 
impact can fully be appreciated and (ii) the circular re-enforcing nature 
of the interactions becomes evident. The circular re-enforcement is of 
particular note, as over time its spiralling course can produce the full 
complement of the chronic/perpetuating biopsychosocial factors 
observed in some of the extreme “heart-sink”- or -“revolving-door” VPH 
patients, that can place a considerable burden on personal, 
professional, financial and even national resources. (16) Finally, it could 
assist in the earlier ‘pro-active’ identification of individual key areas that 
could be specifically targeted. This could potentially reduce 
inappropriate referrals and guide more timely clinically relevant referrals 
and cost effective multidisciplinary interventions. 
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Figure 121 A new holistic, hierarchical, integrated conceptual-working model, 
incorporating the dynamic interplay, of four domains; Psychological, Physiological, 
Clinical & Sociological; along with the incorporation of the novel physiological (ANS) 
regulatory mechanisms as observed in this study. The interplay of factors affecting 
patients with chronic visceral pain hypersensitivity (VPH) disorders, as seen in clinical 
practise can be better understood, as in extreme cases they can exhibit the ‘full 
compliment’ of the biopsychosocial triumvirate.          (For abbreviations and 
explanation see accompanying text.) 
 
7.7 Implications on therapeutic approaches  
 
7.7.1 Psychopharmacology 
Despite laudable progress in gastrointestinal neuroscience research, 
directed towards describing the culpable mechanisms that account for 
development of visceral pain, in conjunction with considerable 
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investment in drug development, translation into tangible 
pharmacological improvements in patient outcomes have remained 
poor. (51, 338) Moreover, given that the contemporary pharmacological 
armamentarium has limited efficacy, and in some cases marked 
concerns regarding safety, (339) it comes as no surprise that the 
multidisciplinary approach utilising a number of psychosocial and 
psychophysiological treatments has been used in the treatment of 
visceral pain. (340, 341) However it is already common practice for 
antidepressants to be used for chronic functional pain disorders. The 
circular observations of visceral pain inducing dyshedonia, and the 
response of negative emotional context e.g. stress and anxiety 
enhancing the visceral hyperalgesia induced provides rationale for how 
antidepressant therapy works. This is relevant for both pharmacological 
and psychological therapies. Because there is a clinical tendency to 
focus on more typical “anti-nociceptive” treatments in functional 
syndromes, whereas evidence suggests that co-morbid emotional 
problems are under diagnosed and undertreated, (364, 365) which if left 
untreated may then lead to less effective treatment responses and 
outcomes. The implication suggested by this thesis is that rather than 
treating either pain or emotion, both need to be simultaneously 
addressed, as they are mutually re-enforcing.  
 
7.7.2 Psychotherapy 
The results from this thesis would suggest the incorporation of the 
behavioural intervention of “paced deep breathing” as part of a 
therapeutic ‘package’ aimed at patients where VPH is suspected. In 
study 4 (the placebo controlled /atropine challenge study), it was 
observed that in both arms of the study there was modulation of the 
induced sensitisation and hyperalgesia suggesting that the non-specific 
(psychological/placebo-effect) component of deep breathing 
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produces analgesia that can modulate spinal nociception and thus 
influence the development of central sensitisation and hyperalgesia. 
(366) This may relate to activity in supraspinal pain modulatory systems 
involving opioids. (367) The behavioural interpersonal interaction may be 
activating these systems by the higher cognitive factors of the 
intervention such as distraction, expectation and anticipation, 
transmitting its effects ‘downstream’ to the spinal dorsal horns to have an 
impact on the development of central sensitisation through the 
modulation of chemical signalling and receptor function. The fact that 
acid-induced sensitisation can be modulated by the non-specific 
(psychological/placebo-effect) component of deep breathing confirms 
that supraspinal mechanisms are important and should also be 
incorporated in treatment interventions modulating pain sensitivity.  
 
However in study 4 the ‘paced deep breathing’ demonstrated efficacy 
over and above that of the atropine’s ‘knock-out’ arm in spite of also 
receiving the nonspecific therapeutic elements associated as above, by 
being “paced”. This strongly suggests that the increased CVT tone per se 
adds additional analgesia in central sensitisation induced VPH, and thus 
could provide additional ‘direct’ clinical efficacy in symptom reduction. 
The intervention could still continue to offer the more traditional ‘indirect’ 
therapeutic use of deep breathing in reducing levels of subcortical and 
visceral arousal, by means of the so-called “calming breath” (368) and 
induction of the “relaxation response”. (369) The results of studies 2 and 4 
could also be applied clinically by using the deep breathing intervention 
in patients undergoing biofeedback training for pain-related diseases. 
Deep breathing techniques may also be used in a variety of chronic 
pain states, which are characterised by clear limitations in response to 
drug treatment, and can be tailored to the individual needs of each 
patient. Furthermore, since the modulation is physiological rather than 
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pharmacological, the treatment is not associated with any negative 
health side effects. 
 
If this is combined with mindfulness (370) and mentalisation strategies, 
(362, 371) the alexithymia, attachment vulnerability and its associated 
misappropriated somatic tension and subsequent activation of the EMS, 
indicated by this thesis, could also be addressed. With regard to the 
attachment vulnerability, more therapeutic skill would be required 
however, as it would suggest the facilitation of the patients’ ability to 
interpret their ‘intrinsic somatic-emotions’ by developing a coherent 
extrinsic life narrative, that incorporates a prefrontal mentalisation22 of 
the subcortical/brainstem arousal patterns/symptoms, and its resulting 
interpersonal implications. Dan Siegel coined the term ‘mindsight’ to 
describe this ability, and states, originally with regard to better parenting, 
but applying equally to pain management, the following:  
 
“A coherent life story is one in which the adult has made sense of 
his or her own childhood experience […or visceral pain symptoms] 
and has insights into how that past has influenced his or her 
development as an adult and as a parent […or patient]. Making 
sense is revealed in a flexible and reflective narrative that is 
predictive of that adult’s child having a secure attachment, […or 
being able to demonstrate better cortical pain regulation in 
chronic sensitising pain conditions].”(373) 
  
                                                      
22 Mentalisation; defined generally as: (i)“To make mental in nature, rather than 
physical”, or in psychology as: (ii) “To understand the behaviour of others as a product 
of their mental state.” 372. Wiktionary. Mentalisation. 
http://enwiktionaryorg/wiki/mentalize. 2013.  
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This mentalisation aspect combined with CBT (374), interpersonal (375) or 
hypnotherapeutic (376, 377) interventions in conjunction with the 
behavioural ‘paced deep breathing’ component would seem to be 
addressing the ‘area of overlap’ in the four domains as referred to in the 
proposed conceptual model above, suggesting the area of ‘most 
return’. (Figure 117) This is where with the least amount of resource input, 
applied to the most relevant clinical areas of this specific patient group, 
could potentially deliver the most cost effective clinical outcomes, as 
illustrated in figure 122. This hypothesis needs to be developed and 
tested with more clinically based research. 
 
Figure 122 Illustrated is an example of a possible new proposed psychotherapy 
treatment, as suggested by this thesis: “Mentalised Paced-Breathing Therapy” (MPT), 
incorporating four distinct psychotherapeutic modalities, as components to a 
therapeutic ‘package’ specifically designed to affect the “area of overlap” of the 
psychological, physiological, clinical & sociological domains; as seen in patients with 
chronic visceral pain hypersensitivity disorders.  
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7.8 Limitations of the oesophageal model 
The amount of practical, established models of injury-induced visceral 
hyperalgesia in humans is limited. Amongst them, the acid induction 
model of OPH, which I used in these studies, is particularly well validated. 
Having been used now in several significant studies’ by a variety of 
independent research groups, considerable experience and data have 
been accumulated with this model. It has provided insights into the 
mechanisms of central sensitisation and the pathophysiology of pain 
hypersensitivity in a number of different FGIDs, e.g. NCCP. There are 
inevitably limitations to any model, no matter how validated, and this 
one is not an exception. These limitations should be appreciated before 
the extrapolation of conclusions to patient populations. 
 
7.8.1 Nature of the sensitising stimulus 
Experimentally, the model consists of a 30-minute infusion of 0.15M HCl in 
the distal oesophagus, which then induces secondary hyperalgesia in 
the non-acid exposed proximal oesophagus. Short-lived pain 
hypersensitivity is produced, with a mean normalisation of nociception 
within 8 hours. (177) This is most likely due to the acute stimulation of 
oesophageal nociceptors such as TRPV1 and ASIC, due to the action of 
the acid giving rise to subsequent induction of spinal central sensitisation, 
which then affects the observed hyperalgesia. With the completion of 
the acid infusion, the noxious stimulus and peripheral drive is removed, 
thus allowing receptor function and the nociceptive processing to 
normalise.  
 
Clinically however, pain hypersensitivity is often a persistent finding in 
patients with functional gastrointestinal disorders. In patients with PI-IBS for 
example, hyperalgesia persists long after the resolution of a previous 
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infectious insult, most likely due to the nociceptive circuits remaining 
active. In previous studies using this model of OPH, gastroscopies were 
performed within 12 hours of experimental acid infusion, (179) which did 
not shown histological evidence of inflammation. Although increased 
cytokine production and receptor translation at the infusion site cannot 
be ruled out, the processes that would be clinically induced in chronic 
gastro-oesophageal reflux disease is most likely to be significantly 
different to those seen in subjects.  
 
Thus, the model’s short duration of induced hyperalgesia, together with 
the lack of any identifiable inflammatory response, would suggest it 
being more reflective of an acute form of “activity dependent” central 
sensitisation. Clinically this form of sensitisation is initially of significance in 
the development of visceral pain hypersensitivity, and hence this model 
is limited in providing information on the mediators of chronic changes in 
synaptic plasticity following injury. Accordingly the relevance of this 
model of OPH has limitations when applied to states characterised by 
long-term post-injury pain hypersensitivity. As it would clearly be unethical 
to develop a model of chronic post-injury pain hypersensitivity in humans, 
this problem deserves further consideration. 
 
As chapters 3 to 6 showed that acid infusion per se was associated with 
increased unpleasantness and anxiety scores, the aversive nature of the 
acid infusion needs also to be considered, as it raises the possibility that 
any sensory or autonomic changes observed might be significantly 
driven by psychological factors. Generalised hypervigilance as being the 
mechanism of observed visceral hyperalgesia can be ruled out, as the 
lack of change in pain threshold on the foot after oesophageal acid 
argues convincingly against this. Selective hypervigilance to visceral 
stimulation however, cannot be completely disqualified. Previous studies 
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with proximal oesophageal evoked potentials following distal 
oesophageal acid infusion have shown a decrease in latency of the 
early components (related to sensory discrimination) with no change in 
the late components (related to cognitive evaluative factors e.g. 
vigilance), (378) which would argue against visceral hypervigilance 
being the mechanism of acid-induced hyperalgesia in the model. 
 
7.8.2 Nature of the pain stimulus 
Oesophageal pain threshold testing in the model is achieved by means 
of electrical stimulation. This modality offers practical beneficial 
characteristics that include: (i) ease of administration, (ii) reproducibility 
(iii) well-defined onset and offset, and (iv) an ensured short latency to 
afferent fibre stimulation. (179) On the other hand, a potential criticism of 
this modality is that it is not as physiological as other modalities in use, like 
for instance mechanical distension or thermal stimulation.  
 
A second negative characteristic of electrical stimulation is that it directly 
depolarises all classes of primary afferents and hence bypasses any 
peripheral receptor mediated transduction, and thus the activity in 
specific nociceptors cannot be inferred. (51) This said, the modality 
remains effective in assessing the contributions of mediators to spinal 
pain processing, allowing for clear information with regard to central 
sensitisation mechanisms. As other modalities may be associated with 
different psychological and/or autonomic effects, it would be prudent in 
future research to replicate some of the findings in this study with 
multimodal oesophageal stimulation. Studies of this kind might provide 
more clinically relevant characterisation of oesophageal sensory 
processing at baseline and after acid sensitisation. 
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7.8.3 Reproducibility, Carryover and Period effect of the model 
Although previous studies with the model (53, 177) did not show 
significant intra-study change in the degree of sensitisation to suggest an 
order effect and as such demonstrated good repeatability of the 
magnitude of acid-induced sensitisation within studies. The data 
presented in this thesis has however reproduced results found on at least 
one occasion using this model. (179) This would suggest that when 
sensitisation is examined across studies, i.e. involving longer periods of 
time with the same subject cohort (more interval studies), the degree of 
acid-induced hyperalgesia might diminish on subsequent studies. 
 
The mechanism of this habituation is unknown but could relate to a 
variety of peripheral and central factors. Neurologically, receptor 
desensitisation – and – down-regulation, increased descending spinal 
pain inhibition, and reduced pain facilitation may reduce neuronal-
sensitivity responses on repeated study. Psychologically, there is a 
gradual reduction of the dopaminergic attenuated ‘novelty response’ 
that affects the quality of subject attention. Due to anxiety habituation 
brought about through repeated behavioural exposure the subjects’ 
emotional valance is also gradually diminished.  Finally, with repeated 
visits due to familiarity, unavoidable changes are facilitated in the 
interpersonal response between research staff and subjects that could 
also have an increasing longitudinal effect.  
 
During the design of the studies in this thesis, the potential of the carry-
over effect was debated in some detail and it was decided that a 
period of at least 2 weeks would address this concern from a standpoint 
of pragmatism. (379) The meantime between visits was 3 weeks 4 days 
(range 2 weeks 1 day – 4 weeks 5 days) for studies 2 and 4 and therefore 
the likelihood of any carry-over effect is small. As is highlighted in the 
  
 
 
303 
 
paper by Mills et al. there is an argument that the carry-over effects of 
interventions across periods as carry-over effects are rare and moreover 
statistical manipulation per se cannot address the impact of a carry-over 
effect as they are often under-powered. (379-381)  
 
Further it is hence recommended that subjects are not studied regularly, 
and that sufficient time intervals between studies are scheduled, such 
that participation in studies remains as far as possible a novel 
experience. Randomised double-blind cross-over study formats are here 
important, with possibly novel “unknown examiners” introduced in the 
later phases of study, that might help to reduce the development of 
encountered order effects. 
 
7.8.4 Applicability of the Results to Clinical Populations 
The studies presented in this thesis have all been performed in healthy 
volunteers, and thus from a psychophysiological perspective it is a 
prerequisite to draw attention to the likelihood of significant differences 
between these individuals and patients with functional gastrointestinal 
disorders. Additionally, there may be further psychological variation 
between volunteers and healthy individuals who do not seek study 
participation. Factors such as anxiety, past experience and openness to 
new experiences may be relevant. Further the model used to explore 
oesophageal sensitivity in these studies is of an acute nature, yet the 
illnesses seen clinically are chronic. Necessarily in using this model, 
research findings’ direct applicability to clinical populations are 
informative, but remains speculative and should be done judiciously. 
 
On the other hand, the oesophageal acid model has been extensively 
validated as a reproducible model of central sensitisation in healthy 
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individuals, and has already shown clinical validity in some conditions. 
For example in patients with NCCP, using this model, exaggerated 
hyperalgesia to acid infusion was demonstrated. (175, 178) Additional 
factors that could also be observed during these studies, were 
accompanying reductions in latency of the early oesophageal evoked 
potential components; suggestive of heightened central sensory 
processing in these patients. As such, the model has some relevance to 
patients with states characterised by oesophageal hypersensitivity and 
can provide useful information, especially in the development of acute 
post acid injury induced central sensitisation. A possible mechanism 
proposed by Sharma, for the development of oesophageal 
hypersensitivity in these patients, could be: 
“… that repeated episodes of acid reflux induce peripheral and 
central sensitisation; the latter may then persist in susceptible 
individuals despite removal of the acid stimulus by appropriate 
[pharmacological] therapies. Subsequent small volumes or sub-
clinical acid exposure may then be sufficient to maintain 
sensitisation and result in sensory dysfunction manifesting as 
hyperalgesia and allodynia.”(179) 
Finally, the research in this thesis doesn’t directly provide an explanation 
for symptoms or hypersensitivity in the group of FGID that is preceded by 
infection or inflammation. In these cases it would focus only on the 
hypersensitivity component of these conditions, which is found in post 
infective hypersensitivity as well as in hypersensitivity de novo. 
 
7.8.5 Validity and Reproducibility of CVT and the Neuroscope 
Central to the findings of this thesis is the validity and reliability of cardiac 
vagal tone (CVT) and the instrument/method by which it was measured. 
Due to the methodological shortcomings of the traditionally established 
  
 
 
305 
 
techniques of measuring autonomic nervous system tone (see 2.12, 
page 96), a commercially available biosignals acquisition system known 
as a “Neuroscope” was used to measure and record cardio vagal tone 
(CVT) in this thesis. The Neuroscope is unique in using a process called 
“phase demodulation” to derive at a measure of cardiac vagal control 
(CVC), and hence to calculate CVT. (226) It is measured in standardised 
units on a Linear Vagal Scale (LVS), where 0 was derived from fully 
atropinised healthy human volunteers. (219) CVT has been 
demonstrated to both a sensitive and specific measure of vagal tone, 
comparable to other indices derived from analysis of heart rate 
variability, (10) and has also been demonstrated to be a reproducible 
measure of parasympathetic nervous system tone over a period of 1 
year. (382) The measurement of cardiac vagal tone has been 
increasingly utilised as a research tool for deriving PNS tone across a 
diverse range of research themes. (271, 311, 383)  
 
The technique and concept of CVT is of interest but not without 
conceptual concerns, particularly as there is a paucity of clinical data 
evaluating patients with known dysfunction of the autonomic nervous 
system using this technique. Similarly to HRV measures, this technique 
does not actually measure vagal tone per se but high-frequency 
modulation of HR. Thus it is based on an identical physiological concept 
as HRV, resting upon the assumption that the short latency of HR 
responses to blood pressure changes reflects the vagal limb of the 
baroreflex arc, in contrast to the longer latency of HR responses due to 
sympathetic activation/deactivation.  
 
Moreover, a continued conceptual concern of all techniques using 
heart rate variability as a surrogate marker of autonomic tone are, by 
definition, derived from cardiotropic parameters. Therefore, their direct 
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applicability and correlation to the autonomic tone occurring at the 
proximal and mid regional and mucosal level of the GI tract is largely 
unknown and warrants further systematic investigation. For instance, it 
would be interesting to concomitantly measure HRV parameters of vagal 
tone in association with other objective physiological markers in the gut. 
For instance one could measure pancreatic polypeptide as its excretion 
is exclusively under vagal control. In addition, it would also be possible to 
measure transient relaxations of the lower oesophageal sphincter as 
these occur as a sequelae of the vago-vagal reflex. Nevertheless, whilst 
these studies remain to be performed, cardiotropic measures do offer a 
potential insight, until further refinement via future technologies. 
 
7.8.6 Study-design and Statistical limitations 
This thesis explores by using a randomised crossover trial design to derive 
the main hypothesis testing study findings. The study design and the 
choice of statistical analysis used could have some methodological 
limitations that deserve attention.  Of note is the use of statistical 
methods for repeat measures in the crossover analyses (i.e. liner mixed 
models), as opposed to the preferred intention to treat analyses, where 
all patients randomised are analysed, despite the intervention they 
actually received. The potential shortcoming could be that the ‘per-
protocol’ analyses may bias the results and may be seen to be used only 
for the rationale that the latter reveals statistical significance and thus of 
interest to be reported; whereas  an additional intention to treat analyses 
would be possibly more appropriate to improve scientific rigor. (384-386) 
Convention would encourage presenting the results with non-sensitisers 
and, if not done, to justify the rationale and to illustrate what the results 
would be if non-sensitisers were included and how the lack of data on 
non-sensitisers could have influenced the results. 
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Even though a “per protocol analysis” could potentially bias the results 
and notwithstanding the fact that this is of paramount importance in 
crossover trials as highlighted in the literature, (384-386) however, these 
principles are not directly applicable to the hypothesis testing studies in 
this thesis. If one considers the relevant studies in turn:  
Study 2 - The study design was such that sensitisation/non-sensitisation 
was defined on the results obtained from the study visit in which the 
participants were exposed to the ‘sham breathing’ arm. If participants 
were randomised to the sham breathing intervention during the first visit 
of study 2, they were excluded and did not attend study 2’s second visit 
where deep breathing would have been studied (see figure 69, page 
206). Conversely, subjects who were randomised to the deep breathing 
intervention during the first visit, and underwent the deep breathing 
protocol during the second visit, could potentially have been included in 
an “intention to treat” analysis. However, it was actively chosen not to 
include this data for the following reasons: 
1. As not all non-sensitisers were exposed to both visits, it was 
deemed not appropriate to present an analysis on a proportion of 
these participants, as this would introduce an element of bias in 
the analysis de novo. 
2. Non-sensitisers were defined as having no reduction, or a 
reduction of <6 mA in proximal oesophageal PT, after acidification 
and therefore such subjects do not display secondary 
hyperalgesia in response to the acid infusion model. Thus, the anti-
hyperalgesic/analgesic effect of deep breathing cannot be 
assessed in this subgroup as they do not sensitise to the stimulus.   
3. If one had included this subgroup in our analysis, it may have 
conversely over-estimated the effect of ‘deep breathing’ and 
‘sham breathing’ as these participants did not sensitise. 
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Study 4 – In study 4, there was a screening visit, after which the non-
sensitising participants were excluded and therefore these subjects were 
not exposed to the ‘deep breathing’ or atropine treatment arm. The 
design of this study included a screening visit as it was judged 
inappropriate and unethical to expose healthy participants to intra-
venous atropine if they were going to be excluded. Hence an “intention 
to treat” analysis would also be inappropriate for similar reasons as stated 
above.  Future studies will have to account for this with improved 
designs. 
 
7.9 Future Directions 
In this thesis I concentrated on using atropine as a muscarinic antagonist 
to enhance visceral pain perception. A future line of enquiry using 
pharmacological agents would be to focus on muscarinic agonists, to 
increase the PMS activity. Alternatively the focus should be on reducing 
the SNS activity by means of modulating catecholamine function. Here 
Alpha 2 agonists: (clonidine) stimulate presynaptic alpha 2 receptors to 
mediate feedback inhibition of noradrenaline release.  Postsynaptic 
alpha 2 receptors in the vicinity of the NTS and rostroventrolateral 
medulla are important determinants of sympathetic outflow. Clonidine 
acts on these receptors to significantly reduce sympathetic outflow to 
the cardiovascular system to cause hypotension and bradycardia. On 
the other hand, Beta agonists: Stimulation of both beta 1 and 2 receptors 
(isoproterenol) increase cardiac contractility, heart rate and cardiac 
output. Beta antagonists: Propanolol is a competitive inhibitor of 
sympathomimetic amines at both beta 1 and beta 2 receptors and 
therefore counteracts the effects of isoprenaline. It reduces heart rate, 
contractility and blood pressure.  
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Hence clonidine and beta-blockers has the potential of acting like 
pharmacological agents producing similar effects to "paste deep 
breathing". Of these clonidine offers the most potential, because of its 
ease of administration, high bioavailability and for its future potential 
therapeutic role. A proposed study could be to use clonidine in this 
model of acid induced VPH, where clonidine will be administered orally 
at a single dose of 5.5 micrograms/kg. Side effects should be monitored 
and the subjects could be given cognitive tasks to perform to control for 
the sedative effects of clonidine.  
 
Further, the factors regarding the healthy volunteers who in spite of 
repeated acid infusion and stress modulation still failed to sensitise, 
remains unclear.  Although some light was shed on possible aspects 
associated with this group in study 3, as such it represents a beginning, 
but more experimentation using this model is still necessary to fully 
understand their phenotype. Potential research here would be to repeat 
acid exposure studies, but this time using a different more effective 
psychological stressor. To date strategies recalling past sad life events, 
(179) as well as exposing subjects to pictures of different emotive faces 
at time of acid exposure, have been proven constructive and could 
offer better opportunities of eliciting more explicit physiological results. 
(268) A second line of enquiry could be to antagonise their endogenous 
opioid systems with naloxone prior to acid infusion in order to determine 
whether sensitisation could then be induced. 
 
The clinical applicability of the results in this thesis remains to be explored. 
The findings of studies 2 and 4 confirmed that autonomic control plays a 
prominent role in the development of central sensitisation and that by 
increasing vagal tone, induced visceral pain hypersensitivity can 
effectively be reversed. These results are encouraging, but remain 
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speculative, as they represent laboratory findings of an acute exposure 
in a healthy volunteer group. Of importance is now to replicate these 
outcomes in patients with chronic visceral pain syndromes. A suggested 
initial study here would be, by using a marker of oesophageal sensitivity, 
to compare the introduction of ‘paced breathing’ in patients in a 
laboratory setting. If these findings remain positive, a further clinical study 
incorporating the ‘paced breathing’, as a component of a specially 
designed treatment strategy in actual patients should be undertaken. A 
potential study that needs to be concluded in the clinical setting would 
be a three tiered randomised control trial, whereby the ‘paced 
breathing treatment intervention’, is compared to a ‘placebo control’ 
using similar psycho-education, but replacing the breathing-component 
with a standard ‘relaxation intervention’, and the medical treatment as 
usual. A second important clinical study would be a ‘head-to-head’ 
comparison study of the ‘paced breathing treatment intervention’ with 
an intervention with proven efficacy like for instance hypnotherapy. The 
impact and cost-effectiveness of treatment strategies should then be 
assessed and compared.  
 
The literature supports the notion that psychophysiological factors e.g. 
trait anxiety and neuroticism, influence an individual’s visceral pain 
sensitivity and tendency to develop post-injury OPH. This thesis goes on to 
imply that these factors are also influenced by alexithymia and 
attachment vulnerability. The data presented would suggest that an 
awareness of these issues might assist in more effective patient 
management, as it has the potential to identify likely patients at higher 
risk of developing chronic pain in individuals suffering with acute visceral 
pain. It could also assist distinguishing between patients who might cope 
poorly with chronic pain, and those who may have difficulty in engaging 
with healthcare services, affecting prognosis and potential healthcare 
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costs. Thus, regarding this issue further powered studies are also required 
to confirm the novel but putative observations concerning the 
alexithymia/attachment association with central sensitisation and in OPH 
patients. A potential study that could clarify this would be an 
epidemiological based cohort study. Here all first attender patients at a 
designated specialist gastroenterology clinic would undergo routine 
alexithymia/attachment profiling, with subsequent outcome follow-up 
relating to diagnosis, treatment and prognosis. A correlation between 
trait vulnerability and outcome could then be highlighted and its clinical 
presence confirmed. A similar study could also be done in a match 
control group in a related medical/surgical clinic to probe if potential 
correlations are specific FGIDs or a general medical finding.  
 
Finally, regarding genetic profiling, it will suffice to say here that it will 
always be a high priority in pain research and all opportunities to possibly 
identify genetic factors should be pursued. 
 
7.10 Conclusions 
The studies in this thesis have investigated the psychophysiological 
modulation of autonomic responses involved in acid-induced 
oesophageal pain hypersensitivity.  
 
My studies suggest that an important role is played by the autonomic 
control in the development of central sensitisation, and demonstrated 
that by increasing PNS tone, induced visceral pain hypersensitivity can 
effectively be reversed. In addition it also demonstrated that the 
processes that determine the development and magnitude of post-injury 
pain hypersensitivity in the human viscera are complex and intertwined. 
Cognitive factors such as anxiety, alexithymia and attachment status 
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influence supraspinal mechanisms and autonomic responses, which in 
turn modulate the development and degree of central sensitisation in 
the viscera. Certain individuals may also be predisposed to greater injury-
induced sensitisation in the viscera based on their psychophysiological 
and genetic profiles.  
 
The development of effective therapies for patients with FGID requires 
the clear understanding of the relevant psycho-pathophysiological 
processes involved and their modulating interactions. Due to the 
complexity of these processes the incorporation of effective 
characterisation of at risk phenotypes and development of specifically 
tailored treatment strategies, may be the key to developing targeted, 
effective and cost-effective therapeutic agents in patients with chronic 
visceral pain syndromes.  
 
Hence in conclusion, the modern physician, just like in the time of 
Hippocrates, may once again make little distinction between emotional 
and physical wellbeing, (2) as physical and mental concepts are once 
again being interchanged and found to be equally relevant at 
procuring diagnosis and cure; but now with greatly increased awareness 
and respect for the complex-intertwined nature of the ‘body/mind’. (3) 
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Appendix One 
 
Additional Technical Specifications 
1. Bespoke naso-oesophageal catheter 
 
 
1 cm
1 cm
1 cm
10 cm
15 cm
5 cm
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2. Dimensions of electrical stimulation paradigm 
 
 
 
 
 
 
Pulse&strength:! !200V,!and!!
! !!!!!!!! !variable!mA!with!incremental!increase!of!2!mA!per!pulse.!
Pulse&width:! !500µs!
Pulse&number:! !single!pulse!(no!train);!!
Pulse&form: &! !square!pulse!(not!sinus!wave);!
Pulse&frequency&:! !0.5Hz!(1puls/2seconds),!!
! ! !repeFFon!in!‘free!run’!mode!(no!delay).!
!
4&
2&
6&
8&
10&
Variable!mA!(200V)!
incremental!increase!
2!mA/pulse!!!
&
NB:&this!is!done!manually!
by!the!invesFgator.!
Pulse!width:!500µs!(square)!
Timing:!0.5Hz!–!‘free!run’!!!
!!!!(the!pulse!is!generated!automaFcally!and!conFnuously.)!
0,5ms!
2000ms!
The!sFmulaFon!paradigm:!
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Appendix Two 
 
Psychological Assessment Questioners 
 
1. Big Five Inventory (BFI)  
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2. The Weinberger Adjustment Inventory (WAI) 
(Not shown here) 
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3. Toronto Alexithymia Scale (TAS- 20)  
Toronto Alexithymia Scale (TAS-20) 
The TAS-20 utilizes a five-point Likert scale with five of the items inversely scored. It is 
hand scored with a maximum score of 100. It uses cutoff scoring: equal to or less than 
51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = 
possible alexithymia. The maximum scores for each of the subscales are: Factor 1 (7 
items): 35; Factor 2 (5 items): 25; Factor 3 (8 items): 40. There are no cutoff scores 
established for each of the three factor subscales. 
F1 - Difficulty Identifying Feelings 
 1.   I am often confused about what emotion I am feeling. 
 3.   I have physical sensations that even doctors don’t understand. 
 6.   When I am upset, I don’t know if I am sad, frightened, or angry. 
 7.   I am often puzzled by sensations in my body. 
 9.   I have feelings that I can’t quite identify. 
 13. I don’t know what’s going on inside me. 
 14. I often don’t know why I am angry. 
 
F-2 - Difficulty Describing Feelings 
 2.   It is difficult for me to find the right words for my feelings. 
 4.   I am able to describe my feelings easily. 
 11. I find it hard to describe how I feel about people 
 12. People tell me to describe my feelings more. 
 17. It is difficult for me to reveal my innermost feelings, even to close friends. 
 
F-3 - Externally-Oriented Thinking 
 5.   I prefer to analyse problems rather than just describe them. 
 8.   I prefer to just let things happen rather than to understand why   
they turned out that way. 
 10. Being in touch with emotions is essential. 
 15. I prefer talking to people about their daily activities rather than their feelings. 
 16. I prefer to watch “light” entertainment shows rather than psychological 
dramas. 
 18. I can feel close to someone, even in moments of silence. 
 19. I find examination of my feelings useful in solving personal 
 problems. 
 20. Looking for hidden meanings in movies or plays distracts from their 
enjoyment. 
  Note: Items 4, 5, 10, 18, and 19 are inversely keyed. 
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Development of the TAS-20 
 In the absence of valid and reliable instruments to measure the 
alexithymia construct, Taylor, Ryan and Bagby (1985) devised the original self-
report Toronto Alexithymia Scale (TAS). They used both empirical and rational 
methods in scale construction, initially defining five domains of alexithymia: (a) 
difficulty describing feelings, (b) difficulty distinguishing between feelings and 
accompanying bodily sensations, (c) lack of introspection, (d) social conformity, 
and (e) impoverished fantasy life and poor dream recall (Taylor et al., 1997). 
Responses were rated with a 5-point Likert scale ranging from ‘strongly 
disagree’ to ‘strongly agree’. After factor and item analysis, the 41 item 
questionnaire was pared to 26 items and four domains that were more 
theoretically consistent with the alexithymia construct. These four domains, or 
factors, were: Factor 1 (F1) difficulty identifying and distinguishing between 
feelings and bodily sensations, Factor 2 (F2) difficulty describing feelings, 
Factor 3 (F3) reduced daydreaming, and Factor 4 (F4) externally oriented 
thinking.  
 While studies demonstrated support for the discriminant and convergent 
validity of the TAS, and the psychometric properties of the TAS were a 
considerable improvement over other available instruments, the construction of 
the TAS prompted refinement of the alexithymia construct and its essential 
facets. Daydreaming, for example, was determined to negatively correlate with 
the first factor (Taylor et al., 1997). In 1992 the attempt at scale reconstruction 
led to the development of a revised, 23 item self-report scale, the TAS-R. 
Continuing shortcomings with the scale prompted further examination of its 
compositional structure. There was high correlation between factors 1 and 2, 
and several items cross-loaded on each factor. Further revision resulted in the 
TAS-20 (Bagby, Parker &Taylor, 1994; Bagby, Taylor & Parker, 1994), a 20-
item self-report scale consisting of 3 factors: Factor 1 (F1) difficulty identifying 
feelings, Factor 2 (F2) difficulty describing feelings, and Factor 3 (F3) externally-
oriented thinking. These three factors represent essential intercorrelated traits 
that are theoretically congruent with the alexithymia construct. The TAS-20 
eliminates the theoretical overlap of the three factors and the cross-loading of 
items that was a liability in earlier versions, and demonstrates good internal 
consistency and test-retest reliability. “The psychometric properties of the TAS 
provide considerable empirical support for the validity of the alexithymia 
construct” (Taylor et al., p. 49). 
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4. Hospital Anxiety and Depression Scale (HADS)  
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5. Spielberger State (SSAI) and Trait (STAI) anxiety Questionnaire 
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6. Vulnerable Attachment Style Questionnaire (VASQ) 
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Appendix Three 
 
Explanatory note BFI: 
 
 
A summary of the factors of the Big Five and their constituent traits:[1] 
 
1. Extraversion – (outgoing/energetic vs. solitary/reserved). Energy, 
positive emotions, surgency, assertiveness, sociability and the 
tendency to seek stimulation in the company of others, and 
talkativeness. 
2. Agreeableness – (friendly/compassionate vs. cold/unkind). A 
tendency to be compassionate and cooperative rather than 
suspicious and antagonistic towards others. It is also a measure of 
ones' trusting and helpful nature, and whether a person is 
generally well tempered or not. 
3. Conscientiousness – (efficient/organised vs. easy-going/careless). 
A tendency to show self-discipline, act dutifully, and aim for 
achievement; planned rather than spontaneous behaviour; 
organized, and dependable. 
4. Neuroticism – (sensitive/nervous vs. secure/confident). The 
tendency to experience unpleasant emotions easily, such as 
anger, anxiety, depression, or vulnerability. Neuroticism also refers 
to the degree of emotional stability and impulse control, and is 
sometimes referred by its low pole – "emotional stability". 
5. Openness to experience – (inventive/curious vs. 
consistent/cautious). Appreciation for art, emotion, adventure, 
unusual ideas, curiosity, and variety of experience. Openness 
reflects the degree of intellectual curiosity, creativity and a 
preference for novelty and variety a person has. It is also 
described as the extent to which a person is imaginative or 
independent, and depicts a personal preference for a variety of 
activities over a strict routine. Some disagreement remains about 
how to interpret the openness factor, which is sometimes called 
"intellect" rather than openness to experience. 
[1] Atkinson RL, Atkinson RC, Smith EE, Bem DJ, Nolen-Hoeksema S. Hilgard's Introduction to 
Psychology (13 ed.). Harcourt College Publishers. 2000: 437. 
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Appendix Four 
 
 
1. Study 1 – Pilot Study: PNS modulation data on pain reporting 
As part of examining the psychological dimension of the cohort in study 
1, the volunteers’ subjective reporting responses as measured by Visual 
Analogue Scale (VAS) scores during different phases of the experiment 
for pain and unpleasantness was recorded at baseline (T0), during the 
acid infusion, and for time points T60, T90 and T120, and compared 
between visits. With regards to the subjective pain experienced, there 
was no statistical difference between visits, but for the unpleasantness, 
there was some differences detected. Of note is the observation that 
immediately (T60) post Psychological stress induction (green graph, 
Figure ax-4.1(B)), the unpleasantness VAS score was the highest, 7.38 
±1.60(SD), p=0.053, but at T120, it was the lowest, 3.43 ±2.30(SD), p=0.019. 
[p values were calculated relative to there difference with regards to 
Screening visit] A second observation was that for both pain and 
unpleasantness during the acid infusion period, the Deep breathing 
protocol produced the lowest subjective ratings.  
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Figure ax-4.1: Subjective rating A: experienced pain in the proximal 
oesophagus, and B: unpleasantness experienced due to the electrical 
sensitivity stimulus, and acid infusion.  
 
Looking at the relationship between subjective pain and unpleasantness 
reported, and the objective pain-stimulation strength actually 
experienced (experimentally delivered), correlations of note were 
detected. During Screening visit there was a negative correlation 
between the average pain threshold (Avr PT) and for both the reporting 
of pain, r=-0.483 (p=0.049) and unpleasantness, r=-0.42 (p=0.093). (Figure 
ax-4.2(A)) A similar finding was seen during the psychological stress 
induction, with regards to the difference in pain threshold (Δ PT) and the 
subjective reporting of pain, r=-0.787 (p=0.036) with unpleasantness, r=-
0.849 (p=0.016). (Figure ax-4.2(B)) Further analysis revealed that the 
correlation was sensitive to the inclusion/exclusion of an outlying point. 
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When the analysis was repeated after the exclusion of the outlier there 
remained statistical significance for unpleasantness, r=-0.892 (p=0.017), 
but not for pain, r=-0.602 (p=0.206). These correlations imply that the 
lower the volunteers’ pain threshold (Avr PT), or the higher there degree 
of sensitivity (ΔPT) were; the more likely they were of reporting the stimulus 
experienced as more painful or unpleasant.  
 
 
Figure ax-4.2: A: The correlation between average pain threshold (Avr 
PT) and subjective reporting on a visual analogue scale (VAS) during 
screening visit. B: The correlation between the difference in pain 
threshold (ΔPT) and) and subjective reporting on a visual analogue scale 
(VAS) during psychological stress protocol. 
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Study 1 – Pilot Study: Pain reporting data tables  
 
 
Subj.&Pain& & T0& Acid& T60& T90& T120& Subj.&Un5pleasantness& & T0& Acid& T60& T90& T120&
SV& AVR& 6.28% 3.45% 6.13% 6.72% 6.70% SV& AVR& 5.93% 4.18% 5.70% 5.82% 6.39%
& SD& 0.87% 2.01% 1.20% 1.41% 1.16% & SD& 1.81% 2.68% 2.11% 1.80% 1.94%
& SEM& 0.21% 0.49% 0.29% 0.34% 0.28% & SEM& 0.44% 0.65% 0.51% 0.44% 0.47%
& n& 17% 17% 17% 17% 17% & n& 17% 17% 17% 17% 17%
& & % % % % % & & % % % % %
DB& AVR& 6.5% 2.8% 6.65% 6.6% 6.8% DB& AVR& 6.65% 3.20% 6.60% 6.80% 6.95%
& SD& 0.71% 2.10% 0.88% 1.17% 0.79% & SD& 1.11% 2.57% 1.60% 1.03% 1.01%
& SEM& 0.22% 0.66% 0.28% 0.37% 0.25% & SEM& 0.35% 0.81% 0.50% 0.33% 0.32%
& n& 10% 10% 10% 10% 10% & n& 10% 10% 10% 10% 10%
& p& 0.496% 0.916% 0.244% 0.999% 0.619% & p& 0.134% 0.819% 0.405% 0.031%*% 0.217%
ST& AVR& 6.38% 3.00% 6.67% 6.55% 6.33% ST& AVR& 5.50% 4.23% 7.38% 6.62% 3.43%
& SD& 0.49% 2.08% 0.47% 0.97% 0.47% & SD& 2.47% 2.52% 1.60% 1.83% 2.30%
& SEM& 0.18% 0.79% 0.18% 0.36% 0.18% & SEM& 0.93% 0.95% 0.61% 0.69% 0.87%
& n& 7% 7% 7% 7% 7% & n& 7% 7% 7% 7% 7%
& p& 0.231% 0.067% 0.103% 0.111% 0.134% & p& 0.656% 0.063% 0.053% 0.377% 0.019%*%
HG& AVR& 6.50% 3.83% 6.63% 6.67% 6.33% HG& AVR& 6.46% 4.00% 6.63% 7.00% 6.29%
& SD& 0.90% 2.66% 0.83% 0.89% 0.78% & SD& 1.27% 2.56% 1.33% 1.13% 1.25%
& SEM& 0.26% 0.77% 0.24% 0.26% 0.22% & SEM& 0.37% 0.74% 0.38% 0.33% 0.36%
& n& 12% 12% 12% 12% 12% & n& 12% 12% 12% 12% 12%
& p& 0.423% 0.245% 0.253% 0.740% 0.491% & p& 0.099% 0.281% 0.321% 0.017%*% 0.687%
A:% B:%
SV: Screening visit protocol 
DB: Deep breathing protocol 
ST: Stress induction protocol 
HG: Handgrip protocol 
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2. Study 5 – GCH-1 Genetic probe ‘well – table’: 
 
 
Genotypes) Haplotypes)
) ) Most)Probable) 2nd)Most)Probable) ATG)
55306432) 55360114) 55378966) H)1) H)2) p) H)1) H)2) p)
rs10483639) rs3783641) rs8007267) ) ) ) ) ) ) ) ) ) )
AM158) 1))1) 1))1) 0))0) 1) 1) ) 1) 1) ) 1) ) ) ) ) ) O/O)
AM101) 1))2) 1))1) 1))1) 1) 1) 1) 2) 1) 1) 1) ) ) ) ) ) O/O)
AM104) 1))2) 1))2) 1))2) 1) 1) 1) 2) 2) 2) 0.993) 2) 1) 1) 1) 2) 2) 0.0068) O/X)
AM106) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1) 1) ) ) ) ) ) O/O)
AM107) 1))2) 1))1) 1))1) 1) 1) 1) 2) 1) 1) 1) ) ) ) ) ) O/O)
AM109) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1) 1) ) ) ) ) ) O/O)
AM110) 1))2) 1))2) 1))2) 1) 1) 1) 2) 2) 2)
0.99314
4) 2) 1) 1) 1) 2) 2) 0.0068) O/X)
AM112) 1))1) 1))2) 1))2) 1) 1) 1) 1) 2) 2) 1) ) ) ) ) ) O/O)
AM113) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1) 1) ) ) ) ) ) O/O)
AM115) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1) 1) ) ) ) ) ) O/O)
AM116) 1))2) 1))2) 1))2) 1) 1) 1) 2) 2) 2) 

 2) 1) 1) 2) 2) 1) 	 O/X)
AM117) 1))2) 1))2) 1))2) 1) 1) 1) 2) 2) 2) 

 2) 1) 1) 2) 2) 1) 	 O/X)
AM118) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1) 1) ) ) ) ) ) O/O)
AM119) 1))2) 1))1) 2))2) 1) 1) 2) 2) 1) 2) 1) ) ) ) ) ) O/O)
AM121) 2))2) 2))2) 2))2) 2) 2) 2) 2) 2) 2) 1) ) ) ) ) ) X/X)
AM123) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1) 1) ) ) ) ) ) O/O)
AM124) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1) 1) ) ) ) ) ) O/O)
AM125) 1))2) 1))2) 1))2) 1) 1) 1) 2) 2) 2) 

 2) 1) 1) 2) 2) 1) 	 O/X)
AM126) 1))2) 1))2) 1))2) 1) 1) 1) 2) 2) 2)
0.99314
4) 2) 1) 1) 2) 2) 1) 0.006856) O/X)
AM127) 1))2) 2))2) 2))2) 1) 2) 2) 2) 2) 2)  ) ) ) )  O/X)
AM128) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1) 1) ) ) ) ) ) O/O)
AM129) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1)  ) ) ) )  O/O)
AM130) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1) 1) ) ) ) ) ) O/O)
AM133) 0))0) 1))2) 1))2) 0) 1) 1) 0) 2) 2)  ) ) ) )  O/X)
AM134) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1) 1) ) ) ) ) ) O/O)
AM138) 0))0) 0))0) 1))1) 0) 0) 1) 0) 0) 1)  ) ) ) )  O/O)
AM141) 1))2) 1))2) 1))2) 1) 1) 1) 2) 2) 2) 

 2) 1) 1) 2) 2) 1) 	 O/X)
AM144) 1))1) 1))1) 1))2) 1) 1) 1) 1) 1) 2)  ) ) ) )  O/O)
AM146) 1))1) 1))1) 1))2) 1) 1) 1) 1) 1) 2)  ) ) ) )  O/O)
AM147) 0))0) 0))0) 0))0) ) ) ) ) ) ) ) ) ) )
AM148) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1)  ) ) ) )  O/O)
AM150) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1)  ) ) ) )  O/O)
AM151) 1))1) 1))1) 1))2) 1) 1) 1) 2) 1) 1)  ) ) ) )  O/O)
AM152) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1)  ) ) ) )  O/O)
AM153) 1))2) 1))2) 1))2) 1) 1) 1) 2) 2) 2)
0.99314
4) 2) 1) 1) 2) 2) 1) 0.006856) O/X)
AM155) 1))2) 1))2) 1))2) 1) 1) 1) 2) 2) 2)
0.99314
4) 2) 1) 1) 2) 2) 1) 0.006856) O/X)
AM162) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1)  ) ) ) )  O/O)
AM164) 1))2) 1))2) 1))2) 1) 1) 1) 2) 2) 2)
0.99314
4) 2) 1) 1) 2) 2) 1) 0.006856) O/X)
AM166) 1))1) 1))1) 1))1) 1) 1) 1) 1) 1) 1) 1) ) ) ) ) ) ) ) O/O)
Haplotype)Frequecies)
Haplotype) Haploview)
Obs) Freq)
1)111) )) 0.69)
2)222) )) 0.19)
3)112) )) 0.06)
4)122) )) 0.03)
5)211) )) 0.03)
6)212) )) 0.01)
7)110) )) )
8)011) )) )
9)022) )) ))
10)001) )) ))
3’# 5’#
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3. Study 5 - HADS profiling data: 
 
 
 
 
 
n" status" number" HADS" "
" Anxiety Depression 
1" Non"sensi3sers" 1" 9" 8"
2" Non"sensi3sers" 7" 6" 8"
3" Non"sensi3sers" 13" 12" 9"
4" Non"sensi3sers" 24" 6" 11"
5" Non"sensi3sers" 25" 9" 8"
6" Non"sensi3sers" 26" 9" 9"
7" Non"sensi3sers" 29" 7" 9"
8" Non"sensi3sers" 30" 10" 8"
9" Non"sensi3sers" 33" 8" 6"
10" Non"sensi3sers" 34" 11" 13"
11" Non"sensi3sers" 41" 8" 13"
12" Non"sensi3sers" 48" 7" 9"
13" Non"sensi3sers" 50" 6" 8"
14" Non"sensi3sers" 52" 9" 10"
15" Non"sensi3sers" 55" 6" 8"
16" Non"sensi3sers" 58" 10" 9"
17" Non"sensi3sers" 62" 10" 10"
18" Non"sensi3sers" 64" 8" 9" n" status" number" HADS" "
19" Non"sensi3sers" 66" 9" 8" " "(O/O)" Anxiety Depression 
" avr$ 8.42" 9.11" " "
" SD$ 23.45" 23.45" 1" Sensi3sers" 4" 13" 7"
" " SEM$ 5.38" 5.38" 4" Sensi3sers" 10" 9" 9"
" " " " " 7" Sensi3sers" 16" 7" 6"
1" Sensi3sers" 4" 13" 7" 8" Sensi3sers" 17" 11" 7"
2" Sensi3sers" 6" 7" 8" 11" Sensi3sers" 21" 10" 6"
3" Sensi3sers" 9" 5" 9" 13" Sensi3sers" 27" 14" 6"
4" Sensi3sers" 10" 9" 9" 20" Sensi3sers" 53" 6" 9"
5" Sensi3sers" 12" 10" 10" " 10" 7.14"
6" Sensi3sers" 15" 8" 9" " "
7" Sensi3sers" 16" 7" 6" " "
8" Sensi3sers" 17" 11" 7" "(0/X,X/X)" "
9" Sensi3sers" 18" 9" 9" 2" Sensi3sers" 6" 7" 8"
10" Sensi3sers" 19" 12" 13" 3" Sensi3sers" 9" 5" 9"
11" Sensi3sers" 21" 10" 6" 5" Sensi3sers" 12" 10" 10"
12" Sensi3sers" 23" 12" 11" 6" Sensi3sers" 15" 8" 9"
13" Sensi3sers" 27" 14" 6" 9" Sensi3sers" 18" 9" 9"
14" Sensi3sers" 28" 14" 7" 10" Sensi3sers" 19" 12" 13"
15" Sensi3sers" 38" 8" 9" 12" Sensi3sers" 23" 12" 11"
16" Sensi3sers" 44" 4" 8" 14" Sensi3sers" 28" 14" 7"
17" Sensi3sers" 46" 9" 9" 15" Sensi3sers" 38" 8" 9"
20" Sensi3sers" 53" 6" 9" 16" Sensi3sers" 44" 4" 8"
" avr$ 9.33" 8.44" 17" Sensi3sers" 46" 9" 9"
" SD$ 2.95" 1.82" 19" Sensi3sers" 51" 10" 9"
" SEM$ 0.68" 0.42" " 9" 9.25"
" " " "
" " t$test:$p=$ 0.259" 0.265" " " t$test:$p=$ 0.480" 0.008"
In"a"comparable"manner"to"pain"thresholds,"analysis"
of"depression"scores"based"on"pain"phenotype"and"
genotype"revealed"that"depression"scores"were"
significantly"lower"in"sensi3sers"who"possessed"the"
pain"protec3ve"haplotype"than"sensi3sers"who"did"
not"or"both"subgroups"of"nonPsensi3sers"(e.g."
depression"score"of"7.1"±0.5(SEM)"(X)"sensi3sers"
p=0.03"vs."9.3"±0.4(SEM)"(O)"sensi3sers"vs."9.7"±"
0.7(SEM)"(X)"non"sensi3sers"vs."8.8"±0.5mA"(O)"nonP
sensi3sers)."
  
 
 
361 
 
 
 
 
 
 
 
 
 
 
Soli Deo Gloria 
